Document:

EX-10.1

 Exhibit 10.1 

NEURONETICS, INC. 
 DISTRIBUTION
AGREEMENT 
 This Distribution Agreement (this “Agreement”) is made and entered into this 12th day of October 2017 (the “Effective Date”) by and between Neuronetics, Inc., a Delaware corporation having its principal offices at 3222 Phoenixville Pike, Malvern, Pennsylvania,
19355, USA (“Company”), and Teijin Pharma Limited, a Japanese company having its principal offices at 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo 100-8585, Japan (“Distributor”). Each of Company and Distributor are sometimes referred to individually in this Agreement as a
“Party” and collectively as the “Parties.” 
 RECITALS 

WHEREAS, Company desires to appoint Distributor as a distributor of the Products (as defined below) in the Territory (as defined below),
subject to the terms and conditions of this Agreement; and 
 WHEREAS, Distributor desires to accept such appointment. 

NOW, THEREFORE, Company and Distributor, intending to be legally bound, agree as follows: 

1. Definitions. 
 1.1 The following terms
shall be defined as follows: 
 1.1.1 “1st Reimbursement Approval” means the initial Reimbursement Approval issued by MHLW.

 1.1.2 “1st Qualifying Approval” means (a) if the Product Approval and/or the 1st Reimbursement Approval requires a
physician to obtain a training certification in respect of use of the System from a person, other than Distributor, its Affiliates or persons acting on behalf of Distributor or its Affiliates, in order to be permitted to use the System to treat
patients on a reimbursed basis, then the first time that any physician in the Territory is granted such certification or (b) if no such training certification is required by the Product Approval or the 1st Reimbursement Approval, then the 1st Reimbursement Approval. 

1.1.3 “1st Reimbursement Revision Approval” means the next permanent Reimbursement Approval issued by MHLW (honshusai)
after the 1st Reimbursement Approval. 
 1.1.4 “Affiliate” means, with respect to a person, any individual, group,
corporation, limited liability company, partnership, joint venture, association, trust and any other legal entity directly or indirectly Controlled by, Controlling, or under common Control with such person. The term “Control” of a
legal entity means the possession, direct or indirect, of the power to: (a) vote more than fifty percent of the voting stock of such legal entity; or (b) direct or cause the direction of the management or policies of such legal entity,
whether through the ownership of securities or partnership or other ownership interests, by contract or otherwise. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 1. 

 1.1.5 “Anti-Corruption Laws” has the meaning set forth in Section 5.5.1.

 1.1.6 “Applicable Law” means all Laws, including cGMP, relevant to each Party’s obligations under this Agreement,
including, without limitation, any rules, regulations, guidelines or other requirements of the FDA and any other Governmental Authority with respect to the manufacture of the Products and rules, regulations, guidelines or other requirements of the
MHLW applicable to the promotion, marketing, distribution and sale of the Products in the Territory. 
 1.1.7 “Baseline
Year” means the Fiscal Year in which either of the Parties or their respective Affiliates commences sales of Home Use Devices in the Territory. 

1.1.8 “Certificate of Conformance” means that certificate to be delivered by Company’s contract manufacturer to
Distributor in the form attached as Schedule L. 
 1.1.9 “Change of Control” means with respect to a Party (a) a
merger or consolidation of such Party with a third party which results in the voting securities of Company outstanding immediately prior thereto ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity
immediately after such merger or consolidation, (b) except in the case of a bona fide equity financing in which such Party issues new shares of its capital stock, a transaction or series of related transactions in which a third party, together
with its Affiliates, becomes the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of Company, or (c) the sale or other transfer to a third party of all or substantially all of such
Party’s business to which the subject matter of this Agreement relates. 
 1.1.10 “Code” has the meaning set forth in
Section 5.6. 
 1.1.11 “Company MHLW Lead Period” means the period from the date of the 1st Reimbursement Approval
until and including the date of the 1st Reimbursement Revision Approval. 
 1.1.12 “Company Trademarks” means (a) the
English language trademarks listed on Schedule D and (b) the katakana trademarks listed on Schedule D. 
 1.1.13
“Company’s Agent” means Vorpal or such other company as Company designates from time to time by sending notice to Distributor. 

1.1.14 “Competitive Product” means [*] 

1.1.15 “Confidential Information” has the meaning set forth in Section 8.1. 

1.1.16 “cGMP” means the current good manufacturing practices applicable to the manufacture of the Product under this Agreement
as defined in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Part 820, and the equivalent Laws in the Territory, each as may be amended and applicable from time to time. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 2. 

 1.1.17 “Default Notice” shall have the meaning set forth in Section 6.3.

 1.1.18 “Defect” means, in respect of a Product, a manufacturing defect, a failure to meet or operate in accordance with
the applicable Specifications or a failure to have been manufactured in accordance with Applicable Law including cGMP, and, in the case of the Software, a failure to operate in substantial compliance with the Software Documentation, and
“Defective” shall be construed accordingly. 
 1.1.19 “Defective Product” means a Product with a Defect.

 1.1.20 “Designated Marketing Authorization Holder” or “DMAH” means the agent approved by the MHLW to act
as the MAH in accordance with and as defined in the Law on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics. 

1.1.21 “Disclosing Party” has the meaning set forth in Section 8.1. 

1.1.22 “Distributor 1st MHLW Lead Election” has the meaning set forth in Section 4.1.2. 

1.1.23 “Distributor 1st MHLW Lead Period” means the [*] period following the date of Distributor’s written notice making
the Distributor 1st MHLW Lead Election. 
 1.1.24 “Distributor 2nd MHLW Lead Election” has the meaning set forth in
Section 4.1.4. 
 1.1.25 “Distributor 2nd MHLW Lead Period” means the [*] period following the date of the 1st
Reimbursement Revision Approval. 
 1.1.26 “Distributor Approvals” has the meaning set forth in Section 4.2. 

1.1.27 “Distributor Quality Plan” means the separate Distributor Quality Plan between the Parties, as amended by the Parties
from time to time. The current Distributor Quality Plan is document number [*] 
 1.1.28 “Distributor Trademarks” has the
meaning set forth in Section 7.2.2 
 1.1.29 “Documentation” shall mean any and all information in written, graphic,
electronic or machine-readable form relating to use or operation of the System, including but not limited to, the System user manual and instructions for use, installation and service of the System provided by Company to Distributor pursuant to this
Agreement. 
 1.1.30 “Dollar,” “Dollars,” “U.S. Dollars” and the symbol
“$” shall mean lawful money of the United States of America. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 3. 

 1.1.31 [*] 

1.1.32 “FDA” means the United States Food and Drug Administration or its successor. 

1.1.33 “Fiscal Year” means the period commencing on April 1 of each calendar year and ending on March 31 of the
subsequent calendar year. 
 1.1.34 “Fixed Transfer Price Period” has the meaning set forth in Section 3.5.1. 

1.1.35 “Force Majeure” has the meaning set forth in Section 14.13. 

1.1.36 “Foreign Manufacturer Accreditation” means the license issued by M1-ILW to a
manufacturer of medical devices located outside of Japan for import and sale of such medical devices in Japan as specified in Article 13-3 of the Pharmaceuticals Affairs Law of Japan. 

1.1.37 “Governmental Authority” means any multinational, national, federal, prefectural, state, local, municipal or other
governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal), in each case, having jurisdiction over the applicable subject matter.

 1.1.38 “Government Official” has the meaning set forth in Section 5.5.1. 

1.1.39 “[*] Baseline” means the Dollar value of Distributor’s purchases of Products from Company during the first Fiscal
Year after the Baseline Year. 
 1.1.40 “[*] Credit” has the meaning set forth in Section 3.12. 

1.1.41 “[*] Device” means any transcranial magnetic stimulation device that is, or is intended to be, marketed for use by [*]
for the treatment of Major Depressive Disorder. 
 1.1.42 “[*] Minimum” means the higher of (a) the Dollar value of
purchases of Products by Distributor from Company during the Baseline Year or (b) the Dollar value of purchases of Products by Distributor from Company during the full Fiscal Year prior to the Baseline Year.] 

1.1.43 “Indemnification Claim Notice” has the meaning set forth in Section 10.2.1. 

1.1.44 “Indemnified Party” has the meaning set forth in Section 10.2.1. 

1.1.45 “Indemnifying Party” has the meaning set forth in Section 10.2.1. 

1.1.46 “Indemnitee” and “Indemnitees” has the meaning set forth in Section 10.2.1. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 4. 

 1.1.47 “Initial Milestone Payment 2” means Milestone Payment 2 calculated using
the Reimbursement Rate set in the 1st Reimbursement Approval. 
 1.1.48 “Initial Payment” has the meaning set forth in
Section 3.1.1. 
 1.1.49 “Initial Period” has the meaning set forth in Section 3.4.2. 

1.1.50 “Initial Sales Forecast” has the meaning set forth in Section 3.4.2. 

1.1.51 “Initial Term” has the meaning set forth in Section 12.1. 

1.1.52 “Initial Transfer Price” has the meaning set forth in Section 3.5.1. 

1.1.53 “Insolvent Party” has the meaning set forth in Section 12.12. 

1.1.54 “[*]” means [*] that the Company and Distributor will develop pursuant to Section 6.1 [*] 

1.1.55 “Laws” means all laws, statutes, rules, regulations, directives, decisions and ordinances of any Governmental
Authority. 
 1.1.56 “Limited License” has the meaning set forth in Section 7.3.1. 

1.1.57 “Losses” has the meaning set forth in Section 10.1.1. 

1.1.58 “MAH” means Marketing Authorization Holder. 

1.1.59 “Major Depressive Disorder” has the meaning set forth in ICD-9
§§ 296.X. 
 1.1.60 “Marketing Materials” has the meaning set forth in Section 7.5. 

1.1.61 “MHLW” means the Japanese Ministry of Health, Labour and Welfare and any successor thereto. 

1.1.62 “Milestone Payment 1” has the meaning set forth in Section 3.1.2. 

1.1.63 “Milestone Payment 2” has the meaning set forth in Section 3.1.3. 

1.1.64 “Minimum Purchase Requirement” has the meaning set forth in Section 3.4.1. 

1.1.65 “Minimum Terms and Conditions of Sale” has the meaning set forth in Section 7.3.4. 

1.1.66 “NeuroStar Product” means the NeuroStar TMS Therapy® System,
Item Number 81-60000-101 as listed in the Product Catalog and set forth in Schedule A. For the avoidance of doubt, the NeuroStar Product does not include the
TrakStar Computer and peripherals, the NeuroStar Treatment Packs or the other items included in the NeuroStar Starter Package. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 5. 

 1.1.67 “NeuroStar Starter Package” means a bundled package of the Products set
forth in Schedule A together with the Limited License. 
 1.1.68 “NeuroStar Treatment Packs” means alignment and
hygiene barrier consumables used in conjunction with NeuroStar Treatment Sessions, Item Number 81-00931-000 as listed in the Product Catalog. 

1.1.69 “NeuroStar Treatment Sessions” or “NSTS” means a single treatment session delivered by the NeuroStar
Product to a patient, comprised of a maximum of 5,000 magnetic pulses and delivered in accordance with the treatment parameters specified by the prescribing physician. The treatment parameters include but are not limited to number of pulses,
stimulation time, stimulation frequency, interval and coil orientation. 
 1.1.70 “New Sales Forecast” has the meaning set
forth in Section 3.4.2. 
 1.1.71 “[*] Development Plan” has the meaning set forth in Section 6.1. 

1.1.72 “Out of Box Failure” means at the time of installation at the customer’s facility of a NeuroStar Starter Package (a) non-conformance to the Certificate of Conformance provided by Company’s contract manufacturer for such NeuroStar Starter Package; or (b) a failure of the NeuroStar Starter Package to pass the
visual inspection procedure set forth in Schedule E or any of the criteria or items set forth in the NeuroStar OUS Installation Record [*], after Distributor or its Technical Support Company follows all installation and troubleshooting
procedures in the NeuroStar Distributor Service Manual [*], other than any such non-conformance or failure caused by Distributor or its Technical Support Company after Company’s delivery of such NeuroStar
Starter Package to Distributor. 
 1.1.73 “Order Forecast” has the meaning set forth in Section 3.2.2. 

1.1.74 “PMDA” means the Pharmaceuticals and Medical Devices Agency and any successor thereto. 

1.1.75 “Post-Reimbursement Approval Channel” means: (a) any customer for the Products in the Territory that treats
patients with Major Depressive Disorder primarily on a reimbursed basis; and (b) any customers of Distributor for the Products obtained prior to receipt of the 1st Reimbursement Approval, whether the 1st Reimbursement Approval is obtained by
Company or Distributor. 
 1.1.76 “Pre-Reimbursement Approval Channel” means any
customer for the Products in the Territory during the period prior to receipt of the 1st Reimbursement Approval, whether the 1st Reimbursement Approval is obtained by Company or Distributor. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 6. 

 1.1.77 “Product” means: (a) the NeuroStar Product, Software, SenStar
Connect, SenStar Treatment Links, NeuroStar Treatment Packs and those other items set forth in Schedules A and O attached to this Agreement, modified as necessary in order for the foregoing to receive the Regulatory Approvals;
(b) all updates and improvements to any the foregoing that are marketed or sold by Company or its distributors in any country for Major Depressive Disorder indications; and (c) such additions, parts and accessories thereto as Company and
Distributor mutually agree from time to time. 
 1.1.78 “Product Approval” means the approval by MHLW of a registration of
the Product that allows for the importation, marketing, promotion, distribution and sale of the Product in the Territory as medical devices for the treatment of Major Depressive Disorder indications that are substantially similar to the Major
Depressive Disorder indications for which the Products are approved in the United States with substantially the same conditions as approved in the United States. 

1.1.79 “Product Catalog” means Company’s catalog of Products available for sale dated as of 2013, as modified by Company
from time to time. 
 1.1.80 “Recall” has the meaning set forth in Section 6.8. 

1.1.81 “Receiving Party” has the meaning set forth in Section 8.1. 

1.1.82 “Redistributable Code” shall mean all third party software that is licensed to Company for redistribution with the
Software. 
 1.1.83 “Regulatory Approvals” means (a) the Product Approval, (b) the Reimbursement Approval and
(c) MAH/DMAH Approval. 
 1.1.84 “Regulatory Authorities” means the MHLW, PMDA and any other governmental body that has
legal authority to regulate the manufacture, distribution or sale of medical devices in the Territory. 
 1.1.85 “Reimbursement
Approval” means a determination by MHLW of the Reimbursement Rate. 
 1.1.86 “Reimbursement Approval Deadline”
means the second anniversary of the date on which MHLW grants the first Product Approval. 
 1.1.87 “Reimbursement Rate”
means the amount set by the MI-ILW from time to time that MHLW will reimburse hospitals and medical clinics for use of transcranial magnetic stimulation devices to treat patients suffering from those Major
Depressive Disorder indications for which Company has obtained Product Approval. 
 1.1.88 “Return Policy” has the meaning
set forth in Section 3.10. 
 1.1.89 “Rolling Termination Right” has the meaning set forth in Section 12.11. 

1.1.90 “Rules” has the meaning set forth in Section 14.4. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 7. 

 1.1.91 “Sales Representatives” has the meaning set forth in Section 2.3.2.

 1.1.92 “SenStar Connect” means Item Number
81-71000-100 as listed in the Product Catalog, a multiple-use consumable integrated flexible circuit that (a) must be
attached to the treatment coil prior to MT or treatment to facilitate contact sensing and magnetic field detection and to decrease the magnetic field at the scalp surface to enhance tolerability during treatment and (b) is used in conjunction
with a hygiene barrier. 
 1.1.93 “SenStar Treatment Link” means the current version of SenStar Treatment Links, Item Number
81-70000-001 as listed in the Product Catalog. 
 1.1.94
“Software” means the software programs, tools and data, whether in source or object code format, embedded or incorporated in the System or used in conjunction with the operation of the Products, including, without limitation,
TrakStar Software, MT Assist, and Redistributable Code incorporated into or delivered with such software. 
 1.1.95 “Software
Documentation” means [*], Rev B: Controlled Release of NeuroStar 2.3.1 System Software and [*], Rev C : Controlled Release of TrakStar 2.3.1 Software, as updated by Company from time to time. 

1.1.96 “Specifications” means (a) prior to the Product Approval, the specifications for the Products set forth in
Schedule M; and (b) after the Product Approval, the specifications for the Products as approved by MHLW from to time and the specifications for the Products set forth in Schedule M as amended by Company from time to time including
in connection with changes to the Products. 
 1.1.97 [*] 

1.1.98 “Steering Committee” has the meaning set forth in Section 2.5.1. 

1.1.99 “Subsequent Year” means each full Fiscal Year immediately following the Baseline Year. 

1.1.100 “System” means the Products, the Software, and single use items and other accessories sold by Company for use with the
Products operating together as an integrated system or tool, including all successors, extensions, new models and upgrades thereto. 

1.1.101 “Taxes” has the meaning set forth in Section 14.12. 

1.1.102 “Technical Support Company” means [*] and such companies as Distributor may designate in writing to Company from time
to time that will assist Distributor in the Territory with the delivery, installation and maintenance of Products and Software and provide technical support and such other assistance to end-user customers as
requested by Distributor. 
 1.1.103 “Term” has the meaning set forth in Section 12.1. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 8. 

 1.1.104 “Territory” means Japan. 

1.1.105 “Third Party Claim” has the meaning set forth in Section 10.1.1. 

1.1.106 “TrakStar Software” means the Company’s practice data management system software including, if any, new versions,
updates and upgrades thereto. 
 1.1.107 “TrakStar Computer” means a stand-alone personal computer that meets the
specifications set forth on Schedule N, as such specifications may be updated by Company from time to time. 
 1.1.108 “Transition
Effective Date” means the first business day that is [*] days before the expiration or termination of this Agreement. 
 1.1.109
“True-Up Payment” has the meaning set forth in Section 3.4.5. 
 1.1.110
“Vorpal” means Vorpal Technologies K.K. 
 1.1.111 “Warranty Period” has the meaning set forth in
Section 9.3.1. 
 1.1.112 “Withholding Party” has the meaning set forth in Section 14.12. 

1.1.113 “Year 2” means the first full Fiscal Year immediately following the first Subsequent Year. 

2. Distributorship Terms. 
 2.1
Appointment and Acceptance. 
 2.1.1 Subject to the terms and conditions of this Agreement, Company hereby appoints Distributor as
Company’s sole and exclusive distributor of Products and provider of NSTS in the Pre-Reimbursement Approval Channel and Post-Reimbursement Approval Channel, and Distributor accepts such appointment.
During the Term, except as set forth in Section 2.1, Company shall (a) neither distribute any Products or provide any NSTS in the Pre-Reimbursement Approval Channel or the Post-Reimbursement Approval
Channel nor appoint another distributor for the Products or NSTS in the Pre-Reimbursement Approval Channel or the Post-Reimbursement Approval Channel and (b) not sell Products to any third party that it
knows or reasonably should know intends to resell the Products or provide NSTS in the Pre-Reimbursement Approval Channel or the Post-Reimbursement Approval Channel. Without limiting the generality of the
foregoing, Company shall not solicit sales of Products or NSTS or promote the sale of Products or NSTS in the Territory except as specifically permitted by Sections 2.1.3 and 2.1.5. If Company receives an inquiry, purchase orders or other orders
from a third party for delivery or sale of Products or provision of NSTS in the Pre-Reimbursement Approval Channel or Post-Reimbursement Approval Channel, Company shall promptly notify Distributor and refuse
to fill any such inquiry, purchase order or other order unless Company is expressly permitted to do so by Sections 2.1.3 or 2.1.5. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 9. 

 2.1.2 Distributor specifically acknowledges that if, despite Company’s use of commercially
reasonable efforts to prevent the unauthorized sale or resale of Products or NSTS in the Territory, Company is unable to stop or prevent such unauthorized sales or resale of Products or NSTS in the Territory in the
Pre-Reimbursement Approval Channel or the Post-Reimbursement Approval Channel, then such unauthorized sale or resales of Products or NSTS in the Territory in the
Pre-Reimbursement Approval Channel or the Post-Reimbursement Approval Channel shall not constitute a material breach of the terms of this Agreement, provided, however, that the Minimum Purchase Requirement
shall be reduced by the amount of any such unauthorized sales or resale in the Post-Reimbursement Approval Channel. 
 2.1.3 Prior to receipt
of the 1st Reimbursement Approval (whether obtained by Company or Distributor), Company shall have the right to sell Products and NSTS outside the Pre-Reimbursement Approval Channel in the Territory only for
indications approved by the MHLW. Prior to receipt of the 1st Reimbursement Approval (whether obtained by Company or Distributor), Company shall have the right to sell Products and NSTS inside the
Pre-Reimbursement Approval Channel in the Territory directly to: (a) [*]; provided that Company: (i) obtains [*] written agreement to comply with such use restriction and to not, as a normal course of
business, distribute, resell, lease or otherwise transfer the Products to any third party; and (ii) uses commercially reasonable efforts to cause [*] compliance with such agreement; and (b) no more than one (1) customer (plus its
Affiliates) other than [*], provided; that: (i) such customer must purchase the Products solely for use at medical clinics owned and operated by the customer or its Affiliates and not for resale; (ii) Company obtains the written agreement
of the customer to not, as a normal course of business, distribute, resell, lease or otherwise transfer the Products to any third party; and (iii) Company uses commercially reasonable efforts to cause such customer to comply with such
agreement. 
 2.1.4 Effective upon receipt of the 1st Reimbursement Approval (whether obtained by Company or Distributor), Company shall not,
directly or indirectly, transfer, sell, or otherwise distribute itself or through any third party, any Products in the Pre-Reimbursement Approval Channel and the Post-Reimbursement Approval Channel except as
set forth in Section 2.1.5. 
 2.1.5 After receipt of the 1st Reimbursement Approval (whether obtained by Company or Distributor),
Company shall have the right to sell Products and NSTS (i) outside the Post-Reimbursement Approval Channel in the Territory for indications approved by the MHLW and (ii) in the Post-Reimbursement Approval Channel in the Territory directly
to [*] or to [*] through [*] or a replacement distributor, solely for use at medical clinics owned and operated by [*], provided that Company: (a) obtains [*] and [*] written agreement to comply with such use restriction and to not, as a normal
course of business, distribute, resell, lease or otherwise transfer the Products to any third party; and (b) uses commercially reasonable efforts to cause [*] and [*] compliance with such agreement. If [*] terminates its business involving use
of the Products, Company may replace [*] with a customer (and its Affiliates) outside the Post-Reimbursement Channel in the Territory; provided that Company: (i) obtains such customer’s written agreement to be bound by and comply with the
same restrictions as applicable to [*] and to not, as a normal course of business, distribute, resell, lease or otherwise transfer the Products to any third party; and (ii) uses commercially reasonable efforts to cause such customer’s
compliance with such 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 10. 

 
agreement. If Company has sold Products to one additional customer pursuant to clause (b) of Section 2.1.3, then upon receipt of the 1st Reimbursement Approval (whether obtained by
Company or Distributor) Distributor shall have the option, exercisable by sending written notice to Company within [*] after Company confirms to Distributor in writing that such customer desires to use Products to treat patients on a reimbursed
basis, to sell Products and NSTS to such customer in the Post-Reimbursement Approval Channel. If Distributor does not exercise such option, then Company shall have the right to sell Products and NSTS to such customer in the Post-Reimbursement
Approval Channel, provided that: (i) such customer must purchase the Products solely for use at medical clinics owned and operated by the customer or its Affiliates and not for resale; (ii) Company obtains the written agreement of the
customer to not, as a normal course of business, distribute, resell, lease or otherwise transfer the Products to any third party; and (iii) Company uses commercially reasonable efforts to cause such customer to comply with such agreement. 

2.1.6 For the avoidance of doubt, nothing in this Agreement limits Company in relation to a [*] Device in the Territory. 

2.2 No Activities Outside the Territory. Distributor shall not solicit sales of Products or promote the sale of Products outside the
Territory. In the event Distributor receives an inquiry, purchase orders or other orders from a third party for delivery or sale of Products outside of the Territory, Distributor shall promptly notify Company and refuse to fill any such inquiry,
purchase order or other order. 
 2.3 Sub-Distributors. 

2.3.1 Distributor shall have the right to appoint its Affiliates as sub-distributors; provided that
Distributor shall cause such Affiliates to comply with Distributor’s obligations under this Agreement and be liable to Company for any failures of such Affiliates to so comply. 

2.3.2 Except as otherwise set forth in Section 2.3.1, Distributor shall not appoint any
sub-distributor of Products in the Territory without the prior written consent of Company, which shall not be unreasonably withheld or conditioned; provided, however, Distributor may sell Products in the
Territory to end-users in the Territory through Distributor’s sales representatives comprising part of its standard sales channels in the normal course of business (“Sales
Representatives”), and such Sales Representatives shall not be deemed sub-distributors mentioned in this provision; provided, further, that: (a) Distributor shall cause each such Sale
Representative to comply with Distributor’s obligations under this Agreement that are applicable to such Sales Representative’s activities; and (b) Distributor shall be liable to Company for any failure of the Sales Representative to
comply with Distributor’s obligations under this Agreement that are applicable to such Sales Representative’s activities. For the avoidance of doubt, agents, distributors affiliated with hospitals, clinics and other end-users and unaffiliated distribution, logistics and similar companies designated by hospitals, clinics and other end-users for the purchase of Products shall not be deemed
to be sub-distributors or Sales Representatives for purposes of this Agreement. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 11. 

 2.4 Independent Contractor Relationship. The relationship of Company and Distributor is
that of independent contractors. This Agreement sets forth the duties and responsibilities of the Parties with respect to each other in furtherance of the purpose of this Agreement. This Agreement does not, however, give either Party the power to
direct or control the day-to-day activities of the other. This Agreement further does not create or imply any relations between the Parties as partners, joint venturers,
or co-owners. Neither Distributor nor its agents and employees are the representatives of Company for any purpose, and they shall have no power or authority as agent, employee or in any other capacity to
represent, act for, bind, or otherwise create or assume any obligation on behalf of Company. Neither Company nor its agents, including the DMAH, and employees are the representatives of Distributor for any purpose, and they shall have no power or
authority as agent, employee or in any other capacity to represent, act for, bind, or otherwise create or assume any obligation on behalf of Distributor. All financial obligations associated with Distributor’s business are the sole
responsibility of Distributor. All financial obligations associated with Company’s business are the sole responsibility of Company. All sales and other agreements between Distributor and its customers are Distributor’s exclusive
responsibility and do not affect Distributor’s obligations under this Agreement. 
 2.5 Steering Committee. 

2.5.1 Establishment of Steering Committee. As soon as practicable after the Effective Date, the Parties shall establish a committee to
facilitate the distribution of the Products in the Pre-Reimbursement Approval Channel and Post-Reimbursement Approval Channel in the Territory under this Agreement (the “Steering
Committee”) in accordance with this Section 2.5. 
 2.5.2 Composition of the Steering Committee. The Steering
Committee shall be comprised of one (1) representative designated by each of the Parties. Each representative shall be a senior executive of the designating Party. Each Party shall appoint its respective initial representative to the Steering
Committee within [*] after the Effective Date, and may from time to time substitute its representative, in its sole discretion, effective upon notice to the other Party of such change. Additional representatives or consultants may from time to time
be invited to attend Steering Committee meetings, subject to such representatives’ and consultants’ written agreement to comply with the requirements of Section 8 and the agreement of each Party. Each Party shall bear its own expenses
relating to attendance at such meetings by its representatives and consultants. 
 2.5.3 Meetings. The Steering Committee shall meet
in accordance with a schedule established by mutual written agreement of the Parties, but no less frequently than once per calendar year or as frequently as needed to discharge its responsibilities under this Agreement. The Steering Committee may
meet by means of teleconference, videoconference or other similar communications equipment. In-person meetings shall alternate between a Company facility in the United States and a Distributor facility in
Japan. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 12. 

 2.5.4 Matters for Steering Committee Discussion or Decision. The Steering Committee shall
serve as a forum for discussion of development, regulatory, commercial and related matters concerning the Products in the Pre-Reimbursement Approval Channel and Post-Reimbursement Approval Channel in the
Territory and have the following powers: 
 (a) approve the New Sales Forecast in accordance with and subject to Section 3.4.2; 

(b) approve the transfer prices for the NeuroStar Starter Packages and other Products after the Fixed Transfer Price Period in accordance with
and subject to Section 3.5.6; 
 (c) be presented with and discuss ideas and plans for updates and improvements to, and new versions
of, the Products and Software for use in the Pre-Reimbursement Approval Channel and Post-Reimbursement Approval Channel; and 

(d) be presented with and discuss information concerning competitive intelligence, market development and best practices concerning the
marketing, promotion, distribution, sale and support of the Products and Software for use in the Pre-Reimbursement Approval Channel and Post-Reimbursement Approval Channel. 

2.5.5 Decision-Making. With respect to the matters set forth in Sections 2.5.4(c) and 2.5.4(d), the Steering Committee has no decision
making power as these matters are discussion only. With respect to the matters set forth in Sections 2.5.4(a) and 2.5.4(b), the Steering Committee shall use reasonable best efforts to reach unanimous agreement on a proposed decision with each Party
(regardless of the number of attendees from the Party at a given meeting) having only one (1) vote. If the Steering Committee is unable to reach unanimous agreement on the matters set forth in Sections 2.5.4(a) or 2.5.4(b) within [*] days prior
to the rules set forth in Sections 2.5.4(a) or 2.5.4(b), as applicable, controlling the decision, then a Party may by written notice to the other Party escalate the relevant decision to a senior executive appointed by each of the Parties. If the
senior executives of both Parties are unable to reach agreement on the relevant decision within such [*] day period, then (a) for matters set forth in Section 2.5.4(a), Section 3.4.2 will control, and (b) for matters set forth in
Section 2.5.4(b), Section 3.5.6 will control. 
 3. Prices and Terms. 

3.1 Initial Payment; Milestone Payments. 

3.1.1 Distributor shall pay Company a non-refundable initial payment of Seven Hundred and Fifty
Thousand Dollars ($750,000) (the “Initial Payment”), such payment to be made by the end of the month following the month in which the Effective Date falls and the Distributor receives an invoice for the Initial Payment. 

3.1.2 Distributor shall pay Company a non-refundable milestone payment of Two Million Dollars
($2,000,000) (the “Milestone Payment 1”) by the end of the month following the month in which Company obtains the first Product Approval for the Product in the Territory, provides written notice thereof to Distributor and
Distributor receives an invoice for Milestone Payment 1. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 13. 

 3.1.3 Distributor shall pay Company a second
non-refundable (other than a potential true-up payment required by Section 3.1.7) milestone payment based on the Reimbursement Rate in accordance with the following
formula (“Milestone Payment 2”): 
 [*] 

3.1.4 If the 1st Reimbursement Approval is not obtained by the Reimbursement Approval Deadline and Distributor makes the Distributor 1st MHLW
Lead Election under Section 4.1.2, then Milestone Payment 2 shall be deemed fully earned and the Reimbursement Rate used in calculating Milestone Payment 2 shall be [*]. 

3.1.5 If Company obtains the 1st Reimbursement Approval by the Reimbursement Approval Deadline and the Reimbursement Rate is less than [*] and
neither Party terminates this Agreement pursuant to Section 12.7.1, then Distributor shall pay Initial Milestone Payment 2 using the Reimbursement Rate in the 1st Reimbursement Approval. Milestone Payment 2 shall then be finally calculated as
follows: 
 (a) If the Reimbursement Rate set in the 1st Reimbursement Revision Approval during the Company MHLW Lead Period is less than
[*] and Distributor makes the Distributor 2nd MHLW Lead Election under Section 4.1.4, then Milestone Payment 2 shall be calculated using [*] as the Reimbursement Rate. 

(b) if the Reimbursement Rate set in the 1st Reimbursement Revision Approval during the Company MHLW Lead Period is less than [*] and
Distributor does not make the Distributor 2nd MHLW Lead Election under Section 4.1.4, then regardless of whether this Agreement is terminated pursuant to Section 12.8.1, Milestone Payment 2 shall be calculated using the Reimbursement Rate
set in the 1st Reimbursement Revision Approval. 
 (c) If the Reimbursement Rate set in the 1st Reimbursement Revision Approval during the
Company MHLW Lead Period is at least [*], then Milestone Payment 2 shall be calculated using the Reimbursement Rate set in the 1st Reimbursement Revision Approval. 

3.1.6 If the Company obtains the 1st Reimbursement Approval by the Reimbursement Approval Deadline and the Reimbursement Rate is at least [*],
then Distributor shall pay Initial Milestone Payment 2 using the Reimbursement Rate in the 1st Reimbursement Approval. Milestone Payment 2 shall then be finally calculated as follows: 

(a) If the Reimbursement Rate set in the 1st Reimbursement Revision Approval during the Company MHLW Lead Period is less than [*] and either
Party elects to terminate the Agreement pursuant to Section 12.7.2, then Milestone Payment 2 shall be calculated using the Reimbursement Rate set in the 1st Reimbursement Revision Approval. 

(b) If the Reimbursement Rate set in the 1st Reimbursement Revision Approval during the Company MHLW Lead Period is less than [*] and neither
Party elects to terminate the Agreement pursuant to Section 12.7.2, then Milestone Payment 2 shall be calculated using the Reimbursement Rate set in the 1st Reimbursement Revision Approval. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 14. 

 (c) If the Reimbursement Rate set in the 1st Reimbursement Revision Approval during the Company
MHLW Lead Period is [*] and Distributor makes the Distributor 2nd MHLW Lead Election under Section 4.1.4, then Milestone Payment 2 shall be calculated using [*] as the Reimbursement Rate. 

(d) If the Reimbursement Rate set in the 1st Reimbursement Revision Approval during the Company MHLW Lead Period is less than [*] and
Distributor does not make the Distributor 2nd MHLW Lead Election under Section 4.1.4 and the Agreement is terminated pursuant to Section 12.8.1, then Milestone Payment 2 shall be calculated using the Reimbursement Rate set in the 1st
Reimbursement Revision Approval. 
 (e) If the Reimbursement Rate set in the 1st Reimbursement Revision Approval during the Company MHLW
Lead Period is at least [*], then Milestone Payment 2 shall be calculated using the Reimbursement Rate set in the 1st Reimbursement Revision Approval. 

3.1.7 Once Milestone Payment 2 is finally calculated pursuant to Sections 3.1.5 or 3.1.6, one of the Parties shall make a payment to the other
as follows: (a) if Milestone Payment 2 (as finally calculated) is more than Initial Milestone Payment 2, Distributor shall pay Company an amount equal to the difference of Milestone Payment 2 (as finally calculated) minus Initial Milestone
Payment 2; or (b) if Milestone Payment 2 (as finally calculated) is less than Initial Milestone Payment 2, Company shall refund Distributor an amount equal to the difference of Initial Milestone Payment 2 minus Milestone Payment 2 (as finally
calculated). 
 3.1.8 Distributor shall pay Company Initial Milestone Payment 2 and Milestone Payment 2 in US Dollars at a fixed exchange
rate of [*] to One Dollar ($1), by the end of the month following the month in which Distributor receives an invoice from Company setting forth a correct calculation of the amounts due to Company. For amounts that Company must refund to Distributor
pursuant to Section 3.1.7, if any, Company shall provide Distributor with a credit in the amount of the refund and Distributor may apply such credit at its discretion against other amounts owed to Company pursuant to this Agreement. If the
credit is not exhausted by the effective date of termination of this Agreement, Company shall pay the remaining balance of the credit in US Dollars by wire transfer in immediately available funds to such bank account as designated by Distributor no
later than [*] after the date this Agreement terminates. 
 3.2 Delivery Lead Time; Order Forecasts. 

3.2.1 Company will notify Distributor of the delivery date(s) for Products within [*] after receipt of Distributor’s purchase order placed
pursuant to Sections 3.2.3 or 3.3.2; provided that such delivery date(s) will be no longer than [*] from the date of Distributor’s purchase order. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 15. 

 3.2.2 Distributor shall, on a monthly basis commencing on the [*] of the month following the
month in which the Effective Date falls and thereafter within the initial [*] of each succeeding month, provide Company with Distributor’s good faith [*] forecast of Distributor’s monthly requirements for the Products, including the
NeuroStar Starter Package (each, an “Order Forecast”). Distributor’s first Order Forecast may not include any NeuroStar Starter Package for delivery in months [*] of such Order Forecast or have more than [*] of NeuroStar
Starter Package in months [*] of such Order Forecast except with Company’s consent in its sole discretion. Distributor may not adjust months [*] of any subsequent Order Forecast except with the consent of Company in its sole discretion. Until
Distributor issues a purchase order, Distributor may adjust the forecast for months five and six of any Order Forecast in succeeding Order Forecasts (i.e. when months [*] on an Order Forecast become months [*] on the next Order Forecast) to an
amount between [*] of the NeuroStar Starter Package per month. If Distributor adjusts the forecast for NeuroStar Starter Packages in month [*] of an Order Forecast to an amount greater than [*] in month [*] on the next Order Forecast, then Company
will use commercially reasonable efforts to respond within [*] as to the extent to which Company will be able to fulfill such a request by Distributor. If Company notifies Distributor that Company can fulfill such request, in whole or in part, then
the Order Forecast for the applicable month will be increased above [*] by the additional number of units that Company agrees to deliver in such month. If Company cannot fulfill such request by Distributor, then the Order Forecast will be [*] of the
NeuroStar Starter Package for the applicable month. Distributor agrees to use commercially reasonable efforts to make each Order Forecast as accurate as possible. 

3.2.3 Promptly after the Effective Date Company and Distributor shall discuss in good faith the initial quantity of Products other than the
NeuroStar Starter Package that Distributor will purchase from Company and the timing of when Distributor will place its initial purchase order for such Products. Distributor will place its initial purchase order for such quantities of such Products
and at such time as agreed by Company and Distributor. 
 3.3 Purchase Orders. 

3.3.1 During the Term, Distributor shall order Products from Company by submitting monthly written purchase orders identifying: Products
ordered by catalog number and quantity and requested delivery date(s); provided that: (a) NeuroStar Starter Packages shall be subject to a minimum individual order of [*]; (h) SenStar Treatment Links shall be subject to a minimum individual
order of [*], packaged in the 50 pack form; (c) Treatment Session Treatment Packs (200 Packs per box) shall be subject to a minimum individual order of [*]; and (d) spare parts can only be ordered on a quarterly basis in quantities to
replenish (or increase) Distributor’s normal inventory of spare parts (which normal inventory until the second anniversary of the date of Product Approval will be equal to or greater than Company’s recommended spare parts inventory level
and thereafter will be determined by Distributor with reference to its experience servicing the Products in the Territory for the installed base of NeuroStar Starter Packages in the Territory), except that until the second anniversary of the date of
Product Approval, if there is a stock out of a particular spare part or an unexpected need for a spare part not normally carried in inventory, Company will accept ad hoc purchase orders therefor. The NeuroStar Product cannot be ordered separate from
a NeuroStar Starter Package. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 16. 

 3.3.2 At the same time that Distributor sends each Order Forecast to the Company (and in any
event no later than the date by which Distributor must send the applicable Order Forecast to the Company), Distributor shall issue purchase orders to Company for the first [*] of requirements for each of the NeuroStar Starter Packages shown on such
Order Forecast and, after issuing the initial purchase order pursuant to Section 3.2.3, for such other Products as Distributor desires to order. Company may elect to treat months one through four of each Order Forecast as binding purchase
orders for NeuroStar Starter Packages if Distributor fails to issue the required purchase order on a timely basis. 
 3.3.3 An purchase
orders for Products are subject to acceptance by Company; provided that Company must accept a purchase order if the order complies with this Agreement including the limitations and requirements of Sections 3.2 and 3.3.1. If Company rejects a
purchase order that it is permitted to reject, Company shall notify Distributor within [*] after receiving the purchase order and state the reason(s) for rejecting the purchase order. If Company does not notify Distributor of the rejection of the
purchase order and state the reason(s) for rejecting the purchase order within the [*], the purchase order shall be deemed accepted. If Company does not accept a purchase order for Products, in whole or part, that otherwise complies with this
Agreement including the limitations and requirements of Sections 3.2 and 3.3.1, then Distributor shall receive a credit against its then-current Minimum Purchase Requirement for the amount of Products that Distributor would have paid Company if
Company had accepted the rejected portion of such purchase order. 
 3.3.4 Purchase orders placed by Distributor and accepted by Company and
the delivery of Products by Company pursuant to such purchase orders shall not be canceled or rescheduled unless mutually agreed upon by both Parties. 

3.3.5 If Company does not deliver NeuroStar Starter Packages or other Products by the dates set forth in purchase orders that Company has
accepted pursuant to this Section 3.3, other than by (a) Distributor not providing all shipping information required by Company including approved carriers, departure port, vessel and sail date within forty (45) days prior to shipment
or (b) damage, loss or other casualty while in transit from Company to the delivery point in the Territory, then, in addition to any other rights or remedies that Distributor may have, Company shall provide Distributor with a credit to be
applied toward Distributor’s future purchase of Products for each day that delivery of the Products is delayed over fifteen (15) days from the delivery date that shall be calculated by multiplying the purchase price of the Products for
which delivery is delayed times 6% and dividing the resulting amount by 360. 
 3.4 Minimum Purchase Requirement. 

3.4.1 After the 1st Qualifying Approval is obtained and for the remainder of the Term, Distributor shall be required to purchase a minimum
annual Dollar value of the Products from Company based on the sales forecasts for the Products in the Territory (“Minimum Purchase Requirement”) or pay Company the True-Up Payment (as
set forth in Section 3.4.5) unless this Agreement is terminated as set forth in Section 12, in which case Distributor’s Minimum Purchase Requirement and True-Up Payment obligations shall be as
set forth in Section 12, as applicable. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 17. 

 3.4.2 The sales forecast to be used to determine the Minimum Purchase Requirement for the period
from the date on which [*] (the “Initial Period”) is set forth in Schedule B (the “Initial Sales Forecast”). No later than [*] prior to the end of each Fiscal Year (starting with the last Fiscal
Year of the Initial Period), the Steering Committee shall meet and discuss in good faith the sales forecast of Products in the Territory for the next Fiscal Year of Distributor during the Term (each, “New Sales Forecast”). If
the Steering Committee and senior executive escalation process set forth in Section 2.5.5 does not result in an agreed New Sales Forecast for any such Fiscal Year by [*], then the New Sales Forecast for such Fiscal Year shall equal [*] However,
if the Company commences the sale or promotion of [*] Devices in the Territory, then [*] For clarity, each New Sales Forecast reflects the Dollar value of the forecasted amount of purchases of the Products by Distributor from Company during the
relevant Fiscal Year. 
 3.4.3 The Minimum Purchase Requirement for the Initial Period shall be [*]; provided, however, that all purchases of
Products after the Product Approval shall count toward satisfying the Minimum Purchase Requirement for the Initial Period. 
 3.4.4 For each
[*], the Minimum Purchase Requirement will be adjusted in accordance with the following: 
 (a) If Distributor’s purchases of Products
from Company [*] the Initial Sales Forecast for the Initial Period or the New Sales Forecast for any subsequent Fiscal Year, then the Minimum Purchase Requirement [*] for the next succeeding Fiscal Year shall be [*] (which by way of example means
that if Distributor [*] the Initial Sales Forecast for the Initial Period, then the Minimum Purchase Requirement for the next Fiscal Year shall be [*]; 

(b) If Distributor’s purchases of Products from Company [*] the Initial Sales Forecast for the Initial Period or the New Sales Forecast
for any subsequent Fiscal Year, then the Minimum Purchase Requirement [*] for the next succeeding Fiscal Year shall be [*]; 
 (c) Except as
set forth in Section 34.4(d), the Minimum Purchase Requirement [*] shall [*]; 
 (d) Notwithstanding Sections 3.4.4(a), 3.4.4(b) and
3.4.4(c), if Distributor commences sales of [*] Devices in the Territory, Company has not sold or promoted [*] Devices in the Territory prior thereto and Distributor’s Dollar value of purchases of Products during any Subsequent Year are [*] of
the [*] Minimum, then the Minimum Purchase Requirement for that Subsequent Year shall [*]; and 
 (e) The Minimum Purchase Requirement for
[*] shall not be more than [*] 
 3.4.5 Distributor shall satisfy its Minimum Purchase Requirement obligations for [*] by either:
(a) purchasing the Dollar value of Products from Company equal to the Minimum Purchase Requirement; or (b) paying Company an amount equal to [*] (each, a “True-Up Payment”).
Distributor shall pay Company each True-Up Payment within [*] and receipt of an invoice from Company. If Distributor satisfies its Minimum Purchase Requirement

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 18. 

 
obligations for any period under clause (b) Distributor shall also have the option to terminate this Agreement on [*] prior written notice to Company and [*]. For the avoidance of doubt,
payment of a True-Up Payment shall not be considered as achieving [*] for purposes of calculating Minimum Purchase Requirement [*]. 

3.5 Transfer Prices. 

3.5.1 The initial transfer price for each NeuroStar Starter Package shall be [*] (the “Initial Transfer Price”) [*]
(the “Fixed Transfer Price Period”). 
 3.5.2 The transfer price of the SenStar Treatment Link will be Sixty Dollars
($60) per one SenStar Treatment Link unit until Company [*] in accordance with Distributor’s reasonable requirements and Company [*]. If Company does not obtain a Reimbursement Approval in the Territory that [*] within [*], then Company and
Distributor shall discuss an adjustment in the transfer price of SenStar Treatment Links in good faith. Upon agreeing to an adjustment in the transfer price of SenStar Treatment Links, the Parties shall amend Schedule J to set forth the new agreed
upon transfer price for SenStar Treatment Links. 
 3.5.3 Until Reimbursement Approval that includes [*] is obtained in the Territory, the
transfer price for orders of [*] will be [*] during [*] and thereafter will be [*]. 
 3.5.4 Distributor must separately order NeuroStar
Treatment Packs as needed from Company. 
 3.5.5 The transfer price for orders of NSTS placed after the date of the Reimbursement Approval
will be determined as set forth in Schedule J for the Fixed Transfer Price Period; provided, however, that if during the Fixed Transfer Price Period the Reimbursement Rate changes, then the NSTS transfer price for orders placed after the
Reimbursement Rate change will be determined in accordance with Schedule J based on the new Reimbursement Rate. 
 3.5.6 The transfer
price for orders of all Products set forth on Schedule O but not set pursuant to Sections 3.5.1 through 3.5.5 will be as set forth on Schedule O and fixed for the Fixed Transfer Price Period. 

3.5.7 [*] prior to the end of the Fixed Transfer Price Period, Company and Distributor shall, through the Steering Committee, meet to discuss
in good faith changes to the transfer prices for the NeuroStar Starter Package and all other Products based on all relevant factors. All new transfer prices for such Products agreed to by Company and Distributor shall apply for a period of [*]. [*]
the Steering Committee shall meet and discuss in good faith changes to such transfer prices based on the factors set forth in the preceding sentence. If the Steering Committee and the escalation process does not result in mutually agreed revised
transfer prices as contemplated by this Section by [*] prior to the end of the Fixed Transfer Price Period or then-current [*], then the transfer prices shall be increased by [*] 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 19. 

 3.5.8 Company shall notify Distributor when Company commences development of a Product that
incorporates major improvements in functionality over the then-current version of the Product and provide periodic status reports regarding the development of such Product to Distributor. Prior to any sale of any Product in the Territory that
incorporates major improvements in functionality over the then current version of the Product, the Parties shall meet and discuss in good faith an adjustment to the transfer price for such Product. 

3.6 Resale Pricing. Distributor shall be free to establish its own resale pricing for Products that it distributes in the Territory.

 3.7 Shipping and Delivery Terms. 

3.7.1 Company shall ship all Products ordered by Distributor pursuant to this Agreement DDP (Incoterms 2010) cleared through customs to
Distributor’s or the Technical Support Company’s facility in Japan as notified by Distributor to Company in writing; provided that the following exceptions to DDP shall apply: (a) Company will use the carrier or carriers approved by
Distributor unless such carrier(s) indicate(s) that they cannot deliver the Products at least [*] prior to the applicable delivery date in which case Company may use an appropriate alternative carrier that is able to timely deliver the Products;
(b) Distributor will reimburse Company for the cost of shipping from Company’s warehouse to the point of delivery in the Territory, associated freight insurance and import duties and tariffs, which amounts Company will invoice to
Distributor on a pass-through basis within [*] after the end of each month and accompanied by copies of invoices or receipts that reasonably document the costs of shipping, insurance and import duties and tariffs for which Company is seeking
reimbursement from Distributor; and (c) Company’s liability to Distributor for damage, loss or other casualty to Products for the period from the shipment from Company’s warehouse to the delivery point in the Territory will be
exclusively limited to prompt re-supply of the same number of Products so damaged, lost or subject to casualty. Company will package each such shipment in accordance with standard practices acceptable to mode
of shipment chosen by Distributor unless Company is permitted pursuant to clause (a) of this Section 3.7.1 to use a different mode of shipping. 

3.7.2 If there is any shortage in the quantity of Products delivered by Company and Distributor notifies Company within [*] after delivery,
Company shall promptly deliver replacement Products in accordance with the terms of this Agreement at Company’s expense to make up such shortfall. 

3.8 Payment. Unless otherwise specified in this Agreement and unless subject to a bona fide dispute, Distributor shall pay all amounts
due and payable under this Agreement by the end of the month following the month in which the Products have been delivered in accordance with this Agreement and Distributor receives an invoice for such Products. Company reserves the right to
withhold shipments of Products or to require payment in full prior to shipment of Products in the event any amounts due Company by Distributor are past due unless such amounts are subject to a bona fide dispute. All such amounts, and any other
payment due pursuant to the terms of this Agreement, shall be paid by wire transfer in United States Dollars to the bank listed below (or such other wire transfer instructions or bank as Company may specify in writing from time to time) or by other
means specified in writing and mutually agreed by both Parties to: 
 Pay to: [*] 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 20. 

 Routing and transit no.:   [*] 

SWIFT Code:   [*] 
 For
credit of:  [*] 
 Final credit account no.:    [*] 

By order of:   (Sender’s name) 

All costs incurred in connection with any such wire transfer shall be the responsibility of Distributor. Amounts due under this Agreement
shall be considered paid as of the day such funds are received by the aforementioned bank. 
 3.9 Late Payments. In addition to the
other rights of Company under this Agreement, all amounts due and owing to Company under this Agreement, but not paid by Distributor on the due date thereof (excluding amounts subject to a bona fide dispute), shall bear interest (in U.S. Dollars) at
the lower of the of [*] per annum or the maximum lawful interest rate permitted under applicable law. Such interest shall accrue on the balance of unpaid amounts from time to time outstanding from the date on which portions of such amounts become
due and owing until payment thereof in full. 
 3.10 Return of Products. Distributor and Company shall follow the procedures set forth
in Schedule F with respect to allegedly Defective Products. 
 3.11 Governing Document. This Agreement, together with its Schedules,
shall supersede any additional, conflicting or supplemental terms used by Company or Distributor in the ordering, shipment and receiving of Products, including without limitation, any purchase orders or order acknowledgements other than ministerial
items such as shipping address, delivery date and quantities. 
 3.12 [*] Credit. If Distributor commences the sale of [*] Devices in
the Territory [*], then Company shall [*] 
 4. Regulatory Approvals; Distributor Approvals; Interactions with Regulatory Authorities. 

4.1 Regulatory Approvals. 

4.1.1 Company shall use commercially reasonable efforts to obtain and shall thereafter maintain all Regulatory Approvals including, in
connection with the first Regulatory Approval, a use results survey period (exclusivity) of [*] and shall provide all information required to be submitted to the Regulatory Authorities or which the Regulatory Authorities request in connection with
the Iryoukiki no Seizo Hanbai Go no Chousa oyobi Shiken no Jisshi no Kijun ni kansuru Shourei (Ministerial Ordinance on Standards for Post Market Surveillance and Testing of Medical Equipment); provided that Company shall not be required to
(a) undertake any clinical trial in order to obtain the Regulatory Approvals including post-marketing studies required by MHLW as a condition to granting any of the Regulatory Approvals unless Distributor agrees to fully fund such
post-marketing studies or (b) make changes to the form, fit or function of any of the Products, except as set forth in Section 6.1. Distributor shall reasonably cooperate with Company’s efforts to secure the Regulatory Approvals. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 21. 

 4.1.2 If, notwithstanding the exercise of its commercially reasonable efforts, Company does not
obtain the 1st Reimbursement Approval by the Reimbursement Approval Deadline, then Distributor may elect to take over the process for obtaining the Reimbursement Approval with the assistance of Vorpal or such other third party(ies) as Distributor
desires (the “Distributor 1st MHLW Lead Election”); provided that such election is made by written notice to Company within ninety (90) days after the Reimbursement Approval Deadline. If Distributor makes the Distributor
1st MHLW Lead Election, then Distributor shall use its commercially reasonable efforts during the Distributor 1st MHLW Lead Period to obtain the 1st Reimbursement Approval, subject to the termination rights set forth in Section 12.6.2. 

4.1.3 If Company obtains the 1st Reimbursement Approval by the Reimbursement Approval Deadline and either (a) the Reimbursement Rate is
[*] and neither Party terminates this Agreement pursuant to Section 12.7.1 or (b) the Reimbursement Rate is [*], then Company shall use its commercially reasonable efforts until the 1st Reimbursement Revision Approval is issued by MHLW to
attempt [*]. 
 4.1.4 If Company obtains the 1st Reimbursement Approval by the Reimbursement Approval Deadline and notwithstanding the
exercise of commercially reasonable efforts, Company is not able [*] then Distributor may elect to take over the process for obtaining the Reimbursement Approval with the assistance of Vorpal or such other third party(ies) as Distributor desires
(the “Distributor 2nd MHLW Lead Election”), provided that such election is made by written notice to Company within ninety (90) days after the date of the 1st Reimbursement Revision Approval. If Distributor makes the
Distributor 2nd MHLW Lead Election, then Distributor shall use its commercially reasonable efforts during the Distributor 2nd MHLW Lead Period [*] subject to the termination rights set forth in Section 12.8.2. 

4.2 Distributor Approvals. Distributor shall use commercially reasonable efforts to obtain and thereafter maintain all approvals,
permits and licenses not within the definition of Regulatory Approvals required for import, marketing and sale of the Products in accordance with the Product Approval including a medical device retail and leasing license for the Product in the
Territory (collectively, the “Distributor Approvals”). 
 4.3 Initial Designation of DMAH and Replacement.
Company’s Agent shall be the initial Designated Marketing Authorization Holder in the Territory. If Company is unable to be hold any of the Regulatory Approvals or Company’s Agent is unable to be the Designated Marketing Authorization
Holder in Japan or is unable to supply Distributor with Products as set forth in Section 6.3, Distributor shall have the right to become the MAH instead of Company and/or Company’s Agent for purposes of allowing Distributor to continue to
market and sell Products in the Territory for business continuity purposes. In such event, Company shall cooperate with Distributor to effect such changes. 

4.4 Interactions with Regulatory Authorities. 

4.4.1 Subject to Distributor’s rights set forth in Sections 4.1 and 4.3, Company is responsible for all interactions with regulatory
authorities in the Territory (including MHLW) which are conducted through the DMAH. Distributor shall reasonably assist Company in any 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 22. 

 
regulatory request or action by providing customer or product information that is requested by regulatory authorities worldwide from Company or the DMAH and support any regulatory actions
required in the Territory. Notwithstanding the foregoing, Distributor will lead all interactions with the MHLW concerning reimbursement during the Distributor 1st MHLW Lead Period and the Distributor
2nd MHLW Lead Period and Company shall reasonably assist Distributor. 
 4.4.2 Company
and the DMAH are responsible for medical device reporting for complaints and/or adverse event reports, conducting such reporting to regulatory agencies in the Territory in compliance with applicable regulatory timelines and regulations, and for
reporting complaints and/or adverse event reports to any other jurisdiction including, but not limited, to the United States. Company is also responsible for working with the DMAH on any issues that arise in clearing the Products through customs in
the Territory. For the avoidance of doubt, Distributor shall have no such responsibility. 
 5. Distributor’s Duties. 

5.1 Distributor’s Efforts. Upon Company’s receipt of the Regulatory Approvals, Distributor shall use its commercially
reasonable efforts to diligently promote the sale of Products in the Territory, in compliance with Applicable Law. Distributor shall do nothing to detract from the good name of Company or the reputation of Products. Without limiting the generality
of the foregoing, Distributor shall have the following obligations with respect to the advertising, promotion, marketing, distribution and sale of Products: 

5.1.1 To undertake its marketing, promotional, distributional and selling activities for the Products in the Territory at its own risk and
expense using a field sales force as soon as reasonably commercially practical after receipt of the Regulatory Approvals; 
 5.1.2 To install
and maintain all Products sold to Distributor and its Affiliates in the Territory; 
 5.1.3 To negotiate in good faith the terms of a
memorandum of good vigilance practice with the DMAH and to comply with the terms of that memorandum once agreed to; 
 5.1.4 To use
commercially reasonable efforts to advertise and promote Products diligently in the Territory, in compliance with Applicable Laws as soon as commercially reasonable after receipt of the Regulatory Approvals; 

5.1.5 To attend and assist at trade shows, physician meetings and other professional gatherings in the Territory, to the extent Distributor
deems it appropriate to promote the sale of Products as soon as reasonably practical after receipt of the Regulatory Approvals. From time to time, Company may make specific reasonable requests of Distributor to attend or assist in international
trade shows, physician meetings and other professional gatherings outside the Territory; 
 5.1.6 To maintain an adequate inventory of
Products and spare parts to support the installed base of Products in the Territory; 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 23. 

 5.1.7 To work according to, and perform its responsibilities under, the Distributor Quality Plan;

 5.1.8 To follow-up on sales leads from potential customers in the Territory referred to
Distributor by Company; 
 5.1.9 Provide Company prior to the commencement of each Fiscal Year: (a) an annual financial forecast in the
Territory that includes Distributor’s assumptions for the Territory; and (b) Distributor’s annual marketing plan that includes information concerning Competitive Product that Distributor is then aware of, trade shows and workshops to
be held in the Territory, advertising and promotion for the Product in the Territory and product and marketing needs in the Territory; and 

5.1.10 Within [*] after the end of each calendar quarter, provide Company with a report describing performance against the then-current sales
forecast (i.e. Initial Sales Forecast or then-current New Sales Forecast) and marketing plan and a brief summary of the reasons for positive and negative variances from such sales forecast and plan with the format of such report being substantially
in the form of Schedule G. The provision of such information to Company does not, in and of itself, provide Company with a right to terminate this Agreement that is independent from and/or in addition to Company’s express termination
rights under this Agreement. 
 5.2 Clinical Studies. 

5.2.1 Except as set forth in Section 5.2.2, Distributor shall not conduct or otherwise support any study of the Products in the Territory
without the prior written consent of Company. 
 5.2.2 Distributor shall solely fund all post-marketing clinical studies in the Territory
subsequently agreed to by Distributor and Company in writing but excluding all post-marketing studies in the Territory required by the MHLW in connection with obtaining the Regulatory Approvals. Distributor’s obligations under this
Section 5.2.2 shall be limited to the direct expenses of clinical studies incurred by Company after the Effective Date and Distributor shall have no obligation with respect to any costs and expenses incurred prior to the Effective Date. 

5.2.3 Distributor shall reasonably cooperate with Company concerning the implementation of clinical studies of the Products in the Territory
described in Section 5.2.2 for the Major Depressive Disorder indications referred to therein. 
 5.3 TrakStar Computer.
Distributor shall be responsible for obtaining and supplying to each purchaser of the NeuroStar Product a TrakStar Computer that is dedicated to use with the NeuroStar Product. Distributor may charge the customer whatever price it determines for the
TrakStar Computer and, as between Distributor and Company, shall be solely responsible for all warranties and service with respect to the TrakStar Computer. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 24. 

 5.4 Company Audit Rights. Distributor shall ensure that an independent third party
selected by Company and reasonably acceptable to Distributor and the Regulatory Authorities, to the extent permitted by Applicable Law, may, during regular business hours, after entering into a confidentiality agreement reasonably acceptable to
Distributor and upon reasonable advance written notice, not more than once annually, (a) examine and inspect Distributor’s facilities or, subject to any third party confidentiality restrictions and other obligations, the facilities of any
Affiliate or Sales Representatives involved in the promotion or sales of the Products in the Territory, and (b) subject to Applicable Law and any third party confidentiality restrictions and other obligations, inspect all data, documentation
and work product relating to the activities performed by Distributor and Distributor’s Affiliates and Sales Representatives engaged in the promotion and sales of Products in the Territory solely for the purposes of determining
Distributor’s compliance with the terms of this Agreement. If an audit discloses that Distributor is not in material compliance with the terms of this Agreement, then notwithstanding the previous sentence Company shall have the right to conduct
a follow-up audit during the same year or thereafter to confirm that the deficiencies discovered during the initial audit have been corrected by Distributor and Distributor is in material compliance with the
terms of this Agreement. This right of Company to audit and inspect the data and documentation of Distributor and Distributor’s Affiliates and Sales Representatives involved in the promotion and sales of the Products in the Territory may be
exercised at any time during the Term upon reasonable notice (subject to each Party’s record retention policies then in effect), or such longer period as shall be required by Applicable Law. 

5.5 Payments to Government Officials. 

5.5.1 Distributor shall not directly or indirectly, for the purpose of obtaining approval, promoting, selling or distributing Products, offer,
pay, or promise to pay, or provide any money, service, gift, or thing of value to any official, agent, employee or representative of a government or government agency such as a public hospital (hereafter collectively “Government
Official”), and shall otherwise comply with the laws and regulations then in effect, if any, governing interactions with Government Officials, including but not limited to, the U.S. Foreign Corrupt Practices Act to the extent applicable
to Distributor (hereafter, the “Anti-Corruption Laws”). Distributor further makes the following representations and warranties as of the Effective Date and covenants in connection with its activities related to this
Agreement: 
 (a) Distributor and its Affiliates are solely responsible for complying, have to its best knowledge complied, and shall
comply, with the Anti-Corruption Laws in connection with performing the obligations of Distributor set forth in this Agreement and have to the best of its and their knowledge not taken and shall not take or fail to take any action, which act or
failure would subject Company to liability under Anti-Corruption Laws in connection with performing the obligations of Distributor set forth in this Agreement; and 

(b) Neither Distributor nor any of its Affiliates has, to its or their best knowledge, offered, paid, given or loaned or promised to pay, give
or loan, or will not offer, pay, give or loan or promise to pay, give or loan, directly or indirectly, money or any other thing of value to or for the benefit of any Government Official in connection with performing the obligations of Distributor
set forth in this Agreement, for the purposes of corruptly: (i) 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 25. 

 
influencing any act or decision of such Government Official in his official capacity; (ii) inducing such Government Official to do or omit to do any act in violation of his lawful duty;
(iii) securing any improper advantage; or (iv) inducing such Government Official to use his influence with a government entity to affect or influence any act or decision of that Government Official, in each instance to direct business to
Distributor or Company. 
 5.5.2 Distributor shall assist and cooperate fully with the efforts of Company to comply with the Anti-Corruption
Laws. In particular, Distributor shall keep accurate books and records and Distributor shall immediately notify Company of any information that bribes or other improper payments are being requested, made or offered by Distributor or its Affiliates
in connection with this Agreement. Upon request of Company, with Distributor’s prior written consent and to the extent applicable to Distributor, Distributor shall make those records which are necessary for Company to verify Distributor’s
compliance with the Anti-Corruption Laws relating to this Agreement available to an auditor selected by Company. If such auditor notices any failure by Distributor to comply with the Anti-Corruption Laws, Distributor agrees that the auditor may
disclose information relating to such Distributor’s failure to Company and, to the extent required by a legal demand by a competent court of law or government body, to third parties. 

5.5.3 Distributor shall truthfully and accurately complete the distributor qualification form and anti-bribery certification which are attached
to Schedule H and deliver such documents to Company promptly after the Effective Date and dated the Effective Date. On each anniversary of the Effective Date during the Term, or the next succeeding business day if any anniversary is not a
business day, Distributor shall deliver to Company an updated anti-bribery certification using Company’s form of anti-bribery certification then required by Company’s anti-bribery and anti-corruption policy (currently document number 14-00023-001, Rev. A). 
 5.5.4 In no event shall Company be
obligated to Distributor under or in connection with this Agreement to act or refrain from acting if Company believes that such act or omission would cause Company to be in violation of the Anti-Corruption Laws. In no event shall Company be liable
to Distributor for any act or omission which Company believes is necessary to comply with the Applicable Law. In no event shall Distributor be obligated to Company under or in connection with this Agreement to act or refrain from acting if
Distributor believes that such act or omission would cause Distributor to be in violation of the Anti-Corruption Laws. In no event shall Distributor be liable to Company for any act or omission which Distributor believes is necessary to comply with
Applicable Law. 
 5.5.5 If Distributor or any of its Affiliates breaches any of the representations, warranties or covenants in this
Section 5.5, and each of which is deemed to be material and continuously made throughout the Term, then, in addition to any other rights Company may have under this Agreement: 

(a) Company may declare a forfeit of any unpaid amounts owing to Distributor and shall be entitled to repayment of any amounts paid or
credited to Distributor, in each case, which are prohibited by the Anti-Corruption Laws; and 
 (b) Company may immediately terminate this
Agreement upon written notice to Distributor. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 26. 

 5.6 Compliance with Code of Conduct for Interactions with Healthcare Providers.
Distributor agrees to comply with the Japan Federation of Medical Devices Associations’: (a) Code of Ethics, as amended from time to time; and (b) Promotion Code of the Medical Devices Industry, as amended from time to time ((a) and (b),
together, the “Code”), and to ensure that all marketing and sales interactions with customers will be conducted in compliance with the Code. 

5.7 Sales and Clinical Training. Distributor shall be responsible for training its personnel who promote Products so that they are
knowledgeable about Products and can represent Products in accordance with the terms of this Agreement and in compliance with Applicable Law. Company shall provide initial training to Distributor’s personnel at Company’s cost and expense
as set forth in Schedule C. Distributor may, at its discretion, have Company provide additional training to its personnel at Distributor’s cost and expense as set forth in Schedule C. 

5.8 Attendance at Meetings. At Company’s request, Distributor shall, at its own expense, have a representative(s) attend a sales
meeting sponsored by Company at least once each year during the Term. 
 5.9 Technical Support. Distributor shall be responsible for
training its personnel who provide technical services for the Products in the Territory or arrange to train personnel of Distributor’s Technical Support Company who will provide technical services for the Products in the Territory. In the
Territory, Distributor shall itself or through its Technical Support Company maintain service personnel qualified to provide repair service and technical support for Products during its normal business hours. 

5.10 Non-Compete. Distributor covenants that during [*], Distributor shall not directly or
indirectly itself or through any Affiliate or licensee manufacture, promote, market, distribute or sell, or assist in the promotion, marketing, distribution or sale of any Competitive Product in the
Pre-Reimbursement Approval Channel or Post-Reimbursement Approval Channel in the Territory; provided, however, that [*] 

6. Company’s Duties. 
 6.1
Development of Products. Subject to the terms and conditions of this Agreement, Company and Distributor shall use commercially reasonable efforts to develop [*], in each case in accordance with [*]. Without limiting the generality of the
foregoing, the Parties shall hold a kick-off meeting regarding development of [*] no later than [*] and work together to reach as soon as reasonably possible a mutually agreed architecture, specification,
development plan and timeline for the development of [*] Development Plan”). Upon the Parties agreeing to the [*] Development Plan in writing, the Company will use its commercially reasonable efforts to develop the [*] in
accordance with the [*] Development Plan and Distributor will reasonably cooperate with and provide such assistance to Company as may be set forth in the [*] Development Plan. After [*], the Parties will discuss in good faith a development agreement
covering [*] under which agreement Distributor would be required to fund such development activities. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 27. 

 6.2 Supply of Products. Subject to the terms and conditions of this Agreement, Company
shall manufacture and supply Distributor’s requirements of the Products that fully meet the Specifications and in full compliance with Applicable Law; provided that following the receipt of the 1St Reimbursement Approval and Company making NSTS
available in the Territory, Company may discontinue SenStar Treatment Link. 
 6.3 Company Inability to Supply Products. If Company
receives a written notice alleging Company’s material breach of or default under any loan or debt financing agreement (the “Default Notice”) and Distributor reasonably determines that such breach or default will result
in Company not being able to supply Distributor with an amount of Product to satisfy the then-current New Sales Forecast or, if for any reason, Company is unable to supply Distributor with Products meeting at least [*], then, in addition to any
other remedies available to Distributor at law or in equity or otherwise pursuant to this Agreement, (a) Distributor may order directly from Company’s contract manufacturers quantities of Products sufficient to satisfy Distributor’s
forecasts that Distributor continues to provide to Company in accordance with Section 3.2 as well as all Products which Company was unable to manufacture and sell to Distributor and (b) all Products that Distributor orders from
Company’s contract manufacturers and all Products that Company was unable to supply and are not supplied by Company’s contract manufacturers shall count toward satisfying Distributor’s Minimum Purchase Requirement at the prices set
forth in this Agreement. As soon as Company is able to demonstrate, to Distributor’s reasonable satisfaction, that Company may resume supply in a manner that complies with this Agreement, Distributor will no longer have the right to place
orders for the Products with Company’s contract manufacturers. Further, until the earlier of a Change of Control of Company or Company’s securities being publicly listed on a securities exchange, Company shall provide quarterly financial
statements to Distributor and immediately notify Distributor of Company’s receipt of a notice alleging Company’s material breach of or default under any loan or debt financing agreement. 

6.4 Technical and Promotional Materials. Company shall furnish Distributor with Company’s technical, clinical and safety
information as reasonably required by Distributor to evaluate, market, promote, distribute and sell Products in the Territory. Without limiting the generality of the foregoing, Company shall provide Distributor with one (1) copy of all
Documentation electronically within [*] after the Effective Date if available as of the Effective Date or [*] after finalization by Company if not available as of the Effective Date. 

6.5 Promotional Materials. Company shall furnish Distributor with Company’s brochures and other marketing materials, which
Distributor may use to prepare its own advertising and promotional materials for use in the Territory. 
 6.6 Marketing Support.
Company shall provide commercially reasonable support to Distributor in connection with Distributor’s marketing, promotion and distribution of the Products in the Territory. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 28. 

 6.7 Product Changes. If Company desires to change (i) the form, fit or function or
(ii) any part, process or manufacturer, which change will require the approval of any of the Regulatory Authorities or would be expected to have a material impact on quality control processes or the quality of the Products, then Company shall
provide Distributor with [*] prior written notice and shall obtain all Regulatory Approvals necessary to allow Distributor to import, market, promote, distribute and sell such changed Product in the Territory as a medical device for the treatment of
Major Depressive Disorder indications that are substantially similar to the Major Depressive Disorder indications for which the Product is then approved in the Territory. Company shall not discontinue any Product unless (a) Company provides
Distributor with at least six (6) months prior written notice of the discontinuance, (b) Company introduces a new Product for use in the Territory that retains reasonably comparable or better functionality as the discontinued Product and
(c) ensures that repair service and compatible service parts and components necessary for after-sales service of the discontinued Products remain available until the earlier of the date that is: (i) [*] after Company discontinues any Product;
or (ii) the end of the Term. 
 6.8 Recall. Company and the DMAH have sole authority to issue a recall or require corrective
action with respect to Products in the Territory (collectively, the “Recall”) including those required by Applicable Law or a regulatory authority in the Territory. In the case of any Recall, Company and DMAH shall be
responsible to plan and lead the Recall with input from the Distributor, and Distributor shall be responsible for executing the plan within the Territory including communications with customers, performing all field activities in the Territory and,
if necessary, the physical return of the Product from the Territory. The Parties shall fully cooperate with each other concerning any Recall. Except to the extent that the Recall is caused by Distributor’s negligence (such improper installation
or service of the Products) or breach of this Agreement, Company shall provide Distributor with replacement Products free of charge and shall reimburse Distributor for its
out-of-pocket expenses and technical service labor at Distributor’s then-current list price for labor. If the Recall is caused by Distributor’s negligence or
Distributor’s material breach of this Agreement, Distributor shall be responsible for the cost of replacement Products and all its expenses incurred in the Recall. 

6.9 Safety Information. Company shall provide to Distributor copies of any correspondence it provides to MHLW or other regulatory
authority in the Territory concerning safety issues with respect to the Products (whether experienced inside or outside the Territory) promptly after sending such correspondence to MHLW or the applicable regulatory authority. 

6.10 Technical Training. Company shall provide initial technical support training to Distributor’s personnel as set forth in
Schedule C at Company’s expense. Distributor may require Company to provide additional technical training to Distributor personnel to be held at a location or locations to be determined by Distributor and at Distributor’s expense as
set forth in Schedule C. 
 6.11 Technical Support. Company shall provide technical support in accordance
with Schedule K. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 29. 

 6.12 Distributor Audit Rights. Company shall ensure that an independent third party
selected by Distributor and reasonably acceptable to Company and any Regulatory Authorities, to the extent permitted by Applicable Law, may, during regular business hours, after entering into a confidentiality agreement reasonably acceptable to
Company and upon reasonable advance written notice, not more than once annually, (i) examine and inspect Company’s facilities or, subject to any third party confidentiality restrictions and other obligations, the facilities of any
subcontractor and the facilities of the DMAH and Company’s Agent, and (ii) subject to Applicable Law and any third party confidentiality restrictions and other obligations, inspect all data, documentation and work product relating to the
activities performed by Company, its subcontractors, DMAH and Company’s Agent, including relating to the Products and their manufacture, solely for the purposes of determining Company’s compliance with the terms of this Agreement. This
right of Distributor to audit and inspect the data, documentation, and work product of the Company, its subcontractors, the DMAH and Company Agent may be exercised at any time during the Term upon reasonable notice (subject to each Party’s
record retention policies then in effect), or such longer period as shall be required by Applicable Law. 
 7. Intellectual Property. 

7.1 Company’s Registration of Trademarks. Promptly after the Effective Date, the Company shall register the English language
Company Trademarks not yet registered in the Territory and the katakana Company Trademarks in the Territory and, once obtained, maintain the registration of such Company Trademarks in the Territory during the Term. 

7.2 Distributor’s Use of Company Trademarks. 

7.2.1 Company hereby grants to Distributor an exclusive (except for those to whom Company may sell Products in the Territory as set forth in
Section 2.1), royalty-free, non-transferable, license to use the Company Trademarks during the Term to import, market, promote, distribute and sell the Products in the
Pre-Reimbursement Approval Channel and Post-Reimbursement Approval Channel in the Territory, with the rights to grant sublicenses to Distributor’s Affiliates, Sales Representatives, subdistributors and
customers. 
 7.2.2 Distributor shall brand the Products with the Company Trademarks at no cost to Distributor; provided that Distributor
shall also have the right to co-brand the Products with Distributor’s trademarks approved by Company (“Distributor Trademarks”), such approval not to be unreasonably withheld. The
ownership of Distributor Trademarks used to co-brand the Products shall remain with Distributor, and Company shall have no rights with respect to the Distributor Trademarks, except for a limited royalty-free
license to use after termination of this Agreement by either Party any Distributor Trademarks that Distributor develops and uses solely in connection with the promotion and distribution of the Products in the Territory. 

7.2.3 Distributor shall use Company Trademarks in accordance with Company’s trademark usage guidelines, a draft of which Company has
provided to Distributor prior to the Effective Date and which Company may update and finalize prior to Distributor promoting sales of Products in the Territory. Company may update such guidelines from time to time on at least [*] prior written
notice; provided that Distributor will not be required to destroy 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 30. 

 
marketing collateral based on the guidelines previously in effect and already produced or under a non-cancelable contract or a contract cancelable only
with a penalty or other payment obligation for production as of the date of such notice. Company shall retain all right, title and interest in and to all Company Trademarks and all usage of the Company Trademarks by Distributor shall inure to the
benefit of Company, except to the extent related to the Distributor Trademarks. Distributor shall take no steps to register any Company Trademarks or any other mark confusingly similar to any of the Company Trademarks, and upon the Transition
Effective Date, Distributor shall not initiate any new use of the Company Trademarks. Distributor shall not use Company Trademarks in any manner that is disparaging or that otherwise portrays Company or Products in a negative light. Company shall
not apply to register the Distributor Trademarks or any trademarks that combine Distributor Trademarks and Company Trademarks in any jurisdiction. 

7.3 Software. 
 7.3.1
Company hereby grants to Distributor a limited, non-exclusive, non-transferable, royalty-free and non-sublicensable right (except
to the Technical Support Company and to customers as set forth in this Section 7.3.1) and license to: (a) use the Software to demonstrate, maintain and support the Products; and (b) supply licensed copies of the Software and grant
sublicenses to use the Software to purchasers of the NeuroStar Products in the Territory solely for use with the Products or a TrakStar Computer (the “Limited License”). For the avoidance of doubt, the Limited License will
remain in effect after expiration or termination of this Agreement solely to allow Distributor’s customers to continue using Products purchased prior to expiration or termination of the Agreement. Distributor obtains no right, title or interest
in or to the Software, except for the Limited License granted pursuant hereto, and Company and its licensors reserve all rights not expressly granted. 

7.3.2 Distributor or the Technical Support Company shall be responsible for loading the TrakStar Software onto the TrakStar Computer and for
loading all new versions, releases updates and bug fixes to the Software released after the applicable Product is placed into inventory at Company’s warehouse. Company shall supply to Distributor or the Technical Support Company, as directed by
Distributor, all new versions, releases, updates and bug fixes to the Software in such format as to enable the Distributor or Technical Support Company to install such new version, release, update or bug fix in the Products purchased by
Distributor’s customers in the Territory and the TrackStar Computer, as applicable. 
 7.3.3 Except as set forth in this
Section 7.3, Distributor may not loan, rent, lease, license or otherwise transfer to any other person, or host on behalf of any other person, the Software, and may not copy, modify, remove, disintegrate, create derivative works from or tamper
with the Software. 
 7.3.4 Distributor shall require all purchasers of the NeuroStar Product in the Territory to enter in an agreement of
sale that contains at least the terms attached to Schedule I for which Distributor may prepare a Japanese version that is revised so as to be enforceable in accordance with the laws of the Territory and in accordance with local custom and
practice (the “Minimum Terms and Conditions of Sale”). Company may update the Minimum Terms and 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 31. 

 
Conditions of Sale from time to time on at least [*] prior written notice to Distributor. Company shall consider in good faith any comments that Distributor may have regarding any updates to the
Minimum Terms and Conditions of Sale. Distributor shall update its terms and conditions of sale for the NeuroStar Product as promptly as possible after expiration of such [*] so as to be consistent with the updated Minimum Terms and Conditions of
Sale, enforceable in accordance with the laws of the Territory and in accordance with local custom and practice and ensure that all new customers for the Products after the completion of the notice period (that is, customers who have not previously
purchased Products from Distributor and who are not purchasing through a purchasing cooperative or other entity that already has a contract with Distributor for the purchase of Products) enter into an agreement of sale that includes at least the
updated Minimum Terms and Conditions of Sale as modified to be in accordance with the laws of the Territory and in accordance with local custom and practice. 

7.3.5 Except as expressly permitted under Applicable Law, Distributor may not decompile, reverse engineer or disassemble the Software and may
not disintegrate the Redistributable Code from the Software. 
 7.4 Documentation. Distributor may copy and distribute the
Documentation as necessary to maintain, support and service the Products; provided that it shall maintain all Company Trademarks and copyright notices thereon. Company hereby grants to Distributor a limited, royalty-free, non-exclusive, non-transferable, and non-sublicensable right and license (except to the Technical Support Company) to: (a) copy,
use and distribute the Documentation to demonstrate, maintain, support and service the Products; and (b) create Japanese versions of the Documentation and copy, use and distribute such translated versions of the Documentation to demonstrate,
maintain, support and service the Products and supply such Documentation to the Technical Support Company and purchasers of the Product in the Territory. Distributor obtains no right, title or interest in or to the Documentation, except as expressly
set forth in this Section 7.4, and Company reserves all rights not expressly granted. 
 7.5 Marketing Materials. Company may
from time to time provide Distributor with certain materials such as, but not limited to: demonstration Products, models, advertising materials, booklets and brochures, reprints of technical articles and marketing plans (the “Marketing
Materials”). The Marketing Materials shall remain the sole property of Company and any such Marketing Materials remaining in the possession of Distributor shall be promptly destroyed, at Distributor’s expense, upon request any time
after the expiration of this Agreement; provided that Distributor may continue to use the Marketing Materials and will not be required to destroy the Marketing Materials until Distributor’s rights under Section 13.2 expire. Distributor
shall also have the right to cross link to Company’s website and to use Company Trademarks on its website to promote and sell the Products in the Territory. 

7.6 Intellectual Property Rights. Except as set forth in this Section 7, Distributor shall have no rights to any intellectual
property rights of Company. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 32. 

 8. Confidential Information. 

8.1 Confidential Information. As used in this Agreement, the term “Confidential Information” means all
information, whether it be written or oral, including all production schedules, lines of products, volumes of business, processes, new product developments, product designs, formulae, technical information, laboratory data, clinical data, patent
information, know-how, trade secrets, financial and strategic information, marketing and promotional information and data, and other material relating to any products, projects or processes of one Party (the
“Disclosing Party”) that is provided to, or otherwise obtained by, the other Party (the “Receiving Party”) in connection with this Agreement. Notwithstanding the foregoing sentence, Confidential
Information shall not include any information or materials that: 
 8.1.1 were already known to the Receiving Party (other than under an
obligation of confidentiality), at the time of disclosure by the Disclosing Party, to the extent such Receiving Party has documentary evidence to that effect; 

8.1.2 were generally available to the public or otherwise part of the public domain at the time of disclosure thereof to the Receiving Party;

 8.1.3 became generally available to the public or otherwise part of the public domain after disclosure or development thereof, as the case
may be, and other than through any act or omission of a Party in breach of such Party’s confidentiality obligations under this Agreement; 

8.1.4 were disclosed to a Party, other than under an obligation of confidentiality, by a third party who had no obligation to the Disclosing
Party not to disclose such information to others; or 
 8.1.5 were independently discovered or developed by or on behalf of the Receiving
Party without the use of the Confidential Information belonging to the other Party, to the extent such Receiving Party has documentary evidence to that effect. 

8.2 Confidentiality Obligations. Each of Distributor and Company shall keep all Confidential Information received from or on behalf of
the other Party with the same degree of care with which it maintains the confidentiality of its own Confidential Information, but in all cases no less than a reasonable degree of care. Neither Party shall use such Confidential Information for any
purpose other than in performance of its obligations or the exercise of its rights pursuant to this Agreement or disclose the same to any other person other than to such of its and its Affiliates’ directors, managers, employees, independent
contractors, agents, consultants or sublicensees who have a need to know such Confidential Information to implement the terms of this Agreement or enforce its rights under this Agreement; provided, however, that a Receiving Party shall advise any of
its and its Affiliates’ directors, managers, employees, independent contractors, agents, consultants or sublicensees who receives such Confidential Information of the confidential nature thereof and of the obligations contained in this
Agreement relating thereto, and the Receiving Party shall ensure (including, in the case of a third party, by means of a written agreement with such third party having terms at least as protective as those contained in this Section 8) that all
such directors, managers, employees, independent contractors, agents, consultants or sublicensees comply with such obligations. Upon 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 33. 

 
expiration or termination of this Agreement, the Receiving Party shall return or destroy all documents, tapes or other media containing Confidential Information of the Disclosing Party that
remain in the possession of the Receiving Party or its directors, managers, employees, independent contractors, agents, consultants or sublicensees, except that the Receiving Party may keep one copy of the Confidential Information in the legal
department files of the Receiving Party, solely for archival purposes. Such archival copy shall be deemed to be the property of the Disclosing Party, and shall continue to be subject to the provisions of this Section 8. It is understood that
receipt of Confidential Information under this Agreement will not limit the Receiving Party from assigning its employees to any particular job or task in any way it may choose, subject to causing such employees to comply with this Section 8.

 8.3 Permitted Disclosure and Use. Notwithstanding Section 8.2 either Party may disclose Confidential Information belonging to
the other Party to the extent such disclosure is reasonably necessary to: (a) comply with or enforce any of the provisions of this Agreement, (b) comply with Applicable Law or (c) to the extent such disclosure is reasonably necessary
to obtain or maintain regulatory approval of a Product, to the extent such disclosure is made to a Governmental Authority. If a Receiving Party deems it necessary to disclose Confidential Information of the Disclosing Party pursuant to this
Section 8.3, the Receiving Party shall give reasonable advance written notice of such disclosure to the Disclosing Party to permit the Disclosing Party sufficient opportunity to object to such disclosure or to take measures to ensure
confidential treatment of such information, including seeking a protective order or other appropriate remedy. Notwithstanding Section 8.2, Distributor may also disclose Confidential Information belonging to Company related to Product
(i) to third parties in connection with the promotion, marketing and sales of Products in the Territory and (ii) to potential subdistributors and potential Sales Representatives (provided that such third parties in clauses (i) and
(ii) are bound by written agreements having terms at least as protective as those contained in this Section 8 with respect to keeping such Confidential Information confidential). The Receiving Party shall notify the Disclosing Party promptly
upon discovery of any unauthorized use or disclosure of the Disclosing Party’s Confidential Information, and will cooperate with the Disclosing Party in any reasonably requested fashion to assist the Disclosing Party to regain possession of
such Confidential Information and to prevent its further unauthorized use or disclosure. 
 8.4 Notification. In the event that a
Receiving Party becomes aware that a third party recipient of Confidential Information has breached its confidentiality obligations, then the Receiving Party shall promptly inform the Disclosing Party of such event, and the Parties will cooperate in
their investigation of such occurrence and enforcement of the provisions of the relevant confidentiality agreement. 
 8.5 Publicity;
Filing of this Agreement. Each Party shall maintain the confidentiality of all provisions of this Agreement, and without the prior written consent of the other Party, which consent shall not be unreasonably withheld, neither Party nor its
respective Affiliates shall make any press release or other public announcement of or otherwise publicly disclose the provisions of this Agreement to any third party, except for: (a) disclosures required any national securities exchange and any
other disclosures made pursuant to any listing agreement with a national securities exchange, in which case the disclosing Party shall provide the nondisclosing 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 34. 

 
Party with at least [*] notice unless otherwise not practicable, but in any event no later than the time the disclosure required by the regulations of the applicable national securities exchange
or listing agreement is made, and (b) disclosures as may be required by Applicable Law, in which case the disclosing Party shall provide the nondisclosing Party with prompt advance notice of such disclosure and cooperate with the nondisclosing
Party to seek a protective order or other appropriate remedy, including a request for confidential treatment in the case of Company for a filing with the Securities and Exchange Commission; and (c) other disclosures for which consent has
previously been given. A Party may publicly disclose without regard to the preceding requirements of this Section 8.5 any information that was previously publicly disclosed pursuant to this Section 8.5. 

8.6 Use of Names. Except as otherwise set forth in this Agreement, neither Party shall use the name of the other Party in relation to
this transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld. 

8.7 No Implied Licenses. All right, title and interest in and to the Disclosing Party’s Confidential Information, including,
without limitation, any intellectual property rights related thereto, shall remain with the Disclosing Party, subject to the limited licenses or rights to use granted to the Receiving Party in this Agreement. Except as otherwise provided in this
Agreement, neither this Agreement, nor the cooperation of the Parties during the Term, shall be deemed to grant to the Receiving Party any right or licenses, express or implied, under any patents or patent applications, or to use or practice any know-how, technology or inventions, owned or controlled by Disclosing Party. Nothing in this Agreement shall be construed to prevent the Disclosing Party from exploiting the Disclosing Party’s Confidential
Information and all patent and other intellectual property rights therein and appurtenant thereto in any manner for any purpose. 
 8.8
Survival. The obligations and prohibitions contained in this Section 8 as they apply to Confidential Information shall survive the expiration or termination of this Agreement for a period of [*]. 

9. Representations and Warranties. 
 9.1
Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party as follows, as of the Effective Date: 

9.1.1 Corporate Existence and Power. It is a company or corporation duly organized, validly existing, and in good standing (only in the
case of Company) under the laws of the jurisdiction in which it is incorporated and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and
as contemplated in this Agreement, including the right to grant the licenses granted by it hereunder. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 35. 

 9.1.2 Authority and Binding Agreement. (a) It has the corporate power and authority
and the legal right to enter into this Agreement and perform its obligations hereunder, (b) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its
obligations hereunder, and (c) this Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms, except
as enforcement may be affected by bankruptcy, insolvency or other similar laws and by general principles of equity. 
 9.1.3 No
Conflicts. The execution, delivery and performance of this Agreement in accordance with its terms by it does not (a) conflict with any agreement, instrument or understanding, oral or written, to which it is a party and by which it may be
bound or (b) violate any Applicable Law. 
 9.1.4 All Consents and Approvals Obtained. Except with respect to the Regulatory
Approvals and Distributor Approvals, (a) all necessary consents, approvals and authorizations of, and (b) all notices to, and filings with all Governmental Authorities and third parties required to be obtained or provided by such Party in
connection with the execution, delivery and performance of this Agreement have been obtained. 
 9.2 Additional Representations,
Warranties and Covenants of Company. Company hereby represents, warrants and covenants to Distributor that: 
 9.2.1 To the knowledge of
Company, the design, manufacture, marketing, sale, offer for sale, importation and use of the Products, Software and the System as of the Effective Date for treatment of Major Depressive Disorder do not infringe or misappropriate the intellectual
property rights of any third party. 
 9.2.2 No claim has been made to Company in writing which alleges that the design, manufacture,
marketing, sale, offer for sale, importation or use of the Products, Software or the System for treatment of Major Depressive Disorder infringes or misappropriates the intellectual property rights of a third party. 

9.2.3 Except with respect to the Redistributable Code, Company is the sole legal and beneficial owner of all Software and intellectual property
rights related thereto, free and clear of any liens or other encumbrances. 
 9.2.4 Company’s agreements with all third parties for the
Redistributable Code are in full force and effect, are enforceable in accordance with their terms by Company and, to Company’s knowledge, the third parties thereto and such agreements will not cease to be so valid and binding and in full force
and effect as a result of the transactions contemplated by this Agreement. 
 9.2.5 Company is the sole legal and beneficial owner of the
Company Trademarks, free and clear of any liens or other encumbrances. To Company’s knowledge (a) there is no reason that would prevent Company from registering the katakana Company Trademarks in the Territory in the IC classes indicated
in Schedule D and (b) no third party is using (other than [*]) or infringing the Company Trademarks in the Territory. Company has not entered (other than a non-exclusive license agreement with [*])
nor during the Term will enter 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 36. 

 
into any agreement granting any right, interest or claim in or to, any Company Trademarks for use in connection with the promotion, import into the Territory, distribution or sale of Products in
the Pre-Reimbursement Approval Channel or Post-Reimbursement Approval Channel to any third party other than non-exclusive license agreements with Eye-Lens and/or [*] that would not interfere with or impair rights granted to Distributor pursuant to this Agreement. 

9.2.6 There is no pending or, to Company’s knowledge, threatened legal, administrative, arbitral or other proceeding, claim, suit or
action against or, to the knowledge of the Company, any governmental or regulatory investigation of Company, nor any injunction, order, judgment, ruling or decree imposed upon or, to Company’s knowledge, threatened to be imposed upon Company
involving the Products, System, Software, Trademarks or Company’s failure to comply with Applicable Law with respect to the Products or that would potentially prevent Company from fulfilling its obligations set forth in this Agreement. 

9.2.7 Neither Company, its Affiliates nor, to Company’s knowledge, its shareholders have entered into any agreement for, or are currently
in any negotiations for, a Change of Control of Company. 
 9.2.8 Company’s agreements with all contract manufacturers for the Products
are in full force and effect, are enforceable in accordance with their terms by Company and, to Company’s knowledge, the third parties thereto and such agreements will not cease to be so valid and binding and in full force and effect as a
result of the transactions contemplated by this Agreement. 
 9.2.9 Company has obtained the written agreement of Company’s contract
manufacturers to accept and honor all orders placed by Distributor pursuant to Section 6.3. 
 9.2.10 To Company’s knowledge, all
work related to obtaining the Regulatory Approvals has been performed in accordance with all Applicable Law. 
 9.2.11 Company has a valid
Foreign Manufacturer Accreditation in respect of the Products and will maintain the Foreign Manufacturer Accreditation during the Term of this Agreement. 

9.3 Limited Product Warranty. 

9.3.1 Company warrants to Distributor that each unit of Product sold to Distributor under this Agreement and the Software distributed in
connection therewith shall: (a) at the time of delivery be free of liens, claims and encumbrances; (b) at the time of delivery comply with the Specifications; and (c) be free from Defects until the earlier of [*] after the date of
installation of such unit of the Product at the end-user customer and [*] after delivery of such unit of the Product to Distributor pursuant to Section 3.7.1 (for the applicable unit of the Product, the
“Warranty Period”). The foregoing warranties set forth in clause (c) of this Section 9.3.1 apply only if Products have not been mishandled, damaged or altered after delivery of the Products to Distributor pursuant
to Section 3.7.1. All claims in respect of the warranty set forth in the foregoing sentence must be made no later than the Warranty Period, and Company shall have no responsibility for claims for breach of the warranty set forth in this
Section 9.3.1 made 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 37. 

 
after expiration of the applicable Warranty Period. Notwithstanding anything to the contrary in this Agreement: (i) the warranties set forth in this Section 9.3.1 shall not apply to any
Defect caused by improper installation or Distributor’s or its customer’s failure to maintain such Products in accordance with documentation provided by Company to Distributor sufficiently prior to such failure so as to have allowed
Distributor or Distributor’s customer a reasonably opportunity to have avoided such failure, provided that such documentation complies with Applicable Law and the provisions of this Agreement; and (ii) Company shall not be obligated to
furnish service under such warranty: (1) to repair damage resulting from attempts by personnel other than Company representatives to repair Products, except for personnel of Distributor or the Technical Service Company who have attempted to
repair damage in accordance with documentation provided by Company to Distributor or the Technical Service Company and caused no additional damage or (2) to repair damage resulting from connection to incompatible equipment or use other than as
set forth in documentation provided by Company to Distributor prior to the occurrence of the Defect. 
 9.3.2 If during the Warranty Period
for a particular unit of Product (other than the Software), Distributor claims that a Product or component thereof does not comply with the warranties set forth in Section 9.3.1, Distributor shall return the allegedly defective Product(s) or
component to Company in accordance with Section 3.10; provided that (a) units of NeuroStar Product that experience an Out of Box Failure may not be returned to Company except in accordance with Section 9.3.5 and (b) for the
avoidance of doubt, in the case of alleged defects that can be addressed by replacement of a part or a field replacement unit, only the alleged defective part or field replacement unit may be returned to Company. Upon confirmation by Company that
the Product(s) do not comply with the foregoing warranties and that the Warranty Period for Product(s) did not expire prior to Distributor making the warranty claim, Company shall at its option and expense and, as Distributor’s sole and
exclusive remedy for Company’s breach of the warranty set forth in Section 9.3.1, repair or replace the defective Product(s) and ship the repaired or replaced Product(s) to Distributor at Company’s expense, or credit
Distributor’s account for such Product(s), provided, however that notwithstanding any other provision of this Agreement, Company itself shall have no obligation to provide repair or other labor services with personnel located in the Territory
(including any labor to uninstall or install any parts). As to alleged Defective Software, upon confirmation by the Company that the Software does not comply with the warranties set forth in Section 9.3.1, Company shall as Distributor’s
sole and exclusive remedy for Company’s breach of the warranties set forth in Section 9.3.1 promptly provide Distributor with a work around, bug fix, patch or other support services that restores operation of the Software to be in
substantial compliance with the Software Documentation. If Company determines that the Product(s) or Software comply with the warranties set forth in Section 9.3.1 or that the Warranty Period for the Product(s) expired prior to Distributor
making the warranty claim, Company shall notify Distributor of such fact and provide to Distributor a report setting forth the analysis and reasoning supporting such determination by the Company (“Warranty Report”). In such a
case Company shall have no obligation to provide warranty service and shall instead comply with Distributor’s direction regarding the disposition of such Product at Distributor’s expense. For the avoidance of doubt, the provisions of this
Section 9.3.2 shall in no way limit Company’s indemnification obligations set forth in Section 10. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 38. 

 9.3.3 If Distributor disagrees with the conclusions set forth in Company’s Warranty Report,
then each Party shall appoint a senior manager to meet and discuss in good faith whether the returned Products contain any Defects. If such senior managers are unable to reach agreement on whether the returned Products contain any Defects within a
period of [*], then either Party may request that an independent third party expert reasonably acceptable to the other Party review the Warranty Report and the returned Products, determine whether the Products contain any Defects and issue a written
report to both Parties describing the review conducted by the third party expert, the determination of whether the returned Products contain any Defects and the reasons for the third party experts determination. The costs of the third party expert
shall be equally borne by each Party. If Company agrees with Distributor as to the existence of Defects in the returned Products, the results of Company’s analysis of the returned Products confirms the existence of a Defect in the Products or
the third party expert concludes that there is a Defect in the returned Products and in all cases that the Warranty Period for the Product(s) did not expire prior to Distributor making the warranty claim, then Company will comply with the remedies
set forth in Section 9.3.1. 
 9.3.4 The cost of
out-of-warranty repairs is subject to Company’s then-current charges. Distributor must authorize such charges prior to Company performing any such repairs. All
charges shall be authorized by Distributor issuing a purchase order therefor. 
 9.3.5 In the case of an Out of Box Failure, Distributor or
its Technical Support Company will, in accordance with the procedures in Schedule K, contact Company’s technical support department and follow all steps recommended by Company to address the Out of Box Failure such that all non-conformances and failures are corrected and the NeuroStar OUS Installation Record ([*]) can be completed showing all items and criteria thereon as complete and satisfied. [*] If after following all steps
recommended by Company to address the Out of Box Failure, a non-conformance or failure continues to prevent Distributor or its Technical Support Company from completing the NeuroStar OUS Installation Record
([*]) showing all items and criteria thereon as complete and satisfied, then Distributor shall return the allegedly defective NeuroStar Starter Package to Company in accordance with Section 3.10. 

9.3.6 Following Distributor’s [*] of NeuroStar Starter Packages at customer locations, Distributor and Company will discuss in good faith
the visual inspection procedure set forth on Schedule E and whether and what adjustments to such procedures should be made to assure high customer satisfaction at time of installation. 

10. Indemnification. 
 10.1
Indemnification. 
 10.1.1 Notwithstanding anything to the contrary contained herein, Distributor shall indemnify, defend and hold
Company and its directors, officers, employees and agents harmless from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) (collectively,
“Losses”) arising in connection with any and all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands, judgments, orders, decrees, stipulations or injunctions by a third party (each a
“Third  

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 39. 

 
Party Claim”) that: (a) seeks recovery of Losses claimed by the employees or agents of Distributor or its Affiliates; (b) asserts breach of warranties made by
Distributor or its Affiliates to purchasers of the Products in the Territory different from or in addition to those made in by Company in this Agreement with respect to the Products; and/or (c) seeks recovery of damages for injury to persons or
damage to property or any other liabilities caused by the willful act, recklessness or negligence of Distributor or its Affiliates, in each case except to the extent that such Losses are subject to indemnification by the Company pursuant to
Section 10.1.2. 
 10.1.2 Notwithstanding anything to the contrary contained herein, Company shall indemnify, defend and hold
Distributor and its directors, officers, employees and agents harmless from and against any and all Losses and arising in connection with any and all Third Party Claims resulting or otherwise arising from: (a) any personal injuries, illness,
death and/or property damages resulting from any Defective Product, which for purposes of this Section 
 10.1.3 shall include design defects
in the Products; (b) any infringement of third party intellectual property rights by the import, marketing, promotion, sale or use of the Products, System, Software or Company Trademarks in the Territory in accordance with this Agreement; and
(c) the negligence, recklessness or willful misconduct of Company and/or the DMAH, in each case except to the extent that such Losses are subject to indemnification by Distributor pursuant to Section 10.1.1. 

10.1.4 In no event shall Company have any obligation or liability to Distributor under this Section 10.1 for any Losses suffered by a
third party as a result of: 
 (a) Distributor or its Affiliates making any warranty, express or implied, to customers that is different
from Company’s warranty set forth in Section 9.3.1; 
 (b) Any design, cosmetic or functional change in Product made intentionally
by Distributor or its Affiliates, except as Distributor may do so in accordance with the Documentation or pursuant to operation of the Software; 

(c) Distributor or its Affiliates not storing, handling, or transporting the Products in accordance with the Documentation provided by Company
to Distributor or service performed by or on behalf of Distributor or any of its Affiliates not in accordance with Documentation provided to Distributor by Company; or 

(d) Distributor or its Affiliates labeling or relabeling Products as any other product or a component of any other product, except that
Distributor or its Affiliates may attach labels to Products in compliance with Applicable Law in the Territory. 
 10.2 Indemnification
Procedures. 
 10.2.1 Notice of Claim. All indemnification claims in respect of any indemnitee seeking indemnity under
Section 10.1.1 or 10.1.2, as applicable (collectively, the “Indemnitees” and each an “Indemnitee”) will be made solely by the corresponding Party (the “Indemnified Party”).
The Indemnified Party will give the indemnifying Party (the “Indemnifying Party”) prompt written notice (an “Indemnification Claim Notice”) of any Losses and any legal

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 40. 

 
proceeding initiated by a Third Party against the Indemnified Party as to which the Indemnified Party intends to make a request for indemnification under 10.1.1 or 10.1.2, as applicable, but in
no event will the Indemnifying Party be liable for any Losses that result from any delay in providing such notice which materially prejudices the defense of such proceeding. Each Indemnification Claim Notice shall contain a description of the claim
and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such time). Together with the Indemnification Claim Notice, the Indemnified Party will furnish promptly to the Indemnifying Party copies of
all notices and documents (including court papers) received by any Indemnitee in connection with the Third Party Claim. 
 10.2.2 Control
of Defense. At its option, the Indemnifying Party may assume the defense of any Third Party Claim subject to indemnification as provided for in 10.1.1 or 10.1.2, as applicable, by giving written notice to the Indemnified Party within thirty
(30) days after the Indemnifying Party’s receipt of an Indemnification Claim Notice. Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal
counsel it selects, and such Indemnifying Party shall thereafter continue to defend such Third Party Claim in good faith. Should the Indemnifying Party assume the defense of a Third Party Claim (and continue to defend such Third Party Claim in good
faith), the Indemnifying Party will not be liable to the Indemnified Party or any other Indemnitee for any legal expenses subsequently incurred by such Indemnified Party or other Indemnitee in connection with the analysis, defense or settlement of
the Third Party Claim, unless the Indemnifying Party has failed to assume the defense and employ counsel in accordance with this Section 10.2.2. 

10.2.3 Right to Participate in Defense. Without limiting Section 10.2.2, any Indemnitee will be entitled to participate in the
defense of a Third Party Claim for which it has sought indemnification hereunder and to employ counsel of its choice for such purpose; provided, however, that such employment will be at the Indemnitee’s own expense unless (a) the
employment thereof has been specifically authorized by the Indemnifying Party in writing, or (b) the Indemnifying Party has failed to assume the defense (or continue to defend such Third Party Claim in good faith) and employ counsel in
accordance with Section 10.2.2, in which case the Indemnified Party will be allowed to control the defense. 
 10.2.4 Settlement.
With respect to any Losses relating solely to the payment of money damages in connection with a Third Party Claim and that will not result in the Indemnitee becoming subject to injunctive relief and as to which the Indemnifying Party will have
acknowledged in writing the obligation to indemnify the Indemnitee hereunder, the Indemnifying Party will have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the
Indemnifying Party, in its reasonable discretion, will deem appropriate (provided, however, that such terms shall include a complete and unconditional release of the Indemnified Party from all liability with respect thereto), and will transfer to
the Indemnified Party all amounts which said Indemnified Party will be liable to pay prior to the time of the entry of judgment. With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the
defense of the Third Party Claim in accordance with Section 10.2.2, the Indemnifying Party will have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss,

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 41. 

 
provided it obtains the prior written consent of the Indemnified Party (which consent will be at the Indemnified Party’s reasonable discretion). The Indemnifying Party that has assumed the
defense of (and continues to defend) the Third Party Claim in accordance with Section 10.2.2 will not be liable for any settlement or other disposition of a Loss by an Indemnitee that is reached without the written consent of such Indemnifying
Party. Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnitee will admit any liability with respect to, or settle, compromise or discharge, any Third Party Claim without first offering to the
Indemnifying Party the opportunity to assume the defense of the Third Party Claim in accordance with Section 10.2.2. 
 10.2.5
Cooperation. If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party will, and will cause each other Indemnitee to, cooperate in the defense or prosecution thereof and will furnish such records,
information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection with such Third Party Claim. Such cooperation will include access during
normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making Indemnitees and other employees and agents
available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party will reimburse the Indemnified Party for all its reasonable out-of-pocket expenses incurred in connection with such cooperation. 
 10.2.6 Expenses of the
Indemnified Party. Except as provided above, the reasonable and verifiable costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any Third Party Claim will be reimbursed on a
calendar quarter basis by the Indemnifying Party, without prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held
not to be obligated to indemnify the Indemnified Party. 
 11. Risk Allocation. 

11.1 Disclaimer. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES SET FORTH IN SECTIONS 9.1, 9.2 AND 9.3, COMPANY MAKES NO OTHER WARRANTIES
OR REPRESENTATIONS, EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, AND COMPANY AND ITS THIRD PARTY SUPPLIERS (IF ANY) HEREBY DISCLAIM ALL OTHER WARRANTIES, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE,
MERCHANTABILITY, AND NON-INFRINGEMENT. 
 11.2 Limitation of Liability. 

11.2.1 WITH THE EXCEPTION OF LIABILITY FOR INDEMNIFICATION UNDER SECTION 10 OR LIABILITY RESULTING FROM INFRINGEMENT OF INTELLECTUAL PROPERTY
RIGHTS, GROSS NEGLIGENCE, WILLFUL MISCONDUCT 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 42. 

 
OR BREACH OF SECTION 8, NEITHER PARTY (THE FIRST PARTY) SHALL BE LIABLE TO THE OTHER PARTY OR ANY THIRD PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, PUNITIVE OR OTHER SIMILAR
DAMAGES (INCLUDING, WITHOUT LIMITATION, ANY LOST PROFITS OR LOST REVENUES) UNDER ANY THEORY OF LIABILITY. THIS LIMITATION SHALL APPLY EVEN WHERE THE FIRST PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

11.2.2 WITH THE EXCEPTION OF LIABILITY FOR INDEMNIFICATION UNDER SECTION 10 OR LIABILITY RESULTING FROM INFRINGEMENT OF INTELLECTUAL PROPERTY
RIGHTS, GROSS NEGLIGENCE, WILLFUL MISCONDUCT OR BREACH OF SECTION 8, IN NO EVENT SHALL COMPANY’S LIABILITY TO DISTRIBUTOR, REGARDLESS OF THE THEORY OF LIABILITY, EXCEED THE GREATER OF (A) US$5 MILLION OR (B) THE AMOUNTS RECEIVED BY
COMPANY FROM DISTRIBUTOR UNDER THIS AGREEMENT (EXCLUSIVE OF REIMBURSEMENT OF PASS THROUGH EXPENSES SUCH AS SHIPPING COSTS AND DUTIES) IN THE TWELVE (12) MONTHS PRIOR TO THE ACCRUAL OF THE CLAIM. 

11.3 Insurance. Each Party shall procure and maintain insurance, including comprehensive general public liability insurance and product
liability insurance, and, in the case of Company clinical trial insurance, adequate and appropriate to cover its obligations hereunder. Certificates of insurance evidencing such coverage will be made available to the other Party upon written
request. 
 12. Term and Termination. 

12.1 Term. The term of this Agreement shall commence on the Effective Date and extend up to and until the end of the seventh (7th) Fiscal Year after Company receives the Product Approval, subject to earlier termination as provided below in this Section 12 (the “Initial Term”). The term of this
Agreement shall be automatically extended for additional periods of two (2) Fiscal Years each such that the remaining term of the Agreement is four (4) years (the Initial Term, as so extended from time to time, the
“Term”) unless either Party provides the other Party with written notice of non-extension not later than two (2) years prior to the end of the Term; provided, however, that if
during the Initial Term Distributor purchases Products from Company totaling at least one hundred percent (100%) of the Dollar value set forth in the Initial Sales Forecast plus one hundred percent (100%) of the Dollar value set forth in each of the
New Sales Forecasts for each subsequent Fiscal Year of the Initial Term, or during the first two (2) Fiscal Years of each extension of the Term, Distributor purchases Products from the Company totaling one hundred percent (100%) of the Dollar
value set forth in each New Sales Forecast for such two (2) Fiscal Years, then (a) any previous notice of non-extension provided by Company shall be null and void and (b) the Term will be
automatically extended for an additional two (2) Fiscal Years. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 43. 

 12.2 Termination for Cost-Sharing, Safety or Use Survey. 

12.2.1 Notwithstanding any other provision of this Agreement, Distributor may terminate this Agreement at any time if Distributor reasonably
believes that it is not commercially reasonable for Distributor to continue to distribute the Products in the Territory for reasons including, but not limited to, safety, efficacy, an unfavorable Reimbursement Rate (which must be below [*] to be
considered unfavorable), introduction of competitive product(s), by providing prior written notice to Company and a reasonable explanation and documentation to Company that supports Distributor’s belief. Upon receipt of such written notice and
explanation with documentation, Company and Distributor shall discuss the matter in good faith for a period of ninety (90) days. If at the end of such ninety (90) day period Distributor and Company cannot agree on whether it is
commercially reasonable for Distributor to continue to distribute the Products in the Territory, or cannot agree on modifications to this Agreement that would make it commercially reasonable for Distributor to continue to distribute the Products,
including revisions to the Minimum Purchase Requirement, True-Up Payment and/or transfer prices, then Distributor may terminate this Agreement by providing one (1) year prior written notice to Company,
and no Minimum Purchase Requirement or True-Up Payment shall apply during such one (1) year period but the Minimum Purchase Requirement for the period prior to notice of termination shall be satisfied or True-Up Payment made and Initial Milestone Payment 2 and Milestone Payment 2 shall not be adjusted or refunded. 

12.2.2 Notwithstanding any other provision of this Agreement, Distributor may immediately terminate this Agreement if notwithstanding the
exercise of its commercially reasonable efforts Company does not obtain a use results survey period (exclusivity) of at least forty eight (48) months in connection with the first Regulatory Approvals; provided that Distributor sends notice of
termination to Company within thirty (30) days after Distributor receives written notice from Company that the use results survey period (exclusivity) is less than forty eight (48) months. If Distributor terminates this Agreement under
this Section 12.2.2, then the Agreement will remain in effect for one year after Distributor sends notice to Company, and no Minimum Purchase Requirement or True-Up Payment shall apply during such one
year period, provided, however, that notwithstanding Section 2.1.1 Distributor will become a non-exclusive distributor during such one year period, and the restrictions on Company promoting or selling
Products in the Territory in the Pre-Reimbursement Approval Channel and the Post-Reimbursement Approval Channel set forth in Sections 2.1.1, 2.1.3 and 2.1.5 shall not apply during such one year period. 

12.3 Termination for Breach. Subject to the other rights of termination set forth in this Agreement, either Party may terminate this
Agreement at any time in the event the other Party breaches this Agreement upon prior written notice to the breaching Party describing the breach in detail and giving the breaching Party thirty (30) days to cure the breach. If the breach has
not been cured within thirty (30) days of receipt of such notice, the Party giving such notice may immediately terminate this Agreement upon notice to the breaching Party. If a breaching Party who has been given written notice and cured a
breach subsequently commits the same breach within six (6) months of such earlier breach, then the other non-breaching Party shall have the right to immediately terminate this Agreement by providing
notice to the breaching Party and the breaching Party shall have no further opportunity to cure. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 44. 

 12.4 Termination for Failure to Achieve the Product Approval. Either Party may terminate
this Agreement immediately by providing prior notice to the other Party in the event that, notwithstanding the exercise of its commercially reasonable efforts, Company does not obtain the first Product Approval and the DMAH within one (1) year
after the Effective Date. 
 12.5 Termination for Failure to Achieve the Distributor Approvals. Company may terminate this Agreement
at time by providing sixty (60) days prior written notice to Distributor in the event Distributor does not obtain the Distributor Approvals within ninety (90) days after the Effective Date or at any time fails to maintain the Distributor
Approvals. If Company terminates this Agreement under this Section 12.5 due to Distributor’s failure to maintain the Distributor Approvals, then Initial Milestone Payment 2 and Milestone Payment 2 shall not be adjusted or refunded and no
Minimum Purchase Requirement or True-Up Payment obligations shall apply to such sixty (60) day period (but shall apply with respect to prior periods on a pro rata basis). 

12.6 Termination for Failure to Achieve the 1st Reimbursement Approval. 

12.6.1 Distributor may terminate this Agreement by providing written notice to Company if, notwithstanding the exercise of its commercially
reasonable efforts, Company does not obtain the 1st Reimbursement Approval by the Reimbursement Approval Deadline. Distributor must provide such written notice to Company no later than ninety (90) days after the Reimbursement Approval Deadline
for such termination to be effective and if Distributor does not provide such written notice with such ninety (90) day period, then Company may terminate this Agreement on written notice to Distributor. Upon a Party giving notice of termination
under this Section 12.6.1, this Agreement shall terminate one (1) year from the date of the notice of termination and, for the avoidance of doubt, Initial Milestone Payment 2 and Milestone Payment 2 shall not be made and no Minimum
Purchase Requirement shall apply during such one (1) year period. 
 12.6.2 If Distributor does not obtain the 1st Reimbursement
Approval by the end of the Distributor 1st MHLW Lead Period or if during the Distributor 1st MHLW Lead Period Distributor decides to cease its commercially reasonable efforts to obtain the 1st Reimbursement Approval, then either Party may terminate
this Agreement by providing written notice to the other Party. If a Party terminates this Agreement under this Section 12.6.2, then this Agreement shall terminate one (1) year from the date of the Party’s written notice of termination
and, for the avoidance of doubt, no Minimum Purchase Requirement shall apply during the Distributor 1st MHLW Lead Period or such one (1) year period and no adjustment or refund shall be made to Milestone Payment 2 already paid. 

12.7 Termination for Failure to Achieve [*] Reimbursement Price. 

12.7.1 Either Party may terminate this Agreement by providing written notice to other Party if Company obtains the 1st Reimbursement Approval
by the Reimbursement Approval Deadline and the Reimbursement Rate in the 1st Reimbursement Approval is [*]. A Party must provide such written notice to other Party no later than ninety (90) days after the date of the 1st Reimbursement Approval
and if neither Party provides such written notice within such 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 45. 

 
ninety (90) day period, then both Parties’ rights under this Section 12.7.1 are rendered null and void. If a Party timely provides its notice of termination under this
Section 12.7.1, then this Agreement shall terminate one (1) year from the date of the Party’s written notice of termination and, for the avoidance of doubt, Initial Milestone Payment 2 and Milestone Payment 2 shall not be made and no
Minimum Purchase Requirement shall apply during such one (1) year period. 
 12.7.2 Either Party may terminate this Agreement by
providing written notice to other Party if the Reimbursement Rate in the 1st Reimbursement Revision Approval is [*]. A Party must provide such written notice to other Party no later than ninety (90) days after the date of the 1st Reimbursement
Revision Approval and if neither Party provides such written notice within such ninety (90) day period, then both Parties’ rights under this Section 12.7.2 are rendered null and void. If a Party timely provides its notice of
termination under this Section 12.7.2, then this Agreement shall terminate one (1) year from the date of the Party’s written notice of termination and, for the avoidance of doubt, Milestone Payment 2 shall be calculated and paid as
set forth in Sections 3.1.6(a) and 3.1.7, and no Minimum Purchase Requirement or True-Up Payment obligations shall apply during such one (1) year period (but shall apply with respect to prior periods).

 12.8 Termination for Failure to Achieve [*] Reimbursement Price. 

12.8.1 Distributor may terminate this Agreement by providing written notice to Company if, notwithstanding the exercise of its commercially
reasonable efforts, Company is not able to increase or maintain the Reimbursement Rate in the 1st Reimbursement Revision Approval to an amount [*]. Distributor must provide such written notice to Company no later than ninety (90) days after the
date of the 1st Reimbursement Revision Approval for such termination to be effective. If Distributor does not provide such written notice within such ninety (90) day period and also does not make the Distributor 2nd MHLW Lead Election under Section 4.1.4 within such ninety (90) day period, then Company may terminate this Agreement on written notice to Distributor. Upon a Party giving notice of
termination under this Section 12.8.1, then this Agreement shall terminate one (1) year from the date of the notice of termination, Milestone Payment 2 shall be paid in accordance with Sections 3.1.5(b), 3.1.6(d) and 3.1.7, as applicable,
and no Minimum Purchase Requirement or True-Up Payment obligations shall apply during such one (1) year period (but shall apply with respect to prior periods). 

12.8.2 If following completion of the Distributor 2nd MHLW Lead Period, Distributor does not obtain a Reimbursement Approval with a
Reimbursement Rate [*] or if during the Distributor 2nd MHLW Lead Period Distributor decides to cease its efforts to attempt to obtain an increased Reimbursement Rate, then either Party may terminate this Agreement by providing written notice to the
other Party. If a Party provides its notice of termination under this Section 12.8.2, then this Agreement shall terminate one (1) year from the date of the Party’s written notice of termination and, for the avoidance of doubt, Initial
Milestone Payment 2 and Milestone Payment 2 shall not be adjusted or refunded and no Minimum Purchase Requirement or True-Up Payment obligations shall apply during such one (1) year period (but shall
apply with respect to prior periods). 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 46. 

 12.9 Termination for Failure to Achieve [*] of Initial Sales Forecast. For a period of
thirty (30) days after the end of the Initial Period, Company may terminate this Agreement by providing one (1) year prior written notice to Distributor if, during the Initial Period, Distributor fails to purchase Products from Company
totaling at least [*] of the Dollar value set forth in the Initial Sales Forecast. If Company exercises its right to terminate this Agreement pursuant to this Section 12.9, then Distributor shall be required to pay Company the True-Up Payment for the Initial Period, however, Distributor shall, following such notice, have no Minimum Purchase Requirement or True-Up Payment obligations for the one
(1) year termination period. 
 12.10 Termination for Failure to Achieve [*] of Fiscal Year Forecast. For a period of thirty
(30) days following the completion of each Fiscal Year, Company may terminate this Agreement by providing one (1) year prior written notice to Distributor if, during such Fiscal Year, Distributor fails to purchase Products from Company
totaling [*] of the Dollar value set forth in the New Sales Forecast for such Fiscal Year. If Company exercises its right to terminate this Agreement pursuant to this Section 12.10, then Distributor shall be required to pay Company the True-Up Payment for the just completed Fiscal Year; however, Distributor shall, following such notice, have no Minimum Purchase Requirement or True-Up Payment obligations for
the one (1) year termination period. 
 12.11 Rolling Termination Right. Company may terminate this Agreement by providing one
(1) year prior written notice to Distributor in the event that if in any two (2) consecutive Fiscal Years after the Initial Period, Distributor fails to purchase Products from Company totaling [*] of the combined Dollar value set forth in
the New Sales Forecasts for such two (2) consecutive Fiscal Years, provided that such notice is given within thirty (30) days after the end of the second Fiscal Year (the “Rolling Termination Right”). [However, if
in either of the two (2) consecutive Fiscal Years used in determining whether the Rolling Termination Right applies, Distributor purchases Products from Company totaling [*] of the Dollar value set forth in the New Sales Forecasts for such
Fiscal Year, then the Rolling Termination Right shall not apply in respect of such two (2) consecutive Fiscal Years. If Company exercises its right to terminate this Agreement pursuant to this Section 12.11, Distributor shall have no
Minimum Purchase Requirement or True-Up Payment obligations for the one (1) year termination period. 

12.12 Termination for Insolvency. Upon the filing of a petition in bankruptcy, insolvency, or reorganization against or by either Party,
or either Party becoming subject to a composition for creditors, whether by law or agreement, or either Party going into receivership or otherwise becoming insolvent (the “Insolvent Party”), this Agreement may be terminated
by the other Party by giving written notice of termination to the Insolvent Party, such termination being effective immediately upon giving of such notice. If, during the Term, in Distributor’s reasonable opinion the Company experiences
financial difficulties including, without limitation, material breach of a loan agreement or default under any debt instrument or security, then upon written notice by Distributor, the Company and Distributor shall enter into good faith discussions
regarding an amendment to the Agreement that would allow Distributor to exclusively continue the distribution and sale of Products in the Territory notwithstanding the financial difficulties of the Company. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 47. 

 12.13 Effects of Termination. Termination or expiration of this Agreement for any reason
will be without prejudice to any rights that will have accrued to the benefit of a Party prior to the effective date of termination or expiration. Distributor hereby expressly and irrevocably waives any rights and claims to any compensation (for
goodwill, recoupment of investment or otherwise) or indemnity, in each case resulting from the termination or non-renewal of this Agreement in accordance with its terms. 

12.14 Survival. The following provisions shall survive expiration or termination of this Agreement: Sections 5.10 (to the extent set
forth therein), 7.2, 7.3, 7.5, 8 (to the extent set forth in Section 8.8), 9.3, and Sections 10 through 14. If any period for such survival is set forth in the foregoing referenced sections, such section shall survive for the specified period.

 13. Transition In Connection with Termination of this Agreement. 

13.1 Transition. Except in the event Distributor terminates this Agreement pursuant to Sections 12.3, 12.4 or 12.12 promptly upon notice
of termination or, if no notice of termination has by then been sent, beginning [*] prior to the expiration of this Agreement, Distributor and Company shall use reasonably cooperate with each other to smoothly transition maintenance, repair and
other customer support functions to Company and in connection therewith, the Parties shall prepare a joint communication acceptable to both Parties to be sent to such customers regarding the transition. Upon the effective date of expiration or
termination of this Agreement, Company (or its agent(s), assignee(s) or designee(s)) shall accept the regulatory, marketing, sales and service responsibilities for the Products in the Territory and Distributor shall have no such responsibilities.
Such responsibilities shall include, but are not limited to, distributing, marketing, selling, shipping, billing and collecting. 
 13.2
Inventory. During the transition period described in Section 13.1, Distributor shall have the right to continue to purchase and sell the Product for use in the Pre-Reimbursement Approval Channel
and Post-Reimbursement Approval Channel in the Territory. Company will apply all unused [*] Credits and credits provided by Company pursuant to Sections 3.1.8, 3.3.5, and 9.3.2 first against Company’s invoices for purchases made during this
period. Within sixty (60) days after the effective date of expiration or termination of this Agreement, Company will repurchase from Distributor any marketable remaining Product inventory as of the effective date of expiration or termination of
this Agreement at Distributor’s acquisition transfer price; provided, however, that Products are in good and saleable condition and in their original packaging. Shipment of repurchased Products will be effected by Distributor for Company’s
account in accordance with Company’s instructions. No later than forty-five (45) days after receipt of the repurchased Products by Company, Company will pay Distributor in cash by wire transfer to such bank account as designated by
Distributor (a) the purchase price for the repurchased Products and (b) the remaining balance of any unused [*] Credits and credits provided by Company pursuant to Sections 3.1.8, 3.3.5, or 9.3.2 as of the effective date of expiration or
termination of this Agreement. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 48. 

 14. General Provisions. 

14.1 Dispute Resolution. Except as provided in Section 14.2, each Party shall use its best efforts to resolve any dispute between
them promptly and amicably and without resort to any legal process if feasible within [*] of receipt of a written notice by one Party to the other Party of the existence of such dispute. Except as provided in Section 14.2, no further action may
be taken under this Section 14.1 unless and until executive officers of each of the Parties have met in good faith to discuss and settle such dispute. The foregoing requirement in this Section 14.1 shall be without prejudice to either
Party’s rights, if applicable, to terminate this Agreement under Section 12. 
 14.2 Litigation Rights Reserved. If any
dispute arises with regard to the alleged breach of Sections 5.10, 7, or 8, a Party may seek any available remedy at law or in equity from a court of competent jurisdiction. 

14.3 Governing Law. This Agreement, and its formation, operation and performance shall be governed, construed, performed and enforced in
accordance with the substantive laws of the State of New York, U.S.A., excluding: (a) its choice of law rules; and (b) the United Nations Convention on Contracts for the International Sale of Goods. 

14.4 Arbitration. Except as set forth in Section 14.2 and this Section 14.4, all disputes, controversies or claims which may
arise between the Parties hereto out of or in relation to or in connection with this Agreement, any breach hereof, including, any claim that this Agreement, or any part hereof, is invalid, illegal or otherwise voidable or void, shall be finally
settled under the Rules of Arbitration of the International Chamber of Commerce (the “Rules”) by three arbitrators. Each Party shall nominate one arbitrator and the two arbitrators so selected shall nominate the third
arbitrator. If the Parties’ two arbitrators cannot agree on a third arbitrator, the third arbitrator shall be appointed by the International Court of Arbitration of the International Chamber of Commerce in accordance with the Rules. The place
of arbitration shall be San Francisco, California, U.S.A. The language of the arbitration shall be English. Unless the Parties otherwise agree, the arbitrators shall apply the International Bar Association Rules on the Taking of Evidence in
International Commercial Arbitration. Unless the Parties otherwise agree, the arbitrators shall not have the power to appoint experts. The arbitrators shall not issue any award, grant any relief or take any action that is prohibited by or
inconsistent with the provisions of this Agreement and may not, under any circumstances, award punitive or exemplary damages except to the extent permitted by Section 11.2. The award rendered by the panel of arbitrators shall be binding upon
the Parties hereto and judgment on the award may be entered in any court having jurisdiction thereof. Each Party shall bear its own attorneys’ fees in connection with any arbitral proceedings and the arbitrators shall not include
attorneys’ fees in any award. Notwithstanding anything to the contrary in this Section 14.4, a Party may seek injunctive relief in any court of competent jurisdiction to prevent or stop a breach of this Agreement, prevent or stop
infringement or intellectual property rights or to compel arbitration under this Section 14.4. 
 14.5 Currency. All amounts
payable under this Agreement shall be paid in U.S. Dollars, unless otherwise specifically indicated and agreed in writing by the Parties. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 49. 

 14.6 Accounting Matters. The Parties do not intend for the activities of the Steering
Committee to be considered deliverables for financial statement purposes such as revenue recognition. Without limiting the generality of the foregoing, the Parties agree that the amounts payable by Distributor pursuant to Section 3.1.1 are
fully earned as of the Effective Date and the payments payable pursuant to Sections 3.1.2 are fully earned upon the date upon which the applicable milestone is achieved. 

14.7 Language. This Agreement may be translated into languages other than English. The English language version shall govern the meaning
and interpretation of this Agreement. 
 14.8 Notices. Any notice, request, or other document to be given to a Party under this
Agreement shall: (i) be in writing; (ii) hand delivered; (iii) sent by internationally-recognized express mail or courier service which provides documentation of receipt; or (iv) sent by facsimile as follows: 

 

			
	If to Company:	  	Neuronetics, Inc.
		  	3222 Phoenixville Pike
		  	Malvern, PA 19355 USA
		  	Attention: Chris Thatcher, President and CEO
		
	If to	  	Teijin Pharma Limited
	Distributor:	  	2-1, Kasumigaseki 3-chome,
		  	Chiyoda-ku, Tokyo 100-8585, Japan
		  	Attention:
		
	With a copy to:	  	Squire Gaikokuho Kyodo Jigyo Horitsu Jimusho
		  	 Ebisu Prime Square Tower, 16th Floor

1-1-39 Hiroo, Shibuya-ku, Tokyo 150-0012,

		  	Japan
		  	Attn: Stephen E. Chelberg

 A Party may change its address for receiving notices, requests or other documents by giving written notice of
the change to the other Party. 
 14.9 No Oral Modifications. This Agreement may not be modified except in writing signed by both
Parties. 
 14.10 No Implied Waiver. The failure of one Party to require performance by the other of any provision of this Agreement
will not affect the right to require performance at a later time. The waiver by one Party of a breach by the other of any provision of this Agreement shall not be a waiver of any later breach of that or any other provision hereof. 

14.11 Assignment. 
 14.11.1
Distributor may not assign this Agreement or any rights or obligations under this Agreement, in whole or in part, to any third party without the prior written consent of Company, which consent shall not be unreasonably withheld or conditioned, and
any assignment by Distributor without such consent will be null and void and of no force or legal effect. Notwithstanding the foregoing sentence, Distributor may assign this Agreement without Company’s consent to an Affiliate in the event of a
merger or consolidation of Distributor with an Affiliate. No assignment shall relieve Distributor of its obligations under this Agreement. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 50. 

 14.11.2 Company may assign this Agreement or any right or obligation under this Agreement, in
whole or in part, to an Affiliate or third party, whether by Change of Control or otherwise, so long as such Affiliate or third party is bound by operation of law to all of Company’s obligations as set forth in the Agreement and
Distributor’s rights hereunder will continue as set forth herein or Company obtains the written agreement of such third party to undertake all of Company’s obligations as set forth in the Agreement and that Distributor’s rights
hereunder will continue as set forth herein, and any assignment by Company without such operation of law or agreement will be null and void and of no force or legal effect. No assignment shall relieve Company of its obligations under this Agreement.

 14.11.3 In the event of an assignment or transfer to an Affiliate, the assigning or transferring Party shall remain responsible (jointly
and severally) with such Affiliate for the performance of such assigned or transferred obligations. 
 14.11.4 To the extent permitted by
this Agreement, this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of Company and Distributor. Any assignment or transfer, or attempted assignment or transfer, by either Party in violation of this
Section 14.11 will be null and void and of no legal effect. 
 14.12 Taxes. Any taxes, levies or other duties
(“Taxes”) paid or required to be withheld under the appropriate tax laws by one Party (“Withholding Party”) on account of monies payable to the other Party under this Agreement shall be deducted from
the amount of monies otherwise payable to the other Party under this Agreement. The Withholding Party shall secure and send to the other Party within a reasonable period of time proof of any such Taxes paid or required to be withheld by the
Withholding Party for the benefit of the other Party. The Parties shall cooperate reasonably with each other to ensure that any amounts required to be withheld by either Party are reduced in amount to the fullest extent permitted by Applicable Law.
No deduction shall be made, or a reduced amount shall be deducted, if the other Party furnishes a document from the appropriate tax Governmental Authorities to the Withholding Party certifying that the payments are exempt from Taxes or subject to
reduced tax rates, according to the applicable convention for the avoidance of double taxation. 
 14.13 Force Majeure. Neither
Company nor Distributor shall be liable in damages, nor shall either of them be subject to termination of this Agreement by the other Party for any delay or default in performing any obligation under this Agreement (except payment obligations) if
that delay or default is due to any cause beyond the reasonable control and without fault or negligence of that Party (“Force Majeure”); provided, however, that in order to excuse its delay or default under this Agreement, a
Party shall notify the other of the occurrence or the cause, specifying the nature and particulars thereof and the expected duration thereof as soon as reasonably practical under the circumstances; and provided further that within [*] after the
termination of such occurrence or cause, such Party shall give notice to the other Party specifying the date of termination thereof. All obligations of the Parties shall return to being in full force and effect upon the termination of such
occurrence or cause (including, without 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 51. 

 
limitation, any payments which became due and payable under this Agreement prior to the termination of such occurrence or cause). If an event of Force Majeure prevents either Party’s
performance hereunder and continues for more than [*], the other Party may terminate this Agreement by giving written notice, however, that any amounts due shall remain payable. For the purposes of this Section 14.13, a “cause beyond
the reasonable control” of a Party shall include, without limiting the generality of the phrase, any act of God, act of any government or other authority or statutory undertaking, industrial dispute, fire, explosion, accident, power
failure, flood, riot or war (whether declared or undeclared), earthquake, tsunami, pandemic or outbreak of communicable disease, such as SARS. 

14.14 Severability. If any provision of this Agreement is declared invalid or unenforceable by an arbitrator or court having competent
jurisdiction, it is mutually agreed that this Agreement shall endure except for such provision declared invalid or unenforceable. In such event, the Parties shall consult and use their best efforts to agree upon a valid and enforceable provision
which shall be a reasonable substitute for such invalid or unenforceable provision in light of the Parties’ original intent upon entry into this Agreement. 

14.15 Headings and References. Section and other headings are for reference only and shall not affect the interpretation or meaning of
any provision of this Agreement. Unless otherwise provided, references to Articles, Exhibits, Sections and Schedules shall be deemed references to Articles, Exhibits, Sections and Schedules of this Agreement. References to this Agreement include
this Agreement as it may be modified, amended, restated or supplemented from time to time pursuant to the provisions hereof. 
 14.16
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument. 

14.17 Entire Agreement. This Agreement, including all Schedules reference in this Agreement, contains the entire agreement between the
Parties with respect to the subject matter hereof and supersedes all previous agreements and understandings, whether written or oral, between the Parties regarding the subject matter hereof. 

14.18 Terms Generally. Unless the context of this Agreement requires otherwise, words importing the singular number shall include the
plural and vice versa. Words importing the masculine gender shall include the feminine. In this Agreement, references to: (a) any statutory or regulatory provisions shall include such provisions as from time to time amended, whether before or
after the date hereof, and shall further include all statutory or regulatory instruments or orders from time to time made pursuant thereto; and (b) any document or agreement shall include such document or agreement as from time to time amended,
supplemented or replaced, whether before or after the date hereof. The words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” Unless otherwise specified,
all of the terms in this Agreement that relate to accounting matters shall be interpreted in accordance with generally accepted accounting principles in effect in the United States of America at the time of such interpretation. 

(signature page follows) 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 52. 

 IN WITNESS WHEREOF, the Parties have signed this Agreement as of the date first set forth above. 

 

			
	COMPANY:
	
	NEURONETICS, INC.
		
	By:	 	 /s/ Chris Thatcher

	Name: Chris Thatcher
	Title:   President and CEO
	
	DISTRIBUTOR:
	
	TEIJIN PHARMA LIMITED
		
	By:	 	 /s/ Akihisa Nabeshima

	Name: Akihisa Nabeshima
	Title:   President

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 . 

 SCHEDULE A 

NEUROSTAR STARTER PACKAGE 
  

									
	 NeuroStar Starter
Package
	  	 	  	 	  	 
	 Catalog

Number
	  	 Item Number
	  	 Starter Kit
Items
	  	 Description
	  	 US$ transfer
Price

	[*]	  	[*]	  		  	[*]	  	[*]
		  		  	[*]	  	[*]	  	[*]
		  		  	[*]	  	[*]	  	[*]
		  		  	[*]	  	[*]	  	[*]
		  		  	[*]	  	[*]	  	[*]
		  		  	[*]	  	[*]	  	[*]
		  		  	[*]	  	[*]	  	[*]
		  		  	[*]	  	[*]	  	[*]
		  		  	[*]	  	[*]	  	[*]
		  		  	[*]	  	[*]	  	[*]
		  		  	[*]	  	[*]	  	[*]
		  		  	[*]	  	[*]	  	[*]
		  		  	[*]	  	[*]	  	[*]
		  		  	[*]	  	[*]	  	[*]

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 . 

 SCHEDULE B 

Distributor Initial Sales Forecast 
  

					
	 Time Period
	  	 NeuroStar TMS

Therapy
 Systems
	  	 Sen Star Treatment

Links / Treatment

Sessions

	 From [*] assuming each period is a full calendar year. If the period from [*] is less than a
full calendar year, then amounts set forth I the two adjacent columns shall be prorated for such period.
	  	[*]	  	[*]
	 First full Fiscal Year after the end of the Fiscal Year [*]
	  	[*]	  	[*]
	 Second full Fiscal Year after the end of the Fiscal Year [*]
	  		  	

 Total Dollar value of sales forecast for the Initial Period= 

Subtotal of Dollar value of NeuroStar TMS Therapy Systems purchased from Company during the Initial Period (calculated using transfer price determined in
accordance with Section 3.5 of the Agreement): 
 + 

Subtotal of Dollar value of SenStar Treatment Links and Treatment Sessions purchased from Company during the Initial Period: (Subtotal of treatment sessions
from above chart) x transfer prices determined in accordance with Section 3.5 of the Agreement. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 SCHEDULE C 

Training and Support Programs 
 Sales
Training Program 
 Appropriate Company staff shall travel at the expense of Distributor to a location of Distributor’s choice and provide sales
training sufficient to make Distributor’s staff skilled in the sales of Products. 
 Clinical Training Program 

Distributor staff to travel at their sole expense to a United States location determined by Company to receive both didactic and hands on training. Expected
duration of training is two (2) weeks. 
 Technical Training Program 

Distributor staff to travel at their sole expense to a United States location determined by Company to receive both didactic and hands on training. Expected
duration of training is one (1) week. Advanced “train the trainer” training can be provided at Distributor’s expense to train Distributor personnel to conduct future distributor trainings. 

Additional Company Required Training 
 Additional sales,
clinical, regulatory, compliance and quality or technical training may be required by Company from time to time. Attendance is mandatory for appropriate Distributor staff and is at Distributor’s expense. Most trainings of this type can be
conducted via webinar. 
 Distributor Requested Training and Support 

Company shall make additional training and support available at Distributor’s request. 

 

					
	 Item Number
	  	 Training and Support Type
	  	 Cost/Day

		  	Sales/Marketing	  	[*]
	 XXX        
	  	Clinical Training and Support (3 day minimum)	  	[*]
	 XXX        
	  	 Technical Service Training and Support: This may include installation, repair and/or training.**

(3 day minimum)
	  	[*]

  

	*	Expenses include economy class airfare and the costs for hotel, meals, and local transportation but not to exceed [*] 

	**	Parts are not included. 

 Pricing after the Fixed Transfer Price Period is subject to mutual agreement of the
Parties. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 SCHEDULE D 

Company Trademarks 
 English Language
Trademarks Registered in Japan 
  

									
	 Mark
	  	Registration
NO./Date	  	App. No.
/Date	  	 Goods/Classes
	  	 Status

	 NEURONETICS
	  	5535065
 11/9/2012
	  	042942
 5/29/2012
	  	Medical, magnetic neuromodulators for the treatment of central nervous system disorders, psychiatric and neurological disorders in International Class 10	  	Registered; Renewal due: 11/9/2022
	 NEUROSTAR
	  	5572813
 04/05/2013
	  	042943
 5/29/2012
	  	Transcranial magnetic stimulation devices consisting of a stimulator and a patient positioning system, namely, a chair and headset in International Class 10	  	Registered; Renewal due: 4/05/2023
	 NEUROSTAR &

Design
	  	5572814
 4/05/2013
	  	042944
 05/29/2012
	  	Transcranial magnetic stimulation devices consisting of a stimulator and a patient positioning system, namely, a chair and headset in International Class 10.	  	Registered; Renewal due: 04/05/2023
	 NEUROSTAR

TMS THERAPY
	  	5572815
 04/05/2013
	  	042945
 05/29/2012
	  	Transcranial magnetic stimulation devices consisting of a stimulator and a patient positioning system, namely, a chair and headset in International Class 10	  	Registered; Renewal due: 04/05/2023
	 SENSTAR
	  	5572816
 04/05/2013
	  	042946
 05/29/2012
	  	Medical devices, namely, a disposable patient interface for use with transcranial magnetic stimulation devices in International Class 10	  	Registered; Renewal 04/05/2023
	 TMS TRAKSTAR
	  	5572817	  	042947	  	Computer application software for use with transcranial magnetic stimulation devices, namely, software for use in database management in International Class 9	  	Registered; Renewal 04/05/2023
	 NEUROSTAR

XPLOR
	  	5631472	  	2012
97829	  	Computer software for use with transcranial magnetic stimulation devices in International Class 9	  	 Registered; Renewal
 due:
11/22/2013

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 Trademarks To Be Registered in English and Katakana in Japan 

 

			
	NEURONETICS (IN KATAKANA CHARACTERS)	  	Medical, magnetic neuromodulators for the treatment of central nervous system disorders, psychiatric, and neurological disorders in Class 10.; • Medical research pertaining to the treatment and diagnosis of central
nervous system disorders in Class 42.• Medical evaluation services pertaining to the treatment and diagnosis of central nervous system disorders Class 44.
		
	 NEUROSTAR (IN KATAKANA CHARACTERS)
	  	Transcranial magnetic stimulation devices consisting of a stimulator and a patient positioning system, namely, a chair and headset in Class 10.
		
	 TMS THERAPY
	  	Transcranial magnetic stimulation devices consisting of a stimulator and a patient positioning system, namely, a chair and headset in International Class 10.
		
	 NEUROSTAR XPLOR (IN KATAKANA CHARACTERS)
	  	Computer software for use with transcranial magnetic stimulation devices, namely, software for use in database management in Class 9; • Transcranial magnetic stimulation devices consisting of a stimulator and a patient
positioning system, namely, a chair and headset in Class 10.
		
	 TMS TRAKSTAR (IN KATAKANA CHARACTERS)
	  	Computer application software for use with transcranial magnetic stimulation devices, namely, software for use in database management in Class 9.
		
	 SENSTAR (IN KATAKANA CHARACTERS)
	  	Medical devices, namely, a disposable patient interface for use with transcranial magnetic stimulation devices in International Class 10.

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

			
	 MT ASSIST (IN KATAKANA CHARACTERS)
	  	Computer software for aiding in the computation of the optimal stimulation level for the treatment of central nervous system disorders, including psychiatric and neurologic disorders computer software for aiding in the
computation of the optimal stimulation level for the treatment of central nervous system disorders, including psychiatric and neurologic disorders in Class 10.
		
	 PRECISION PULSE TMS (IN KATAKANA CHARACTERS)
	  	Electric coils, electric circuits and electric control consoles for use with transcranial magnetic stimulation devices in Class 9.

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 SCHEDULE E 

Visual Inspection Procedure 
  

	1)	At the time of installation, a visual inspection under normal room lighting and areas where parts and products are viewed under normal use is conducted to ensure that no damage occurred to the NeuroStar Starter Package
during shipment and transportation. 

  

	2)	Crates must be inspected when they are received and any damage identified must be noted at that time in accordance with the carrier’s damage reporting procedure. Crate damage at time of receipt by Distributor is
considered in-transit damage and is not covered by these instructions. Distributor may make a warranty claim for NeuroStar Product damaged in-transit. 

 

	3)	The person witnessing or performing the visual inspection at the time of installation must be a trained NeuroStar Field Service Engineer. 

 

	4)	The treatment chair should be inspected for the following: 

  

	 	a)	Cushion for any rips, tears or holes. 

  

	 	b)	Covers for scratches, cracks, or breakage. 

  

	 	c)	Frame for bends or breakage. 

  

	 	d)	Adjustable feet to ensure they are not bent or crooked. 

  

	 	e)	Missing or loose hardware. 

  

	5)	The console should be inspected for the following: 

  

	 	a)	Covers for scratches, cracks, or breakage. 

  

	 	b)	Wheels to ensure they are not bent or crooked. 

  

	 	c)	Missing or loose hardware. 

  

	 	d)	Display screen to ensure no damage. 

  

	6)	Head support 

  

	 	a)	Cushion for any rips, tears, or holes. 

  

	 	b)	Covers for scratches, cracks, or breakage. 

  

	 	c)	Missing or loose hardware. 

  

	7)	A NeuroStar Starter Package which fails a prescribed visual inspection must not be put into service until the issue is resolved. 

  

	8)	If an issue is identified as part of the visual inspection conducted at time of installation, the NeuroStar Field Service Engineer witnessing or performing inspection should attempt to resolve the issue according to the
Distributor Service Manual and in accordance with the individual’s FSE Training. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 SCHEDULE F 

Return of Products 
 Any product for which
Distributor receives a technical complaint and for which a repair 1s determined to be required, Distributor will replace the part using a product Field Replacement Unit. 

Return of Products requires that Distributor complete and print a Technical Event Report in such format as Company shall notify to Distributor from time to
time and attach it to the Field Replacement Unit. Distributor must also email the completed Technical Event Report to Company at such email address as notified by Company to Distributor, such email being as of the Effective Date:
oustechservices@neuronetics.com. Distributor ships Field Replacement Units to be returned to Company at Distributor’s expense. Distributor will ship Products as soon as practicable where a potential safety issue is asserted. Otherwise,
Distributor will ship items for return so they are received by the Company within 30 days after Distributor receives the items from their customer. Timely shipment is required for Company to investigate and address complaints within required
timeframes. 
 Company Technical Support logs emailed information from the Technical Event Form into Company’s complaint database and processes the
complaint according to Company’s complaints procedure. Returned items are processed by Company according to Company’s non-conforming material (NMR) procedure. 

Replacement parts are sent at Company’s expense to Distributor for parts which are under warranty. The cost of repairs and shipping to Distributor for
Product not under warranty is the responsibility of Distributor. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 SCHEDULE G 
  

	
	Quarterly Update

 Strategic Growth Drivers Full Year 2017 

 

					
	 	  	 Initiative / Program
	  	 Implementation date

	1	  		  	
	2	  		  	
	3	  		  	
	4	  		  	
	5	  		  	

 [*] 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 SCHEDULE H 

Anti-Bribery Due Diligence Documentation 

(see attached) 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 NEURONETICS 

Anti-Bribery Compliance Certification 

Pursuant to the Distribution Agreement between Neuronetics, Inc., and Teijin Pharma Limited, dated 10 October I hereby certify: 

[*] 
 [*] 

[*] 
 COMPANY NAME: Teijin Pharma Limited 

PRINT NAME: Yasuhiko Kuriyama 
 TITLE: General Manager, Home
Healthcare New Business Development Division 
 SIGNATURE: /s/ Yasuhiko Kuriyama 

DATE: October 10, 2017 
 25-80057-000 Rev A 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 NEURONETICS 

Distributor Qualification Form 
 You are
requested to complete this form and return it to your Neuronetics’ Business Development representative. To ensure accurate information is provided, each section should be complete by or reviewed with your companies’ department
representatives. 
 [*] 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 SCHEDULE I 

Minimum Terms and Conditions of Sale 
  

	1.	The System [this term will be defined in Distributor’s agreement with its customer] is sold to the customer with the understanding that the operation of the System must be undertaken only in a manner that is
compliant with the NeuroStar TMS Therapy System User Manual. The System can only be used in accordance with the laws of Japan. 

  

	2.	Use of the System by a customer is permitted only by users authorized in accordance with the laws of Japan. Such operators are referred to as “Authorized Users.” 

 

	3.	The customer shall be responsible to ensure that all Authorized Users have the requisite training and skill required to use the System as defined by all applicable regulatory and medical authorities in Japan. Customer
will, at all times, ensure that it and its employees and agents and all Authorized Users 

  

	4.	Distributor grants the customer and its Affiliates that will use the Products a limited, nonexclusive, non-transferable (except as set forth in Item IO below) and non-sublicensable (except as expressly provided in Item 6 below) right and license to operate and use the Software (along with any written or electronic documentation provided with the Software or System) solely in
conjunction with the operation and use of the System. The customer obtains no right, title or interest in or to the Software, except for the limited license so granted, and Distributor and its licensors reserve all rights not expressly granted.

  

	5.	The customer and its Affiliates may use the Software only in connection with the use and operation of the System in accordance with Neuronetics, Inc.’s instructions as conveyed by Distributor to customer or the
documentation. Except as expressly provided in Item 6 below, customer may not loan, rent, lease, license or otherwise transfer to any other person, or host on behalf of any other person, the Software, and may not copy, modify, remove, disassemble,
create derivative works from or tamper with the Software except to an Affiliate that will use the Products. Any attempted transfer or use of the Software without the prior consent of Distributor, except as expressly provided in Item 6 or 10 below,
will void the license. 

  

	6.	A customer that is a leasing or finance company that has acquired a System or Systems for the purpose of leasing such System(s) to a third party shall be permitted to sublicense the Software licenses granted hereunder
to the lessee(s) of such System(s) provided that all such lessees agree in writing to be bound by these minimum end-user license agreement terms. Any such sublicense shall terminate upon the expiration or
termination of the underlying lease agreement. 

  

	7.	Customer may use the TrakStar Software and the associated documentation only for its or its Affiliates own internal use on the computer system provided with the NeuroStar TMS Therapy System or a replacement computer as
authorized and installed by Distributor. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 . 

	8.	Customer may not copy or otherwise reproduce the Software or documentation. Except as expressly permitted under applicable law, customer may not decompile, reverse engineer or disassemble the Software in an attempt to
derive or use the source code therefrom. 

  

	9.	Software may include Redistributable Code, which is the property of Neuronetics, Inc.’s licensors, and protected under United States and international copyright, trade secret or other proprietary rights laws, as
well as international treaties. Distributor grants to customer and its Affiliates a limited, non-exclusive, non-sublicensable and nontransferable right and sub-license to use and display the Redistributable Code solely in connection with the authorized use of the Software in connection with the operation of the System and in conformance with the other minimum end-user license agreement terms. Except as expressly permitted under applicable law, customer and its Affiliates may not reproduce, redistribute, decompile, reverse engineer or disassemble the Redistributable Code
and may not dis-integrate the Redistributable Code from the Software. 

  

	10.	Customer may only transfer the Software and the Redistributable Code as part of a sale or transfer of the System to a third party and the third party must agree to the minimum
end-user license terms as a condition to such transfer, provided however that customer may transfer the Software and the Redistributable Code to an Affiliate along with the System. 

 

	11.	DISTRIBUTOR AND NEURONETJCS SHALL NOT BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL, INDIRECT OR SPECIAL DAMAGES OF ANY KIND, INCLUDING BUT NOT LIMITED TO DAMAGES FOR LOST REVENUE OR LOST PROFITS, LOSS OF DATA, LITJGATJON
EXPENSE, DAMAGE TO REPUTATION, LOSS OF BUSINESS OR ANY OTHER FINANCIAL LOSS ARISING OUT OF OR IN CONNECTION WITH THE SOFTWARE. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 SCHEDULE J 

NeuroStar Treatment Session Transfer Price Table 
  

			
	 Reimbursement Rate/Treatment Session in
JPY
	  	 NeuroStar Treatment Sessions in USD

	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 1. If the reimbursement price falls between two reimbursement prices set forth in above, then the transfer price
will be determined in accordance with the following formular: 
 [*] 

2. If the reimbursement price determined by MHLW is lower than the lowest reimbursement price set forth in the above table, then [*] reimbursement price
determined by MHLW is higher than the highest reimbursement price set forth in the above table, then [*] 
 3. If the reimbursement rate determined by MHL W
is paid as a single payment for a complete course of treatment, this reimbursed amount will be divided by the number of treatments foreseen as a course of treatment by MHLW or 30, whichever is smaller, to determine the Reimbursement Rate/Treatment
Session used in the table above in determining the transfer price. If the reimbursement varies by treatment session, the average reimbursement over a treatment course of 30 treatment sessions will be used for the Reimbursement Rate/Treatment Session
in the table above in determining the transfer price. If any other reimbursement scenario is set by MHLW, the average reimbursement over a 30 treatment course will be used for the Reimbursement Rate/Treatment Session in the table above in
determining the transfer price. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 SCHEDULE K 

NNI Technical Support 

See Attached 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 NEURONETICS 
  

			
	Standard Operating Procedure	  	
	Page 1 of 10	  	UNCONTROLLED IF PRINTED
	26-20057-000 Rev C	  	Distributor Quality Plan, Teijin

  

	1.	PURPOSE 

  

	 	1.1	This Distributor Quality Plan (this “Plan”) specifies processes, procedures and resources for distribution, service and defect management of Products (as defined in Section 4) that are clinically
available in the Territory (as defined in Section 4). 

  

	 	1.2	This Plan is intended to ensure compliance with Applicable Laws (as defined in Section 4) including those cited in Section 3.0 Reference Documents. 

 

	2.	SCOPE 

  

	 	2.1	This procedure applies to processes and procedures conducted for Products distributed in the Territory by Distributor (as defined in Section 4). 

 

	 	2.2	This procedure applies to employees of Company (as defined in Section 4) and Distributor in the Territory. 

  

	3.	REFERENCE DOCUMENTS 

  

	 	3.1.	21 CFR Part 820, Quality System Regulations 

  

	 	3.2.	ISO 13485:2003, Medical Devices - Quality Management Systems 

  

	 	3.3.	MHLW Pharmaceuticals and Medical Device Act (Japan) 

  

	 	3.4.	MHLW Ministerial Ordinance No. 169, 2004, Good Manufacturing Practices (Japan) 

  

	 	3.5.	20-40000-000, Quality Manual 

  

	 	3.6.	26-20013-000, Work Instruction- Medical Event Reporting to Neuronetics 

 

	 	3.7.	25-80031-000, Medical Event Form 

  

	 	3.8.	15-50038-000, OUS Technical Event Recording procedure 

 

	 	3.9.	20-30036-000, Distributor Training 

  

	 	3.10.	25-11512-000, NeuroStar OUS Installation Record 

  

	4.	DEFINITIONS 

  

	 	4.1.	“Agreement” means the Distribution Agreement between Company and Distributor as amended from time to time. 

  

	 	4.2.	“Applicable Laws” means all Laws, including cGMP, including, without limitation, any rules, regulations, guidelines or other requirements of the FDA and any other Governmental Authority with
respect to the manufacture of the Products and rules, regulations, guidelines or other requirements of MHLW applicable to the promotion, marketing, distribution and sale of the Products in the Territory. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 NEURONETICS 
  

			
	Standard Operating Procedure	  	
	Page 2 of 10	  	UNCONTROLLED IF PRINTED
	26-20057-000 Rev C	  	Distributor Quality Plan, Teijin

  

	 	4.3.	“Business Day” means a day (other than Saturday or Sunday) on which banks are open for business in Tokyo, Japan, and in New York, New York. 

 

	 	4.4.	“cGMP” means the current good manufacturing practices applicable to the manufacture of the Products as defined in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Part 820, and the
equivalent Laws in the Territory, each as may be amended and applicable from time to time. 

  

	 	4.5.	“Company’’ means Neuronetics, Inc., a Delaware corporation having its principal offices at 3222 Phoenixville Pike, Malvern, Pennsylvania, 19355, USA. 

 

	 	4.6.	“Distributor” means Teijin Pharma Limited, a Japanese company having its principal offices at 2-1, Kasumigaseki
3-chome, Chiyoda-ku, Tokyo 100-8585, Japan. 

 

	 	4.7.	“DMAH” means the agent approved by the MHLW to act as the marketing authorization holder in accordance with and as defined in the Law on Securing Quality, Efficacy and Safety of Pharmaceuticals,
Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics. 

  

	 	4.8.	“Event of Special Interest” means any of the following events regardless of its causal relationship to use of the Products: (a) seizure: patient experiences a seizure; (b) pregnancy: a
patient receiving therapy with the Products is pregnant or becomes pregnant; (c) worsening illness or suicide attempt/suicidal ideation: a patient is hospitalized due to worsening illness, makes a suicide attempt or the occurrence of a
completed suicide; or (d) Device-Device Co-Administration: lf TMS Therapy is administered in a patient with an implanted medical device and a device-device interaction is suspected or occurs.

  

	 	4.9.	“FDA” means the United States Food and Drug Administration and any successor thereto. 

  

	 	4.10.	“Governmental Authority’’ means any multinational, national, federal, prefectural, state, local, municipal or other governmental authority of any nature (including any governmental division,
subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal), in each case, having jurisdiction over the applicable subject matter. 

 

	 	4.11.	“Laws” means all laws, statutes, rules, regulations, directives, decisions and ordinances of any Governmental Authority. 

 

	 	4.12.	“Medical Event” means any event that requires clinical attention or intervention and is determined by the evaluating clinician to be possibly related, probably related, or definitely related to
the use of the Products or for which exact causal relationship cannot be determined at time of event or report. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 NEURONETICS 
  

			
	Standard Operating Procedure	  	
	Page 3 of 10	  	UNCONTROLLED IF PRINTED
	26-20057-000 Rev C	  	Distributor Quality Plan, Teijin

  

	 	4.13.	“MHLW” means the Japanese Ministry of Health, Labour and Welfare and any successor thereto. 

  

	 	4.14.	“PMDA” means the Japanese Pharmaceuticals and Medical Devices Agency and any successor thereto. 

  

	 	4.15.	“Products” means the products the Distributor distributes in the Territory pursuant to the Agreement. 

  

	 	4.16.	“Territory” means Japan. 

  

	5.	RESPONSIBILITIES 

  

	 	5.1.	Company shall: 

  

	 	•	 	Be responsible for the manufacture, shipping, exportation and importation of the Products for use in the Territory in compliance with all Applicable Laws including the standards and regulations as cited in
Section 3.0. 

  

	 	•	 	Be responsible for ensuring that export and import documentation are obtained for the Products leaving the US and entering the Territory. 

 

	 	•	 	Obtain a quality agreement with the DMAH and operate according to the requirements of said agreement. 

  

	 	•	 	Provide and/or review quality and regulatory information relative to the Products distributed in the Territory in a timeframe sufficient for timely action in accordance with Company’s quality management system and
Applicable Laws. 

  

	 	•	 	Provide advance notification to DMAH of changes to the Product in sufficient time to allow for review and approval by PDMA, if required. Periodically provide relevant post-market surveillance information to Distributor
pertaining to device performance. 

  

	 	•	 	Provide annual distributor training per procedure 20-30036-000, Distributor Training. 

 

	 	•	 	Consult with DMAH for interactions with MHLW, PDMA and other relevant Governmental Authorities in the Territory related to use of the Products in the Territory. 

 

	 	•	 	Perform its obligations set forth in the Agreement in compliance with Applicable Laws. 

  

	 	•	 	Document and communicate to DMAH in a timely manner information relevant to the safe and effective operation of the Products in the Territory including product defects, technical event complaints, medical event
complaints, and any quality complaints related to the Products. 

  

	 	•	 	Communicate to Distributor in a timely manner updated instructions for the safe and effective operation of the Products in the Territory. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 NEURONETICS 
  

			
	Standard Operating Procedure	  	
	Page 4 of 10	  	UNCONTROLLED IF PRINTED
	26-20057-000 Rev C	  	Distributor Quality Plan, Teijin

  
  

	 	5.2.	Distributor shall: 

  

	 	•	 	Ship, store, distribute, install and service the Products in the Territory in accordance with the Agreement. 

  

	 	•	 	Perform its obligations set forth in the Agreement in compliance with Applicable Laws. 

  

	 	•	 	Perform its activities in the Territory with respect to the Products in accordance with Applicable Laws. 

  

	 	•	 	Track and document the Products at installation, servicing and repair and retain and maintain such documentation in accordance with Sections 5.3.2 and 5.10.2. 

 

	 	•	 	Document and communicate to Company and DMAH in a timely manner information relevant to the safe and effective operation of the Products in the Territory including product defects, technical event complaints, medical
event complaints, and any quality complaints received from Distributor’s customers related to the Products. 

  

	 	•	 	Respond promptly to all inquiries from Distributor’s customers, including but not limited to, customer feedback and service requests. 

 

	 	•	 	Collaborate with Company and the DMAH in the investigation of complaints, adverse event reports and technical events and determination of closure or corrective actions, including DMAH’s notification of Governmental
Authorities 

  

	 	•	 	Obtain a quality agreement with the with the DMAH and operate according to the requirements of said agreement. 

  

	 	5.3.	Control of Records 

  

	 	5.3.1.	Company shall ensure that applicable data and documents are housed in a secured and access-controlled SharePoint site that is dedicated to information and records shared between Company and Distributor.

  

	 	5.3.2.	Distributor shall create records for identification and traceability of the Products distributed by Distributor in the Territory and maintain such records for the longer of the timeframe required by Applicable Laws or
15 years. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 NEURONETICS 
  

			
	Standard Operating Procedure	  	
	Page 5 of 10	  	UNCONTROLLED IF PRINTED
	26-20057-000 Rev C	  	Distributor Quality Plan, Teijin

  

	 	5.4.	Infrastructure and Work Environment 

  

	 	5.4.1.	Distributor shall use a storage environment which prevents damage and maintains the shelf and operating life of the Products while the Products are stored at facilities under Distributor’s control in the Territory
prior to delivery to Distributor’s customers. 

  

	 	5.4.2	Distributor shall or shall ensure that Distributor’s subcontractors follow the installation procedures for the Products at customer sites as set forth in documentation provided by Company to ensure a safe
operational environment for clinical use. 

  

	 	5.5.	Service and Technical Events and Medical Events 

  

	 	5.5.1.	Distributor and Company will follow the processes and procedures set forth in Appendices A and B, as applicable, in relation to service and technical events and medical events related to the Products reported by
Distributor’s customers in the Territory. 

  

	 	5.6.	Recall and Advisory Notices 

  

	 	5.6.1.	DMAH in collaboration with Company shall communicate with Governmental Authorities in the Territory regarding any recalls, advisory notices and other regulatory actions. 

 

	 	5.6.2.	Distributor shall assist in any regulatory request or action or advisory notice or recall by providing directly to Company and DMAH all customer, traceability and inventory information in its possession or control that
is needed to assess and respond to such request or action, provide such advisory notice or perform such recall. 

  

	 	5.6.3	Company and the DMAH have sole authority to issue a recall or require corrective action with respect to Products in the Territory including those required by Applicable Laws or a Governmental Authority in the Territory.

  

	 	5.6.4	Company and DMAH are responsible to plan and lead the recall with input from Distributor, and Distributor shall be responsible for executing the plan in the Territory including distributing communications to customers,
performing all field activities in the Territory creating and maintaining required records, including inventory records and, if necessary, the physical return of Products from the Territory. 

 

	 	5.6.5	Company and DMAH with the assistance of Distributor are responsible for preparing advisory notices and other communications to customers. 

 

	 	5.6.6	Company shall communicate to DMAH and Distributor reportable regulatory actions initiated outside of the Territory that are applicable to the Products distributed in the Territory including recalls and advisory notices
and coordinating any required actions with DMAH and Distributor. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 NEURONETICS 
  

			
	Standard Operating Procedure	  	
	Page 6 of 10	  	UNCONTROLLED IF PRINTED
	26-20057-000 Rev C	  	Distributor Quality Plan, Teijin

  

	 	5.7.	Customer Feedback 

  

	 	5.7.l.	Distributor shall collaborate with Company and DMAH directly in matters of vigilance and post-market surveillance. 

  

	 	5.7.2.	Distributor shall report product complaints to Company and DMAH in writing within ten (10) Business Days from the date of receipt of the product complaint. 

 

	 	5.7.3.	Distributor shall report urgent issues including Medical Events and Events of Special Interest within two (2) business days after Distributor receives a report of any such issue from its customer or a physician
using a NeuroStar Product in the Territory sold by Distributor and, to the extent applicable, in accordance with Appendix A. 

  

	 	5.8.	Design and Development 

  

	 	5.8.1.	Company shall provide Distributor with six (6) months prior written notice of any changes (i) the form, fit or function of any of the Products or (ii) any part, process or manufacturer of the Products,
which change will require the approval of any Governmental Authority in the Territory or would be expected to have a material impact on the quality control processes or the quality of the Products. 

 

	 	5.9.	Product Inspection 

  

	 	5.9.1.	Company shall ensure that appropriate inspection certification(s) for the Products are kept on file at Company or at DMAH, as applicable. 

 

	 	5.9.2.	Company shall provide certificates of conformance that verify that all Products meet all device specifications. 

  

	 	5.9.3.	Company shall ensure that DMAH receives and inspects the Products in accordance with the inspection procedure agreed between Company and DMAH. 

 

	 	5.9.4.	Distributor shall receive delivery of Products from the carrier after DMAH releases the Products in the Territory. 

  

	 	5.9.5.	Distributor is responsible for installing the Products at the customer site and performing all inspection and other procedures required by NeuroStar OUS Installation Record (25-11512-000) and providing the completed NeuroStar OUS Installation Record to Company. 

  

	 	5.10.	Identification and Traceability 

  

	 	5.10.1.	Control numbers or unique device identifiers are used by Company for tracking inventory location, distribution, installation, and, as necessary, shelf life of the Products. The control numbers are necessary in the
investigation of complaints and/or recall activities. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 NEURONETICS 
  

			
	Standard Operating Procedure	  	
	Page 7 of 10	  	UNCONTROLLED IF PRINTED
	26-20057-000 Rev C	  	Distributor Quality Plan, Teijin

  

	 	5.10.2.	Distributor is responsible for maintaining ID and traceability for the NeuroStar TMS Therapy System, SenStar Treatment Link, SenStar Connect and serialized components (Field Replaceable Units) that are stored and used
in service and distribution in the Territory. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 NEURONETICS 
  

			
	Standard Operating Procedure	  	
	Page 8 of 10	  	UNCONTROLLED IF PRINTED
	26-20057-000 Rev C	  	Distributor Quality Plan, Teijin

  
 

 
 Appendix A 

CONFIDENTIAL & PROPRIETARY INFORMATION OF NEURONETICS, INC. 

NOT TO BE REPRODUCED OR USED IN ANY MANNER OTHER THAN WITH THE EXPRESS WRITTEN PERMISSION OF NEURONETICS INC. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 NEURONETICS 
  

					
	Standard Operating Procedure	  		  	
	Page 9 of 10	  		  	UNCONTROLLED IF PRINTED
	26-20057-000 Rev C	  		  	Distributor Quality Plan, Teijin

 Appendix B 
  

 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 NEURONETICS 
  

					
	Standard Operating Procedure	  		  	
	Page 10 of 10	  		  	UNCONTROLLED IF PRINTED
	26-20057-000 Rev C	  		  	Distributor Quality Plan, Teijin

 REVISION INFORMATION 
  

									
	 Rev
	  	 CN No
	  	 Written/Revised By
	  	 Date
	  	 Revision Description

					
	A	  	4673	  	John Pellechia	  	08SEP2016	  	Initial Release
					
	B	  	5193	  	Karen Heart	  	04OCT2017	  	 Flowchart updated to include notification to distributor of receipt of technical event report and parts.

Updated to include DMAH in reporting of medical events

					
	C	  	5198	  	Karen Heart (Tim Atkins)	  	05OCT2017	  	Synchronization of language to reflect contract information.

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 NEURONETICS 

Page 1 of 5 
  

							
	Document Name:	  	XX-XXXXX-XXX Japanese Distributor Installation and Technical Event Recording	  	Effective Date:	  	1-Aug-17
	Revision Letter:	  	A	  	Last Review Date:	  	1-Aug-17

 PURPOSE 
 The purpose of
this document is to define the process by which Distributor completes installation activities and records and communicates technical events for the Products. 

SCOPE 
  

	 	•	 	This procedure is applicable as a part of Distributor’s responsibilities for product quality assurance as described in the Distributor Quality Plan. 

 

	 	•	 	This procedure also covers Distributor’s responsibility to complete installation records for the equipment it installs. 

  

	 	•	 	Neuronetics Technical Service provides support to Distributor including training, documentation and advanced trouble shooting. 

3.0 REFERENCE DOCUMENTS 
  

	 	3.1	26-20057-000 Distributor Quality Plan 

  

	 	3.2	25-80055-000 Distributor Technical Event Form 

  

	 	3.3	25-11512-000 NeuroStar OUS Installation Record 

  

	 	3.4	20-85200-000 Customer Complaint 

  

	 	3.5	20-83000-000 Non-conforming material procedure 

 

	 	3.6	52-40027-000 NeuroStar Distributor Service Manual 

4.0 DEFINITIONS 
  

	 	4.1	“Agreement” means the Distribution Agreement between Company and Distributor as amended from time to time. 

  

	 	4.2	“Company” means Neuronetics, Inc., a Delaware corporation having its principal offices at 3222 Phoenixville Pike, Malvern, Pennsylvania, 19355, USA. 

 

	 	4.3	“DMAH” means the agent approved by the MHLW to act as the marketing authorization holder in accordance with and as defined in the Law on Securing Quality, Efficacy and Safety of Pharmaceuticals,
Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics. 

  

	 	4.4	“Distributor’ means Teijin Pharma limited, a Japanese company having its principal offices at 2-1, Kasumigaseki
3-chome, Chiyoda-ku, Tokyo 100-8585, Japan. 

 

	 	4.5	“DSO” or “Distributor Service Organization” means the group within the Distributor that is responsible for installation and field service of the Products in the Territory.
The DSO may be Distributor’s Technical Support Company (as defined in the Agreement). 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 NEURONETICS 

Page 2 of 5 
  

							
	Document Name:	  	XX-XXXXX-XXX Japanese Distributor Installation and Technical Event Recording	  	Effective Date:	  	1-Aug-17
	Revision Letter:	  	A	  	Last Review Date:	  	1-Aug-17

  

	 	4.6	“NTS” or “Neuronetics Technical Service” means a group within Neuronetics Field Service that provides third level support. Third level support is defined as advanced field service troubleshooting,
Field Service Engineer training, service documentation creation and service system development. 

  

	 	4.7	“Out of Box Failure” is as defined in the Agreement. 

  

	 	4.8	“Products” means the products the Distributor distributes in the Territory pursuant to the Agreement. 

  

	 	4.9	“Territory” means Japan. 

 5.0 RESPONSIBILITIES 

 

	 	5.1	Director of Field Service - Ensures that Distributor’s field service/technical support organizations are trained on equipment install procedures and technical event reporting process. 

 

	 	5.2	DSO is responsible for completing technical event report(s) and installation record(s) and forwarding to Neuronetics technical support via “OUS Technical Support” email and to the DMAH. 

6.0 PROCEDURE 
  

	 	6.1	Distributor Service Organization (Installation Activity- See Attachment B for Flow Chart) 

  

	 	6.1.1	DSO completes installation activity and fills out NeuroStar OUS Installation Record (25-11512-000). 

 

	 	6.1.2	Installation record is provided to Neuronetics technical support via email oustechservices@neuronetics.com or equivalent electronic transfer as well as to the DMAH. 

 

	 	6.1.3	An Out of Box Failure during the installation process is processed per Section 6.2 of this document and Sections 9.3.2 and 9.3.5 of the Agreement. 

 

	 	6.2	Distributor Service Organization (Technical Event Recording—see Attachment A for Flow Chart) 

  

	 	6.2.1	DSO receives technical complaint from NeuroStar customer. DSO may contact Neuronetics technical support if required. 

  

	 	6.2.2	DSO services product and completes the repair. DSO completes Technical Event Report (25-80055-000), and emails completed form to
Neuronetics via “email (oustechservices@neuronetics.com) as well as to the DMAH. Neuronetics Technical Support logs information from Technical Event Report into the complaint database (lnfor system). 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 NEURONETICS 

Page 3 of 5 
  

							
	Document Name:	  	XX-XXXXX-XXX Japanese Distributor Installation and Technical Event Recording	  	Effective Date:	  	1-Aug-17
	Revision Letter:	  	A	  	Last Review Date:	  	1-Aug-17

  

	 	6.2.3	DSO prints completed technical event report (25-80055-000) and attaches to the field replaceable unit. 

 

	 	6.2.4	DSO ships defective Field Replaceable Unit to Neuronetics. 

  

	 	6.2.5	Neuronetics receives Field Replaceable Unit which is processed via Neuronetics Complaints procedure and non-conforming material (NMR) process. 

 

	 	6.2.6	Replacement is sent by NNI for parts which are under warranty. 

  

	 	6.2.7	For parts that are not under warranty, the DSO places an order for a replacement part. 

  

	 	6.2.8	Neuronetics will report in writing appropriate information to Distributor concerning root cause analysis, likelihood of re-occurrence, impact on Product performance, workarounds
and planned fixes, as applicable. Such reporting will generally be completed within two to four weeks after Neuronetics’ receipt of the technical event report and defective Field Replaceable Unit. 

7.0 AVAILABILITY OF NEURONETICS TECHNICAL SUPPORT 
  

	 	7.1	Neuronetics provides live technical support by phone and email from 8AM ET (USA) to 6PM ET (USA). An answering service answers the technical support phone number after hours. Neuronetics generally responds to technical
support requests within 24 hours after receipt other excluding weekend and holidays. 

 8.0 QUALITY RECORDS 

 

	 	8.1	Neurostar OUS Installation Record (25-11512-000) 

  

	 	8.2	OUS Technical Event (25-80055-000) 

9.0 ATTACHMENTS 
  

	 	9.1	Attachment A- Process flow chart 

  

	 	9.2	Attachment B- Install flow chart 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 Page 4 of 5 
  

							
	Document Name:	  	XX-XXXXX-XXX Japanese Distributor Installation and Technical Event Recording	  	Effective Date:	  	[*]
	Revision Letter:	  	A	  	Last Review Date:	  	[*]

 Attachment A – Technical Event Process 
  

 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Page 5 of 5 
  

							
	Document Name:	  	XX-XXXXX-XXX Japanese Distributor Installation and Technical Event Recording	  	Effective Date:	  	[*]
	Revision Letter:	  	A	  	Last Review Date:	  	[*]

 Attachment B – Technical Event Process 
  

 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

			
	NEURONETICS	  	NeuroStar – OUS Installation Record

 NeuroStar TMS Therapy System 

Installation / Operation Qualification 
  

	Note:	Please refer to the NeuroStar Distributor Service Manual, 52-40027-000, for the detailed installation procedures. This form is to be used
as a final verification to ensure that proper installation has been achieved after all procedures have been completed. This form must be completed by a NeuroStar-ce11ified Field Service Engineer. If any items in this form do not pass final
inspection refer to the NeuroStar Distributor Service Manual, 52-40027-000, to correct the failure. The NeuroStar System is considered correctly installed when all items
on this checklist are completed and all criteria are passed. 

  

											
	Mobile Console and Coil	  	Completed	  	Pass/Fail Criteria	  	Verification
(Pass/Fail)	  	Comments	  	Initial & Date
						
	Mobile Console System Self-Test	  	☐	  	All start-up tests display “pass”	  		  		  	
						
	Coil Test Pulse passes left side	  	☐	  	Test-pulse test displays “Magnetic Field Strength Pass”	  		  		  	
						
	LCD display is calibrated correctly	  	☐	  	 LCD screen element accurately
 activates on
touch
	  		  		  	
						
	Mobile Console Stop button (Emergency Stop Button)	  	☐	  	System stops when LCD stop button is touched	  		  		  	
						
	Full range movement of Gantry	  	☐	  	Brakes energize to allow full range of movement of Gantry to mechanical stop	  		  		  	
						
	Wheels lock properly on the Mobile Console	  	☐	  	Locking mechanism engages and wheels are unable to move	  		  		  	
						
	Coil Output Test (WI 26-20024-000)	  	☐	  	 Pulse Width is 3 182μs

Test Result                  μs
	  		  		  	
						
	Visual Inspection of Mobile Console and Coil conducted per Visual Inspection Procedure	  	☐	  	Completed procedure with no issues	  		  		  	
	Treatment Chair	  	Completed	  	Pass/Fail Criteria	  	Verification
(Pass/Fail)	  	Comments	  	Initial & Date
						
	Memory Settings for M1 and M2	  	☐	  	Chair executes command correctly and passes angle check	  		  		  	
						
	Visual Inspection of Chair conducted per Visual Inspection Procedure	  	☐	  	Completed procedure with no issues	  		  		  	
	Head Support	  	Completed	  	Pass/Fail Criteria	  	Verification
(Pass/Fail)	  	Comments	  	Initial & Date
						
	A/P Bar Laser	  	☐	  	Laser remains energized for a period of 30-45 seconds	  		  		  	
						
	Full range of motion	  	☐	  	SOA, LC, A/P Bar, and front/back support achieve motion to mechanical stop	  		  		  	
						
	Visual Inspection of Head Support conducted per Visual Inspection Procedure	  	☐	  	Completed procedure with no issues	  		  		  	

  

											
	Computer / Software	  	Completed	  	Pass/Fail Criteria	  	Verification
(Pass/Fail)	  	Comments	  	Initial &
Date
						
	Customer computer with TrakStar software installed	  	☐	  	Verify version is correct	  		  		  	

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 Form completion 
  

					
	Completed By:	  	Title:	  	Date:

 Authorized Representative or DMAH Retains Form 

 

					
	Completed By:	  	Title:	  	Date:

 Neuronetics Retains Form 
  

					
	Completed By:	  	Title:	  	Date:

 Return form to Neuronetics Technical Support via email to oustechservices@neuronetics.com 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 SCHEDULE L 

Certificate of Conformance 

See Attached 
 [*Three
Pages Redacted*] 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 SCHEDULE M 

Specifications 
 See
Attached 
 [*Twenty-Four Pages Redacted*] 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 SCHEDULE N 

Track Computer Specifications 
  

			
	Processor	  	Pentium M or Pentium 4 at 1GHz or faster
		
	Operation System	  	Windows 7 Professional or later
		
	RAM	  	2GB (min)
		
	Hard Drive	  	60GB HD @5400 rpm (min)
		
	ROM Drive	  	48x CD ROM (min)
		
	Graphics	  	 1024 x 768 minimum resolution
  

32 bit color

		
	Display/Monitor	  	19” LCD Flat Panel (min)
		
	Web Browser	  	Google Chrome
		
	Internet	  	Internet access with separate network card and anti-virus software.
		
	Network	  	Isolated, secure, wired networking with NeuroStar(s)
		
	Accessories	  	Standard keyboard, mouse, printer

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 SCHEDULE O 

Accessories And Service Parts 
  

							
	 Replacement NeuroStar Product Accessories

 

	 Catalog Number
	  	 Item Number
	  	 Description
	  	 US$ transfer Price

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	
	 Accessories
  

	 Catalog Number
	  	 Item Number
	  	 Description
	  	 US$ transfer Price

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	
	 Service Parts
  

	 Catalog Number
	  	 Item Number
	  	 Description
	  	 US$ transfer Price

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	
[*]

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

							
		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  		  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

		  	 [*]
	  	 [*]
	  	 [*]

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.2

 Exhibit 10.2 

Execution Version 
 SIXTH
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 
 by and among 

NEURONETICS, INC. 
 and

 THE STOCKHOLDERS LISTED HEREIN 

Dated as of June 1, 2017 

 TABLE OF CONTENTS 

 

									
	 	  	Page	 
	1. PREEMPTIVE RIGHTS	  	 	2	 
				
		  	1.1.	 	Grant of Rights	  	 	2	 
				
		  	1.2.	 	New Securities	  	 	3	 
				
		  	1.3.	 	Notice	  	 	3	 
				
		  	1.4.	 	Acceptance of Offer	  	 	4	 
				
		  	1.5.	 	Company Sales of Refused Securities	  	 	4	 
				
		  	1.6.	 	Reduction in Amount of Offered Securities	  	 	4	 
				
		  	1.7.	 	Completion of Purchase	  	 	4	 
				
		  	1.8.	 	Reservation of Rights	  	 	5	 
				
		  	1.9.	 	Termination of Rights	  	 	5	 
		
	2. COVENANTS	  	 	5	 
				
		  	2.1.	 	Budgets	  	 	5	 
				
		  	2.2.	 	Investments	  	 	5	 
				
		  	2.3.	 	Annual Financial Statements	  	 	5	 
				
		  	2.4.	 	Quarterly and Monthly Financial Statements	  	 	6	 
				
		  	2.5.	 	Officers’ Certificates	  	 	6	 
				
		  	2.6.	 	Other Financial Information	  	 	6	 
				
		  	2.7.	 	Other Information; Inspection and Audit Rights	  	 	7	 
				
		  	2.8.	 	Rights to Attend Meetings, Etc	  	 	7	 
				
		  	2.9.	 	Notices of Litigation, Etc	  	 	8	 
				
		  	2.10.	 	Records and Accounts	  	 	8	 
				
		  	2.11.	 	Corporate Existence; Maintenance of Properties	  	 	8	 
				
		  	2.12.	 	Insurance	  	 	9	 
				
		  	2.13.	 	Taxes	  	 	9	 
				
		  	2.14.	 	Compliance with Laws, Contracts, Licenses, and Permits	  	 	9	 
				
		  	2.15.	 	Transactions with Affiliates	  	 	9	 
				
		  	2.16.	 	Key Personnel	  	 	10	 
				
		  	2.17.	 	Changes to the Management Team	  	 	11	 
				
		  	2.18.	 	Indebtedness	  	 	11	 
				
		  	2.19.	 	Agreements Relating to Intellectual Property	  	 	11	 

  
 -i- 

 TABLE OF CONTENTS 

(continued) 
  

									
	 	  	 	 	 	  	Page	 
				
		  	2.20.	 	Termination of Rights	  	 	11	 
				
		  	2.21.	 	Remedies	  	 	11	 
				
		  	2.22.	 	Right of First Refusal Upon Issuances of Common Stock	  	 	11	 
				
		  	2.23.	 	Qualified Small Business Stock	  	 	11	 
				
		  	2.24.	 	FCPA Compliance	  	 	12	 
		
	3. REGISTRATION RIGHTS	  	 	12	 
				
		  	3.1.	 	Demand Registrations	  	 	12	 
				
		  	3.2.	 	Piggyback Registrations	  	 	14	 
				
		  	3.3.	 	Lockup Agreements	  	 	16	 
				
		  	3.4.	 	Registration Procedures	  	 	16	 
				
		  	3.5.	 	Cooperation by Prospective Sellers, Etc.	  	 	18	 
				
		  	3.6.	 	Registration Expenses	  	 	19	 
				
		  	3.7.	 	Indemnification	  	 	20	 
				
		  	3.8.	 	Contribution in Lieu of Indemnification	  	 	22	 
				
		  	3.9.	 	Rule 144 Requirements; Form S-3 Registrations	  	 	22	 
				
		  	3.10.	 	Participation in Underwritten Registrations	  	 	24	 
				
		  	3.11.	 	Limitations on Subsequent Registration Rights	  	 	24	 
		
	4. DEFINITIONS	  	 	24	 
		
	5. MISCELLANEOUS PROVISIONS	  	 	32	 
				
		  	5.1.	 	Amendments, Consents, Waivers, Etc.	  	 	32	 
				
		  	5.2.	 	Notices	  	 	33	 
				
		  	5.3.	 	Counterparts	  	 	34	 
				
		  	5.4.	 	Captions	  	 	34	 
				
		  	5.5.	 	Binding Effect and Benefits	  	 	34	 
				
		  	5.6.	 	Assignment of Rights	  	 	34	 
				
		  	5.7.	 	Construction	  	 	35	 
				
		  	5.8.	 	Further Assurances	  	 	35	 
				
		  	5.9.	 	Severability	  	 	35	 
				
		  	5.10.	 	Equitable Relief	  	 	35	 
				
		  	5.11.	 	Entire Agreement	  	 	35	 

  
 -ii- 

 TABLE OF CONTENTS 

(continued) 
  

									
	 	  	 	 	 	  	Page	 
				
		  	5.12.	 	Publicity	  	 	35	 
				
		  	5.13.	 	Confidentiality	  	 	36	 
				
		  	5.14.	 	Governing Law	  	 	36	 
				
		  	5.15.	 	Jurisdiction	  	 	36	 

  
 -iii- 

 SIXTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

This Sixth Amended and Restated Investors’ Rights Agreement (this “Agreement”), dated as of June 1, 2017, is by and
among Neuronetics, Inc., a Delaware corporation (the “Company”), those holders of Series A-1 Preferred Stock listed on the Schedule of Series A-1
Stockholders attached hereto (the “Series A-1 Stockholders”), those holders of Series A-2 Preferred Stock listed on the Schedule of Series A-2 Stockholders attached hereto (the “Series A-2 Stockholders”), those holders of Series B Preferred Stock listed on the Schedule of Series B
Stockholders attached hereto (the “Series B Stockholders”), those holders of Series C Preferred Stock listed on the Schedule of Series C Stockholders attached hereto (the “Series C Stockholders”), those
holders of Series D Preferred Stock listed on the Schedule of Series D Stockholders attached hereto (the “Series D Stockholders”), those holders of Series E Preferred Stock listed on the Schedule of Series E
Stockholders attached hereto (the “Series E Stockholders”), those holders of Series F Preferred Stock listed on the Schedule of Series F Stockholders attached hereto (the “Series F Stockholders”), those
holders of Series G Preferred Stock listed on the Schedule of Series G Stockholders attached hereto (the “Series G Stockholders”), and each person or entity that subsequently becomes a party to this Agreement (the
“Additional Stockholders,” and, together with the Series A-1 Stockholders, the Series A-2 Stockholders, the Series B Stockholders, the Series C
Stockholders, the Series D Stockholders, the Series E Stockholders, the Series F Stockholders and the Series G Stockholders, collectively, the “Stockholders”). 

WHEREAS, the Series A-1 Stockholders own of record an aggregate of 4,800,000 shares of Series A-1 Preferred Stock of the Company; 
 WHEREAS, the Series A-2
Stockholders own of record an aggregate of 25,384,615 shares of Series A-2 Preferred Stock of the Company, which were issued pursuant to the terms of that certain Series
A-2 Stock Purchase Agreement, dated as of April 3, 2003 (the “Series A-2 Purchase Agreement”); 

WHEREAS, the Series B Stockholders own of record an aggregate of 17,000,000 shares of Series B Preferred Stock of the Company, which were
issued pursuant to the terms of that certain Series B Stock Purchase Agreement, dated as of March 4, 2005 (the “Series B Purchase Agreement”); 

WHEREAS, the Series C Stockholders own of record an aggregate of 20,958,084 shares of Series C Preferred Stock of the Company, which were
issued pursuant to the terms of that certain Series C Preferred Stock Purchase Agreement, dated as of August 2, 2006 (the “Series C Purchase Agreement”); 

WHEREAS, the Series D Stockholders own of record an aggregate of 49,426,229 shares of Series D Preferred Stock of the Company, which were
issued pursuant to the terms of that certain Series D Preferred Stock Purchase Agreement, dated as of August 20, 2009 (the “Series D Purchase Agreement”); 

 WHEREAS, the Series E Stockholders own of record an aggregate of 44,470,799 shares of Series E
Preferred Stock of the Company, which were issued pursuant to the terms of that certain Series E Preferred Stock Purchase Agreement, dated as of May 13, 2011 (the “Series E Purchase Agreement”); 

WHEREAS, the Series F Stockholders own of record an aggregate of 102,334,194 shares of Series F Preferred Stock of the Company, which were
issued pursuant to the terms of that certain Series F Preferred Stock Purchase Agreement, dated as of April 24, 2015 (the “Series F Purchase Agreement”); 

WHEREAS, in connection with the acquisition of the Series F Preferred Stock, the Company, the Series
A-1 Stockholders, the Series A-2 Stockholders, the Series B Stockholders, the Series C Stockholders, the Series D Stockholders, the Series E Stockholders and the Series
F Stockholders entered into a Fifth Amended and Restated Investors’ Rights Agreement, dated as of April 24, 2015 (as amended from time to time thereafter, the “Prior Agreement”); 

WHEREAS, the Series G Stockholders are acquiring shares of Series G Preferred Stock pursuant to the terms of that certain Series G Preferred
Stock Purchase Agreement (the “Series G Purchase Agreement”) dated even herewith; and 
 WHEREAS, but for the execution and
delivery of this Agreement by the Company and the Stockholders, the Series G Stockholders would not be willing to enter into the Series G Purchase Agreement or to consummate the transactions thereby contemplated, which transactions will benefit the
Company. 
 NOW, THEREFORE, in order to induce the Series G Stockholders to consummate the transactions contemplated by the Series G
Purchase Agreement, the parties hereby amend and restate, and replace in its entirety, the Prior Agreement as follows: 
 Certain terms used
in this Agreement are defined in Section 4 hereof. 
 1.  PREEMPTIVE RIGHTS. 

1.1. Grant of Rights. Unless waived by the written consent of the Required Senior Preferred Holders (provided that such waiver does not adversely affect
the rights hereunder of any Substantial Stockholder in a manner different from or disproportionate to any adverse effect such waiver would have on the rights of any other Substantial Stockholder), and the Company hereby grants to each Substantial
Stockholder, and any permitted assignee of each such Substantial Stockholder described in Section 5.6 (each a “Right Holder”), the right to purchase up to its pro rata share of any New Securities that the Company may,
from time to time, propose to sell or issue (the “Available New Securities”). Each such Right Holder’s pro rata share of the Available New Securities for purposes of this Section 1, is equal to the ratio of
(i) the number of shares of Common Stock issued and outstanding or issuable upon conversion of any shares of Preferred Stock of the Company convertible into shares of Common Stock then held of record by such Right Holder, to (ii) the sum
of the total number of shares of the Common Stock issued and outstanding or issuable upon conversion of any then-outstanding shares of Preferred Stock of the Company convertible into shares of Common Stock. 

  
 -2- 

 1.2. New Securities. “New Securities” shall mean any equity securities of the
Company, whether now authorized or not, and rights, options or warrants to purchase said equity securities, and securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for said equity securities;
provided, that “New Securities” does not include (i) shares of Common Stock issued by the Company pursuant to stock dividends, stock splits, recapitalizations and similar transactions; (ii) shares of Common Stock
issued upon conversion of shares of Preferred Stock that are outstanding on the date hereof; (iii) shares of capital stock of the Company issued upon exercise, conversion or exchange of Derivative Securities (as defined in Section 4
hereof) that are outstanding on the date hereof; (iv) shares of Common Stock, or options, warrants or other rights to acquire shares of Common Stock, that are issued or issuable by the Company to officers, directors, employees or consultants of
the Company with the prior approval of the Board of Directors of the Company (the “Board of Directors”) or an appropriate committee thereof pursuant to the Company’s Amended and Restated 2003 Stock Incentive Plan, as amended,
or any other stock option, stock purchase or other plan approved by the Board of Directors, and the stockholders if necessary; (v) securities issued in consideration of the grant by or to the Company of marketing rights, license rights or
similar rights or in consideration of the exchange of proprietary technology (for which raising equity capital was not a significant purpose of such issuance), in each such case with prior Super Board Approval; or (vi) securities issued in
connection with acquisitions or strategic alliances or issued to landlords, commercial financing or leasing companies (for which raising equity capital was not a significant purpose of such issuance), in each such case with prior Super Board
Approval. 
 1.3. Notice. The Company shall not issue, sell or exchange, agree to issue, sell or exchange, or reserve or set aside for
issuance, sale or exchange any New Securities unless the Company shall first deliver to each Right Holder a written notice of any proposed or intended issuance, sale or exchange of New Securities (the “Offer”), which Offer shall
(i) identify and describe the New Securities, (ii) describe the price and other terms upon which they are to be issued, sold or exchanged, and the number or amount of the New Securities to be issued, sold or exchanged, (iii) identify
the persons or entities, if known, to which or with which the New Securities are to be offered, issued, sold or exchanged, and (iv) offer to issue and sell to, or exchange with, each such Right Holder (A) the amount of New Securities that
each such Person is entitled to purchase pursuant to Section 1.1 and (B) any additional portion of the New Securities required to be offered pursuant to Section 1.1 as any such Person shall indicate it will purchase or acquire should
any other Right Holders subscribe for less than the amount of New Securities that each such Person is entitled to purchase pursuant to Section 1.1 (the “Undersubscription Amount”). Each Right Holder shall have the right, for a
period of 30 days following delivery of the Offer, to elect to purchase or acquire, at the price and upon the other terms specified in the Offer, the number or amount of New Securities described above. The Offer by its terms shall remain open and
irrevocable for such 30-day period. 

  
 -3- 

 1.4. Acceptance of Offer. To accept an Offer, in whole or in part, a Right Holder must
deliver a written notice to the Company prior to the end of the 30-day period of the Offer, setting forth the amount of New Securities that such Person elects to purchase and the Undersubscription Amount (if
any) that such Person elects to purchase (the “Notice of Acceptance”). If the amount of New Securities subscribed for by all Right Holders is less than the amount of New Securities to which all Right Holders are entitled, then each
Right Holder who has set forth an Undersubscription Amount in its Notice of Acceptance shall be entitled to purchase, in addition to the amount of New Securities subscribed for, the Undersubscription Amount it has subscribed for; provided,
that should the Undersubscription Amounts subscribed for exceed the difference between the amount of New Securities to which all Right Holders are entitled pursuant to Section 1.1 and the amount of New Securities actually subscribed for (the
“Available Undersubscription Amount”), each Person’s Undersubscription Amount shall be reduced such that the Available Undersubscription Amount is allocated among such Persons pro rata, based on the amount of New
Securities that each such Person is entitled to purchase pursuant to Section 1.1 (but not in excess of their respective Undersubscription Amounts), with any Available Undersubscription Amount after such reallocation being further reallocated in
the same manner until the entire Available Undersubscription Amount has been so allocated. 
 1.5. Company Sales of Refused Securities.
The Company shall have 90 days from the expiration of the period set forth in Section 1.3 above to issue, sell or exchange all or any part of such New Securities as to which a Notice of Acceptance has not been given by the Right Holders (the
“Refused Securities”), but only upon terms and conditions (including unit prices and interest rates) which are not more favorable in any material respect to the acquiring party or parties or less favorable in any material respect to
the Company than those described in the Offer. 
 1.6. Reduction in Amount of Offered Securities. In the event the Company shall
propose to sell less than all the Refused Securities (any such sale to be in the manner and on the terms specified in Section 1.5 above), then each Right Holder may, at its sole option and in its sole discretion, reduce the number or amount of
the New Securities specified in its Notice of Acceptance to an amount that shall be not less than the number or amount of the New Securities that such Person elected to purchase pursuant to Section 1.4 above multiplied by a fraction,
(i) the numerator of which shall be the number or amount of New Securities the Company actually proposes to issue, sell or exchange (including New Securities to be issued or sold to the Right Holders pursuant to Section 1.4 above prior to
such reduction) and (ii) the denominator of which shall be the amount of all New Securities that the Company initially proposed to offer, sell or exchange as described in the Offer. In the event that any Right Holder so elects to reduce the
number or amount of New Securities specified in its Notice of Acceptance, the Company may not issue, sell or exchange more than the reduced number or amount of the New Securities unless and until such securities have again been offered to the Right
Holders in accordance with Section 1.3 above. 
 1.7. Completion of Purchase. Upon the closing of the issuance, sale or exchange of all
or less than all the Refused Securities, the Right Holders shall acquire from the Company, and the Company shall issue to the Right Holders, the number or amount of New Securities specified in 

  
 -4- 

 
the Notices of Acceptance, as reduced pursuant to Section 1.6 above if applicable, upon the terms and conditions specified in the Offer. Any obligations of the Right Holders to purchase any
New Securities after delivery of Notices of Acceptance will be subject in all cases to the preparation, execution and delivery by the Company and the Right Holders, as applicable, of a purchase agreement relating to such New Securities reasonably
satisfactory in form and substance to the Right Holders, as applicable, and their respective counsel. 
 1.8. Reservation of Rights. Any New
Securities not acquired by the Right Holders or other persons in accordance with Section 1.5 above may not be issued, sold or exchanged until they are again offered to the Right Holders under the procedures specified in this Agreement. 

1.9. Termination of Rights. The prohibitions and rights provided in this Section 1 will not apply to, and will terminate upon (i) the closing
of a Qualified Public Offering, or (ii) any Acquisition in connection with which the stockholders of the Company receive cash and/or unrestricted securities that are actively traded on a national securities exchange and are of an entity subject
to and in compliance with the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, whichever event occurs first. 
 2.
COVENANTS. The Company covenants that for so long as any shares of Preferred Stock are outstanding, the Company will comply (and should it at any time have any Subsidiaries, cause each of such Subsidiaries to comply) with each of the following
covenants, except as otherwise waived by the written consent of the Required Senior Preferred Holders. 
 2.1. Budgets. The Company will
deliver to each Substantial Stockholder, as soon as practical after preparation thereof, but in no event later than 30 days prior to the beginning of each fiscal year of the Company, preliminary, and in no event later than 30 days after the
beginning of each fiscal year of the Company, final, pro forma financial projections and budgets (which will contain projected balance sheets and statements of income, retained earnings and cash flows (including capital expenditures)) for the
Company for such fiscal year, including month-by-month projections and budgets, which final, pro forma financial projections and budgets shall have been approved
by the Board of Directors, which approval shall be by Super Board Approval. 
 2.2. Investments. The Company will not have outstanding, or
acquire or commit itself to acquire or hold, any investment in excess of $100,000 not in the budget delivered pursuant to Section 2.1, except for (a) short-term government obligations or other cash equivalent investments, and
(b) other investments made by the Company in accordance with the Corporate Investment Policy of the Company, approved September 15, 2006, as amended from time to time, or any replacement policy adopted with the prior approval of the Board
of Directors, which approval must be by Super Board Approval. 
 2.3. Annual Financial Statements. As soon as available and in any event
within 90 days after the close of each fiscal year of the Company, the Company will deliver to each Substantial Stockholder a balance sheet and statements of income, retained earnings and cash flows, audited by KPMG LLP or another reputable
independent public accounting firm approved by the Board 

  
 -5- 

 
of Directors, which approval shall be by Super Board Approval, showing the financial condition of the Company as of the close of such fiscal year and the results of its operations during such
fiscal year. Each of the financial statements delivered hereunder will be certified by such accounting firm without material qualification to have been prepared in accordance with GAAP consistently applied. 

2.4. Quarterly and Monthly Financial Statements. 

(a) As soon as available, and in any event within 30 days after the end of each of the first three fiscal quarters of each fiscal year
of the Company, commencing with the first fiscal quarter ending after the date hereof, the Company will deliver to each Substantial Stockholder an unaudited balance sheet and statements of income, retained earnings and cash flows of the Company, and
a summary of bookings and backlog, as of the end of and for such fiscal quarter, subject to the absence of footnotes and to adjustments consisting of normal year-end accruals, the effect of which, both
individually and in the aggregate, is not material. 
 (b) As soon as available, and in any event within 30 days after the end of
each month, commencing with the first month ending after the date hereof, the Company will deliver to each Substantial Stockholder unaudited balance sheets and statements of income and cash flows of the Company as of the end of each such month,
subject to the absence of footnotes and to adjustments consisting of normal quarter-end and year-end accruals, the effect of which, both individually and in the
aggregate, is not material. The Company will also deliver, along with such unaudited balance sheets and statements of income and cash flows, a comparison of the unaudited balance sheets and statements of income and cash flows of the Company as of
the end of each such month against (i) the final pro forma financial projections and budgets for such month, and (ii) the balance sheets and statements of income and cash flows of the Company as of the end of such month for the
prior year. 
 2.5. Officers’ Certificates. Together with delivery of financial statements of the Company pursuant to Sections 2.3 and
2.4(a) above, the Company will deliver to each Substantial Stockholder a certificate of the Company signed by the chief executive or financial officer of the Company stating that such statements have been prepared in accordance with GAAP and present
fairly the financial position of the Company as of the dates specified and the results of its operations and cash flows with respect to the periods specified (in the case of the financial statements delivered under Section 2.4(a), subject to
the absence of footnotes and to adjustments consisting of normal quarter-end or year-end accruals, the effect of which, both individually and in the aggregate, is not
material). 
 2.6. Other Financial Information. The Company will further deliver to each Substantial Stockholder as soon as practical after
preparation thereof but in no event (in the case of clause (a) below) later than 10 days prior to the beginning of the fiscal period to which such financial forecast relates, complete and correct copies of (a) all quarterly (if any) or
annual budgetary analyses or forecasts of the Company not referred to in Section 2.1 hereof, in the form customarily prepared by management for its own internal use or the use of the Board of Directors, (b) all registration statements
proposed to be filed by the Company under the 

  
 -6- 

 
Securities Act, and (c) all other financial and other reports prepared for the use of the Board of Directors and/or any bank lender to the Company (and not otherwise required to be delivered
hereunder). 
 2.7. Other Information; Inspection and Audit Rights. 

(a) From time to time upon the request of a Substantial Stockholder, the Company will (i) furnish to such holder such information
regarding the business, affairs, finances and prospects of the Company as is prepared by the Company in the ordinary course of business or as can be readily prepared from materials prepared by the Company in the ordinary course of business, and will
make available to such holder, such officers, directors, key employees and accountants of the Company as such holder may reasonably request, and (ii) permit each Substantial Stockholder to visit and inspect the Company’s properties upon
reasonable advance notice and during normal business hours. 
 (b) Each Substantial Stockholder will have the right during normal
business hours to examine the books and records of the Company, to make copies, notes and abstracts therefrom, to discuss the Company’s affairs with the officers, directors, key employees and accountants of the Company, and to make or cause to
be made an independent examination and/or audit (at such holder’s expense) of the books and records of the Company. 
 2.8. Rights to Attend
Meetings, Etc. The Company will call and hold a meeting of its Board of Directors at least once each fiscal quarter, and will reimburse the reasonable travel expenses of each director incurred in connection with such director’s attendance
at each meeting of the Company’s Board of Directors and/or any committee thereof. Each Series A-2 Substantial Stockholder, each Series B Substantial Stockholder, Investor Growth Capital, QPIV, New
Leaf, Pfizer, Polaris, GE Ventures and CHV (without duplication) also shall have the right to appoint one participating, but non-voting, observer (each, an “Observer”) (so long as no director
designated by such Series A-2 Substantial Stockholder or such Series B Substantial Stockholder, as the case may be, pursuant to Section 1.2 of the Stockholders’ Agreement is currently serving on the
Board of Directors; provided, that each of Investor Growth Capital’s, QPIV’s, New Leaf’s, Pfizer’s, Polaris’, GE Ventures’ and CHV’s right to appoint an Observer shall exist without regard to the current
composition of the Board of Directors). Any Observer appointed pursuant to this Section 2.8 shall be entitled to receive notice of all Board meetings in the same manner that such notice is delivered to the Company’s directors, shall be
entitled to receive all materials delivered to the Company’s directors in connection with Board meetings (subject to the execution of confidentiality agreements as the Company may reasonably request), and shall be entitled to participate (in a non-voting capacity) in all Board meetings; provided however, that only the Observers appointed by CHV, GE Ventures, Onset IV, L.P. and QPIV may attend Board meetings in person; provided
further, that if the director designee of the Stockholder who designates such Observer is unable to attend a board meeting in person, then the Observer may attend such meeting in person irrespective of the foregoing. Notwithstanding the
foregoing, the Company may withhold any information and exclude any such Observer from any meeting or materials of its Board of Directors for that period of time that the Company believes in good 

  
 -7- 

 
faith that access to any information or attendance at any meeting or materials (i) would result in a clear conflict of interest (in which case such Observer may be excluded only from that
portion of a meeting or materials in which such conflict of interest exists), (ii) where sharing certain information considered in the meeting or materials would result in a breach by the Company of a duty of confidentiality to a third party (in
which case such Observer may be excluded only from that portion of a meeting or materials during which such information is considered), and (iii) would adversely affect the attorney-client privilege between the Company and its counsel with
respect to such information. 
 2.9. Notices of Litigation, Etc. The Company will promptly give to each Substantial Stockholder notice of any
litigation or any administrative proceeding to which the Company may hereafter become a named party, excepting only those in which the only relief sought is money damages in an amount not exceeding $100,000 in any one instance, or $250,000 in the
aggregate with respect to all such litigations or proceedings. Upon the request of a Substantial Stockholder, the Company will promptly furnish to such Substantial Stockholder copies of all correspondence, notices, pleadings, reports and other
documents in connection with any litigation or proceeding in which it is currently involved or of which it is required to give notice hereunder or that may be received from any governmental agency or other person asserting a claim or potential claim
against the Company, except with respect to such correspondence, notices, pleadings, reports and other documents that the Company reasonably believes are subject to attorney-client privilege, work-product doctrine, or such other evidentiary
privilege or similar doctrine. Promptly after the receipt thereof, the Company will provide to each Substantial Stockholder copies of any reports (including management letters and reports and letters with respect to the adequacy of the
Company’s internal accounting controls) submitted by independent accountants with respect to the Company. 
 2.10. Records and Accounts.
The Company will keep true and accurate records and books of account in which full, true and correct entries will be made so as to permit the preparation of financial statements in accordance with GAAP and maintain adequate accounts and reserves in
accordance with good accounting practice for all taxes (including income taxes), all depreciation, depletion, obsolescence and amortization of its properties, all contingencies and all other reserves. 

2.11. Corporate Existence; Maintenance of Properties. The Company will preserve and keep in full force and effect its corporate existence,
rights and franchises. The Company will not engage in any business other than as presently conducted by it, businesses reasonably ancillary thereto and other businesses approved by the Board of Directors, which approval must be by Super Board
Approval. The Company will maintain all of its properties used or useful in the conduct of its business in good condition, repair and working order and cause to be made all necessary repairs, renewals, replacements, betterments and improvements
thereof, all as in the judgment of the Company may be necessary so that the business carried on in connection therewith may be properly and advantageously conducted at all times; provided, however, that nothing in this Section 2.11 will
prevent the Company from discontinuing the operation and maintenance of any of such properties if such discontinuance is, in the judgment of the Company, desirable in the conduct of its business and does not in the aggregate materially and adversely
affect the business of the Company. 

  
 -8- 

 2.12. Insurance. The Company will use commercially reasonable efforts in good faith to obtain by no later
than July 15, 2017 and thereafter maintain in place key-man life insurance with respect to the life of the Chief Executive Officer of the Company, with such policy having a death benefit of at least
$1,000,000, payable to the Company; provided, however, that such insurance may not be canceled without at least 30 days’ prior written notice to the Substantial Stockholders delivered by the Company in accordance with Section 5.2 of
this Agreement. The Company will maintain this key-man life insurance with respect to the Chief Executive Officer for so long as such person continues to be employed by the Company; and the Company will
maintain with financially sound and reputable insurance companies, funds or underwriters insurance of the kinds, covering the risks (including directors’ and officers’ liability) and in the relative proportionate amounts usually carried by
reasonable and prudent companies conducting businesses similar to that of the Company. The Company shall use its commercially reasonable efforts to maintain in full force and effect director and officer liability insurance with a coverage amount
typical for similarly situated companies, which insurance shall not be cancelable by the Company without prior approval by the Board of Directors. 

2.13. Taxes. The Company will pay and discharge, or cause to be paid and discharged, before they become delinquent, all taxes, assessments and other
governmental charges imposed upon the Company or any of the properties, sales or activities of the Company, or any part thereof, or upon the income or profits therefrom, as well as all claims for labor, materials or supplies, which, if unpaid might
by law give rise to a Lien upon any of its properties; provided, however, that any such tax, assessment, charge, levy or claim need not be paid if the validity or amount thereof is currently being contested in good faith by appropriate
proceedings and if the Company has set aside on its books adequate reserves with respect thereto. 
 2.14. Compliance with Laws, Contracts, Licenses, and
Permits. The Company will comply in all material respects with (a) its charter documents and by-laws, (b) all judgments, decrees, orders, statutes, rules and regulations binding on or applicable
to the Company or its business or properties, and (c) any agreement or instrument to which it is a party or by which it or any of its properties are subject (including the Other Agreements). If at any time any authorization, consent, approval,
permit or license from any officer, agency or instrumentality of any government becomes necessary or required in order that the Company may fulfill any of its obligations hereunder, the Company will promptly take or cause to be taken all necessary
steps within its power to obtain such authorization, consent, approval, permit or license and will promptly furnish evidence thereof. 
 2.15.
Transactions with Affiliates. The Company will not engage in any transaction with any Affiliate on terms more favorable to the Affiliate than would have been obtainable by an unaffiliated person on an arms’-length basis in the ordinary
course of business. Without limiting the foregoing sentence, the Company will not, without the affirmative vote or consent of the Super Board Approval, amend, waive any valuable right under, enter into any agreement in 

  
 -9- 

 
conflict with, or terminate any agreement with any officer or key employee of the Company, including any agreement relating to confidentiality, ownership or assignment of any intellectual
property to the Company or non-competition with the Company. 
 2.16. Key Personnel. 

(a) The Company will not engage any employee unless such person first executes and delivers to the Company an agreement, in
substantially the form attached hereto as Exhibit A, with respect to: (i) the confidentiality of the Company’s proprietary and/or confidential information; (ii) the assignment to the Company of any and all rights they might
have or acquire with respect to technology, inventions, developments, etc., developed in connection with their employment relationship with the Company and (iii) a covenant not to compete with the Company (unless the Board of Directors, by
Super Board Approval, determines that such person is not a key employee). 
 (b) The Company will not engage any consultant (other
than academic institutions or individuals governed by the rules, regulations and/or policies of an academic institution) or advisor (including any member of an advisory board of the Company established by the Board of Directors) with access to
confidential information or trade secrets, unless such person first executes and delivers to the Company an agreement containing provisions substantially similar in content to the provisions contained in Exhibit A relating to:
(i) confidentiality of the Company’s proprietary and/or confidential information; and (ii) the assignment to the Company of any and all rights such person might have or acquire with respect to technology, inventions, developments,
etc., developed in connection with their consulting relationship with the Company. 
 (c) The Company will not engage any academic
institution or individuals governed by the rules, regulations and/or policies of an academic institution unless (i) such person first executes and delivers to the Company an agreement containing provisions substantially similar in content to
the provisions contained in Exhibit A relating to confidentiality of the Company’s proprietary and/or confidential information and (ii) the Company uses commercially reasonable efforts in good faith to obtain from such person an
agreement containing provisions substantially similar in content to the provisions contained in Exhibit A relating to the assignment to the Company of any and all rights such person might have or acquire with respect to technology,
inventions, developments, etc., developed in connection with their consulting relationship with the Company; provided, that if the resulting assignment agreement, if any, is not so substantially similar or no such assignment is forthcoming,
then the Company will not engage such person unless such person first executes and delivers to the Company an agreement containing provisions relating to the Company’s right or option to license from such person rights such person might have or
might acquire with respect to such technology, inventions, developments, etc. 
 (d) The compensation of all officers, senior
management and key employees of the Company will be as determined from time to time by the Compensation Committee of the Board of Directors. 

  
 -10- 

 2.17. Changes to the Management Team. The Company will not appoint, terminate or remove the Chief
Executive Officer or other Key Officers without the affirmative vote or consent of the Super Board Approval. 
 2.18. Indebtedness. The Company will
not incur any indebtedness in excess of $500,000 individually or $1,000,000 in the aggregate in any twelve (12) month period, without the affirmative vote or consent of the Super Board Approval. 

2.19. Agreements Relating to Intellectual Property. The Company will not enter into any material agreement with respect to any material Intellectual
Property of the Company (including both licenses of such Intellectual Property to the Company and by the Company to third parties) without the affirmative vote or consent of the Super Board Approval. 

2.20. Termination of Rights. The covenants set forth in this Section 2 will terminate (i) upon the closing of a Qualified Public Offering,
(ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon any Acquisition; provided, however, that with regard to (iii), the covenants
set forth in Sections 2.3, 2.4 and 2.7 shall not terminate unless the stockholders of the Company receive cash and/or unrestricted securities that are actively traded on a national securities exchange and are of an entity subject to and in
compliance with the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, whichever event occurs first. 
 2.21.
Remedies. In case any one or more of the covenants and/or agreements set forth in this Agreement shall have been breached by any party hereto, the party or parties entitled to the benefit of such covenants or agreements may proceed to protect
and enforce its or their rights, either by suit in equity and/or action at law, including, but not limited to, an action for damages as a result of any such breach and/or an action for specific performance of any such covenant or agreement contained
in this Agreement. The rights, powers and remedies of the parties under this Agreement are cumulative and not exclusive of any other right, power or remedy which such parties may have under any other agreement or law. No single or partial assertion
or exercise of any right, power or remedy of a party hereunder shall preclude any other or further assertion or exercise thereof. 
 2.22. Right of First
Refusal Upon Issuances of Common Stock. The Company shall not issue shares of Common Stock constituting greater than 1% of the issued and outstanding Common Stock (for purposes of this calculation only, after giving effect to the conversion
and/or exercise of all then outstanding Derivative Securities) to any person unless, as a condition to such issuance, such person (i) provides the Company with a
right-of-first-refusal on such shares substantially equivalent to that provided by Section 3.2(a) of the Stockholders’ Agreement, and (ii) agrees to
restrictions on the sale of such shares of Common Stock no less restrictive in any manner than those provided by Section 3.3 hereof. 
 2.23.
Qualified Small Business Stock. The Company shall use commercially reasonable efforts to cause the shares of Series G Preferred Stock, Series F Preferred Stock, Series E Preferred Stock and Series D Preferred Stock issued pursuant to the Series
G Purchase 

  
 -11- 

 
Agreement, Series F Purchase Agreement, Series E Purchase Agreement and Series D Purchase Agreement, respectively, to constitute “qualified small business stock” as defined in
Section 1202(c) of the Code; provided, however, that such requirement shall not be applicable if the Board of Directors determines, in its good-faith business judgment, that such qualification is inconsistent with the best interests of
the Company. The Company shall prepare and submit to the Internal Revenue Service any reports that may be required under Section 1202(d)(1)(C) of the Code and the regulations promulgated thereunder. In addition, if the Company proposes to enter
into a transaction which would (solely as a result of such transaction and not as a result of an action or fact specific to any Substantial Stockholder) result in the loss of benefits under Section 1202 of the Code to such Substantial
Stockholders, the Company will promptly notify the Substantial Stockholders prior to the implementation of such proposed transaction. 
 2.24. FCPA
Compliance. The Company shall not, and shall not permit any of its subsidiaries or affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to, promise, authorize
or make any payment to, or otherwise contribute any item of value to, directly or indirectly, any non-U.S. government official, in each case, in violation of the U.S. Foreign Corrupt Practices Act
(“FCPA”) or any other applicable anti-bribery or anti-corruption law. The Company shall, and shall cause each of its subsidiaries and affiliates to, cease all of its or their respective activities, as well as remediate any actions
taken by the Company, its subsidiaries or Affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation of the FCPA or any other applicable anti-bribery or
anti-corruption law. The Company shall, and shall cause each of its subsidiaries and affiliates to, maintain systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure
compliance with the FCPA or any other applicable anti-bribery or anti-corruption law. 
 3. REGISTRATION RIGHTS. 

3.1. Demand Registrations. 
 (a)
Request for Demand Registration. 
 (i) Commencing upon 180 days after the closing of the Initial Public Offering,
subject to the limitations set forth in the following paragraphs of this Section 3.1, the Holders of 20% of the then-outstanding Registrable Securities may at any time give to the Company a written request for the registration (a
“Demand Registration”) by the Company under the Securities Act of all or any part of the Registrable Securities held by such Holders. Within ten business days after the receipt by the Company of any such written request, the Company
will give written notice of such request to all Holders. 
 (ii) Subject to the limitations set forth in the following
paragraphs of this Section 3.1, after the receipt of a written request for a Demand Registration, (A) the Company will be obligated to include in such Demand Registration all Registrable Securities with respect to which the Company
receives from Holders the written requests 

  
 -12- 

 
of such Holders for inclusion in such Demand Registration within 20 days after the date on which the Company gives to all Holders a written notice of registration request pursuant to
Section 3.1(a)(i) of this Agreement, and (B) the Company will use its best efforts in good faith to effect promptly the registration of all such Registrable Securities. All written requests made by Holders pursuant to this
Section 3.1(a)(ii) will specify the number of Registrable Securities to be registered and will also specify the intended method of disposition thereof. Such method of disposition will, in any case, be an underwritten offering unless the Holders
of at least 40% of the Registrable Securities to be included in such Demand Registration otherwise request. 
 (iii) The
registration statement filed pursuant to a Demand Registration pursuant to this Section 3.1(a) may, subject to the limitations set forth in Section 3.1(c) hereof, include other securities of the Company which are held by persons other than
the Holders who, by virtue of agreements with the Company, are entitled to include their securities in any such registration. 
 (b)
Limitations on Demand Registrations. 
 (i) The Company will not be obligated to effect more than two Demand
Registrations pursuant to Section 3.1(a) of this Agreement. 
 (ii) Any registration initiated by Holders as a Demand
Registration pursuant to Section 3.1(a) hereof will not count as a Demand Registration for purposes of Section 3.1(b)(i) of this Agreement if (A) any shares are included in such registration for the account of the Company and/or
stockholders other than Holders, or (B) such registration does not become effective or at least 50% of all Registrable Securities held by Holders and requested by them to be included in such registration are not actually sold pursuant to such
registration. 
 (iii) The Company will not be obligated to effect the Demand Registration of any Registrable Securities
pursuant to Section 3.1(a) hereof during the period commencing on the date falling 90 days prior to the Company’s estimated date of filing of, and ending on the date 180 days following the effective date of, any registration statement
pertaining to any registration initiated by the Company, for the account of the Company and/or stockholders other than Holders (other than with respect to securities registered solely in connection with acquisitions, employee benefit plans and the
like), if the written request of Holders for such Demand Registration pursuant to Section 3.1(a) hereof is received by the Company after the Company has given to all Holders a written notice stating that the Company is commencing an
underwritten registration initiated by the Company and provides reasonable evidence that it commenced activities directly related to such filing before receiving the written request of the Holders; provided, however, that the Company will use
its best efforts in good faith to cause any such registration statement to be filed and to become effective as expeditiously as is reasonably possible. 

  
 -13- 

 (iv) The Company will not be obligated to effect any Demand Registration of
Registrable Securities for any 90-day period following receipt of any written request for registration if, in the good faith judgment of the Board of Directors, the filing of any registration statement during
such 90-day period would adversely affect a material proposed or pending acquisition, merger or similar corporate event to which the Company is or expects to be party. The Company may rely on this
Section 3.1(b)(iv) only one time during any 12-month period whether in connection with a registration pursuant to Section 3.1(a) or Section 3.9(a). 

(c) Priority in Demand Registrations. If the managing underwriters in any Demand Registration advise the Company that the number
of securities proposed to be included in such registration exceeds the Underwriters’ Maximum Number therefor, then: (i) the Company will be obligated to include in such registration that number of Registrable Securities requested by
Holders to be included in such registration as does not exceed the Underwriters’ Maximum Number, and such number of Registrable Securities will be allocated pro rata among such Holders on the basis of the number of Registrable Securities
held by each such Holder; (ii) if the Underwriters’ Maximum Number exceeds the number of Registrable Securities requested by Holders to be included in such registration, then the Company will be entitled to include in such registration
that number of securities as has been requested by the Company to be included in such registration for the account of the Company and that is not greater than such excess; and (iii) if the Underwriters’ Maximum Number exceeds the sum of
the number of Registrable Securities that the Company is obligated under clause (i) above to include in such Demand Registration plus the number of securities that the Company proposes to offer and sell for its own account in such registration,
then the Company may include in such registration that number of other securities as security holders other than Holders may have requested be included in such registration and that is not greater than such excess, and such number of securities will
be allocated pro rata among such security holders on the basis of the number of such securities requested to be included in such registration by each such security holder. Neither the Company nor any of its other security holders will be
entitled to include any securities in any underwritten Demand Registration unless the Company or such security holders (as the case may be) agree in writing to sell such securities on the same terms and conditions as apply to the Registrable
Securities held by Holders to be included in such Demand Registration. 
 (d) Selection of Underwriters. If any Demand
Registration is an underwritten offering, the investment bankers and managing underwriters in such registration will be selected by the Company with the approval of a majority in interest of the initiating Holders, such approval not to be
unreasonably withheld or delayed. 
 3.2. Piggyback Registrations. 

(a) Rights to Piggyback. 

(i) If (and on each occasion that) the Company proposes to register any of its securities under the Securities Act, either for
the Company’s own account or for the account of any of its security holders (other than for Holders pursuant to Section 3.1 

  
 -14- 

 
hereof) (each such registration not withdrawn or abandoned prior to the effective date thereof, a “Piggyback Registration”), the Company will give written notice to each of the
Holders of such proposal not later than the earlier to occur of (A) the tenth day following the receipt by the Company of notice of exercise of any registration rights by any persons, and (B) 30 days prior to the anticipated filing date of such
Piggyback Registration. Notwithstanding the foregoing, the Company will not be obligated to give notice to Holders as to, or to include any Registrable Securities in, any registration (y) on Form S-8 or
similar limited-purpose form of registration statement effected solely to implement an employee benefit plan, or (z) any registration on Form S-4 or similar limited-purpose form of registration statement
effected solely to implement an acquisition or business combination transaction. 
 (ii) Subject to the provisions contained
in paragraphs (b) and (c) of this Section 3.2 and in the last sentence of this clause (ii): (A) the Company will be obligated to include in each Piggyback Registration all Registrable Securities with respect to which the
Company receives, within 20 business days after the date on which the Company has given written notice of such Piggyback Registration to Holders pursuant to Section 3.2(a)(i) hereof, the written requests of such Holders for inclusion in such
Piggyback Registration, and (B) the Company will use its best efforts in good faith to effect promptly the registration of all such Registrable Securities. Holders will be permitted to withdraw all or any part of their Registrable Securities
from any Piggyback Registration at any time prior to the effective date of such Piggyback Registration. 
 (b) Priority in
Piggyback Registrations. If a Piggyback Registration is an underwritten registration, and the managing underwriters thereof give written advice to the Company of an Underwriters’ Maximum Number, then: (i) the Company will be obligated
to include in such registration that number of Registrable Securities that have been requested by Holders to be so included and which is not less than 25% of the Underwriters’ Maximum Number, and such number of Registrable Securities will be
allocated pro rata among such Holders on the basis of the number of Registrable Securities held by each such Holder; (ii) the Company will be entitled to include in such registration that number of securities that the Company proposes to
offer and sell for its own account in such registration and which does not exceed the difference between the Underwriters’ Maximum Number and the number of Registrable Securities that the Company is required under clause (i) above to
include in such registration; and (iii) if the Holders have been permitted to include in such registration all Registrable Securities that they have requested so to include and the Underwriters’ Maximum Number exceeds the sum of the number
of Registrable Securities that the Company has been requested to include in such registration for the account of Holders and the number of securities that the Company proposes to offer and sell for its own account in such registration, then the
Company may include in such registration that number of other securities that persons other than Holders have requested be included in such registration and which is not greater than such excess. 

  
 -15- 

 (c) Selection of Underwriters. In any Piggyback Registration, the
Company will have the right to select the investment bankers and managing underwriters in such registration. 
 3.3. Lockup Agreements. 

(a) Restrictions on Public Sale by Stockholders. Subject to the Company’s compliance with the terms of
Section 3.2, each of the Stockholders, if the Company or the managing underwriters so request of the Stockholders in connection with the Company’s first underwritten registration, will not, without the prior written consent of the Company
or such underwriters, effect any public sale or other distribution of any equity securities of the Company, including any sale pursuant to Rule 144, under the Securities Act, during a period of up to 180 days plus such additional period (up to an
additional fifteen (15) days) as may reasonably be requested by the Company or such underwriter to accommodate regulatory restrictions on (i) the publication or other distribution of research reports or (ii) analyst recommendations
and opinions, including (without limitation) the restrictions set forth in Rule 2711(f)(4) of the Financial Industry Regulatory Authority and Rule 472(f)(4) of the New York Stock Exchange, as amended, or any similar successor rules);
provided, that each officer and director of the Company and each other person who is also an Affiliate of the Company enter into similar agreements, and provided, further, that to the extent that any such officer, director or
other Affiliate of the Company is released (in whole or in part) from such lock-up agreement prior to its scheduled termination date, each Stockholder executing such a
lock-up agreement will have a proportionate percentage of its securities released from such lock-up agreement. 

(b) Restrictions on Public Sale by Company. The Company will not effect any public sale or other public distribution of equity
securities or securities exercisable or exchangeable for, or convertible into, equity securities, during the seven days prior to, and during (i) in the case of the Company’s first registration to become effective, the 180-day period, or (ii) in the case of any subsequent registration, the 90-day period, following the effective date of such underwritten registration, except in
connection with such underwritten registration. 
 3.4. Registration Procedures. If (and on each occasion that) the Company becomes obligated to
effect any registration of any Registrable Securities hereunder, the Company will use its best efforts in good faith to effect promptly the registration of such Registrable Securities under the Securities Act and to permit the public offering and
sale of such Registrable Securities in accordance with the Holders’ intended methods of disposition thereof, and, in connection therewith, the Company, as expeditiously as is reasonably possible, will: 

(a) prepare and file with the Commission a registration statement with respect to such Registrable Securities, and use its best efforts
in good faith to cause such registration statement to become effective and remain effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been
completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of the Company or an underwriter of Common Stock (or
other securities) of the Company, from selling any securities included in such registration; 

  
 -16- 

 (b) prepare and file with the Commission such amendments and supplements to such
registration statement and the prospectus included in such registration statement as may be necessary or advisable to comply in all material respects with the provisions of the Securities Act with respect to the disposition of all securities covered
by such registration statement or as may be necessary to keep such registration statement effective and current; 
 (c) furnish to
each seller of Registrable Securities such reasonable number of copies of such registration statement, each amendment and supplement thereto (in each case including all exhibits thereto), the prospectus included in such registration statement
(including each preliminary prospectus) and such other documents as any such seller may reasonably request in order to facilitate the disposition of the Registrable Securities held by such seller; 

(d) enter into such customary agreements and take all such other action in connection therewith as any Holder may reasonably request in
order to expedite or facilitate the disposition of such Registrable Securities; 
 (e) use its best efforts in good faith (i) to
list the Registrable Securities to be registered in such registration on each securities exchange or quotation system on which similar securities of the Company are then listed (or if not so listed, then on each securities exchange or quotation
system on which securities of companies similar to the Company are then listed), and (ii) to register or qualify the Registrable Securities covered by such registration statement under such securities or blue sky laws of such jurisdictions as
any Holder may reasonably request and do any and all such other acts and things as may be reasonably necessary or advisable to enable such seller to consummate the disposition in such jurisdictions of the Registrable Securities held by such seller;
provided, however, that the Company will not be required in connection with such blue sky registration or qualification to qualify to do business or file a general consent to service of process in any such jurisdiction; 

(f) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual
and customary form, with the managing underwriter of such offering; 
 (g) in the event of any underwritten public offering, furnish
and address to the underwriters (and provide to the Holders a copy thereof) a signed (i) opinion of counsel for the Company, dated the effective date of the registration statement, and (ii) “comfort” letter signed by the independent
public accountants who have certified the Company’s financial statements included in the registration statement, covering substantially the same matters with respect to the registration statement (and the prospectus included therein) and (in
the case of the comfort letter, with respect to events subsequent to the date of the financial statements), as are customarily covered (at the time of such registration) in opinions of issuer’s counsel and in comfort letters delivered to the
underwriters in underwritten public offerings of securities; 
 (h) promptly notify the Holders of the effectiveness of such
registration statement and any stop order, and furnish to the Holders such number of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may
reasonably request in order to facilitate the disposition of Registrable Securities owned by them; 

  
 -17- 

 (i) following the effective date of such registration statement, notify the Holders of any
request by the Commission that the Company amend or supplement such registration statement, or the associated prospectus; 
 (j)
notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus
included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of
the circumstances then existing; 
 (k) cause all such Registrable Securities registered pursuant to this Section 3 to be listed
on a national exchange or trading system and on each securities exchange and trading system on which similar securities issued by the Company are then listed; 

(l) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and a CUSIP number for
all such Registrable Securities, in each case not later than the effective date of such registration; and 
 (m) make generally
available to its security holders, and deliver to each Holder participating in the registration statement, an earnings statement of the Company that will satisfy the provisions of Section 11(a) of the Securities Act covering a period of 12
months beginning after the effective date of such registration statement, as soon as reasonably practicable after the termination of such 12-month period. 

3.5. Cooperation by Prospective Sellers, Etc. 

(a) Each prospective seller of Registrable Securities will furnish to the Company, in writing, such information regarding itself, the
Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such prospective seller’s Registrable Securities as the Company may reasonably require from
such seller, and otherwise reasonably cooperate with the Company in connection with any registration statement with respect to such Registrable Securities. 

(b) The failure of any prospective seller of Registrable Securities to furnish any information or documents in accordance with any
provision contained in this Section 3 will not affect the obligations of the Company under this Section 3 to any remaining sellers who furnish such information and documents unless, in the reasonable opinion of counsel to the Company or
the underwriters, such failure impairs or may impair the viability of the offering or the legality of the registration statement or the underlying offering. 

  
 -18- 

 (c) In the event that, in the judgment of the Company, it is advisable to suspend use of a
prospectus included in a registration statement due to pending material developments or other events that have not yet been publicly disclosed and as to which the Company believes public disclosure would be detrimental to the Company, the Company
shall deliver to each selling Holder a certificate signed by the Company’s President or Chief Executive Officer stating that the Board of Directors of the Company has made such determination in good faith, and, upon receipt of such notice, each
such selling Holder shall immediately discontinue any sales of Registrable Securities pursuant to such registration statement until such selling Holder has received copies of a supplemented or amended prospectus or until such selling Holder is
advised in writing by the Company that the then current prospectus may be used and has received copies of any additional or supplemental filings that are incorporated or deemed incorporated by reference in such prospectus. During any such suspension
period, none of the Company’s executive officers or directors shall offer or sell any Registrable Securities pursuant to or in reliance upon the registration statement (or the prospectus relating thereto). Notwithstanding anything to the
contrary herein, the Company shall not exercise its rights under this paragraph (c) to suspend sales of Registrable Securities for a period in excess of 60 days in any 365-day period and the obligations
of the Company with respect to maintaining any registration statement current and effective will be extended by a period of days equal to the aggregate period any such discontinuance or suspension hereunder is in effect. 

(d) At the end of any period during which the Company is obligated to keep any registration statement current and effective as provided
by Section 3.4 hereof (and any extensions thereof required by the preceding paragraph (c) of this Section 3.5), the Holders included in such registration statement will discontinue sales of shares pursuant to such registration
statement upon notice from the Company to such Holders of its intention to remove from registration the shares covered by such registration statement which remain unsold, and such Holders will notify the Company of the number of shares registered
that remain unsold promptly after receipt of such notice from the Company. 
 3.6. Registration Expenses. 

(a) The Company will be responsible for and will pay all costs and expenses incurred or sustained in connection with or arising out of
each registration pursuant to this Section 3, including all registration and filing fees, fees and expenses of compliance with securities or blue sky laws (including reasonable fees and disbursements of counsel for the underwriters in
connection with the blue sky qualification of Registrable Securities), printing expenses, messenger, telephone, and delivery expenses, fees and disbursements of counsel for the Company, reasonable fees and disbursements of one counsel representing
the Holders, fees and disbursements of all independent certified public accountants (including the expenses relating to the preparation and delivery of any special audit or comfort letters required by or incident to such registration), and fees and
disbursements of underwriters (excluding discounts and commissions), the reasonable fees and expenses of any special experts retained by the Company on its own initiative or at the request of the managing underwriters in connection with such
registration, and fees and expenses of all (if any) other persons retained by the Company (all 

  
 -19- 

 
such costs and expenses, collectively, “Registration Expenses”). The Company will also pay its internal expenses (including all salaries and expenses of its officers and
employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the securities to be registered on each securities exchange or quotation system on which similar
securities of the Company are then listed (or if not so listed, then on each securities exchange or quotation system on which securities of companies similar to the Company are then listed). 

(b) The Company will not bear the cost of nor pay for any stock transfer taxes imposed in respect of the transfer of any Registrable
Securities to any purchaser thereof by any Holder of Registrable Securities in connection with any registration of Registrable Securities pursuant to this Section 3. 

(c) To the extent that Registration Expenses incident to any registration are, under the terms of this Section 3, not required to
be paid by the Company, each Holder of Registrable Securities included in such registration will pay all Registration Expenses that are clearly solely attributable to the registration of such Holder’s Registrable Securities so included in such
registration, and all other Registration Expenses not so attributable to one Holder will be borne and paid by all sellers of securities included in such registration pro rata in proportion to the number of securities so included by each such
seller. 
 3.7. Indemnification. 

(a) Indemnification by Company. The Company will indemnify each Holder joining in a registration and each underwriter of the
securities so registered, the officers, directors and partners and stockholders of each such person and each person who controls (within the meaning of the Securities Act) any of the foregoing, and their respective successors and assigns, against
any and all Damages arising out of or based on any untrue statement (or alleged untrue statement) of any material fact contained in any prospectus, offering circular or other document incident to any registration, qualification or compliance (or in
any related registration statement (or any amendment or supplement thereto), notification or the like) or any omission (or alleged omission) to state therein any material fact required to be stated therein or necessary to make the statements therein
not misleading, or any violation by the Company (or any of its agents or Affiliates) of any rule or regulation promulgated under the Securities Act, the Exchange Act, any state securities law applicable to the Company and relating to any action or
inaction required of the Company in connection with any such prospectus, registration statement, qualification or compliance; provided, however, that the Company will not be liable in any such case to the extent that any such Damages arise
out of or are based on any untrue statement or omission based upon written information furnished to the Company in an instrument duly executed by such Holder, underwriter, officer, director, partner or controlling person and stated to be
specifically for use in such prospectus, registration statement, offering circular or other document. 
 (b) Indemnification by
Each Holder. Each Holder including Registrable Securities in a registration will indemnify each underwriter of the securities so registered, the Company and 

  
 -20- 

 
its officers and directors and each person, if any, who controls (within the meaning of the Securities Act) any of the foregoing, and their respective successors and assigns, against any and all
Damages arising out of or based on any untrue statement (or alleged untrue statement) of any material fact contained in any prospectus, offering circular or other document incident to any registration, qualification or compliance (or in any related
registration statement (or any amendment or supplement thereto), notification or the like) or any omission (or alleged omission) to state therein any material fact required to be stated therein or necessary to make the statement therein not
misleading, but only if and to the extent that such statement or omission was made in reliance upon written information furnished to such underwriter or the Company in an instrument duly executed by such Holder and stated to be specifically for use
in such prospectus, offering circular or other document (or related registration statement, notification or the like) or any amendment or supplement thereto; provided, however, that the indemnity agreement contained in this
Section 3.7(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld, delayed or conditioned; and
provided, further, that each Holder’s liability with respect to any particular registration will be limited to an aggregate amount equal to the net proceeds received by such Holder from the Registrable Securities sold by such Holder in
such registration. 
 (c) Indemnification Proceedings. Each party entitled to indemnification pursuant to this
Section 3.7 (the “indemnified party”) will give notice to the party required to provide indemnification pursuant to this Section 3.7 (the “indemnifying party”) promptly after such indemnified party
acquires actual knowledge of any claim as to which indemnity may be sought, and will permit the indemnifying party (at its expense) to assume the defense of any claim or any litigation resulting therefrom; provided, that counsel for
the indemnifying party, who will conduct the defense of such claim or litigation, must be reasonably acceptable to the indemnified party, and the indemnified party may participate in such defense at such indemnified party’s expense; and;
provided, further, that the failure by any indemnified party to give notice as provided in this paragraph (c) will not relieve any indemnifying party of its obligations under this Section 3.7 except if and to the extent that such
failure results in a failure of actual notice to the indemnifying party and such indemnifying party is actually prejudiced solely as a result of such failure to give notice. Notwithstanding the preceding sentence, an indemnified party (together with
all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party
by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. No indemnifying party, in the
defense of any such claim or litigation, will, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or
plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. The reimbursement required by this Section 3.7 will be made by periodic payments during the course of the investigation or defense, as
and when bills are received or expenses incurred, and may be conditioned upon an undertaking by the indemnified party to reimburse the indemnifying party in the event the indemnified party is finally determined by a court of competent jurisdiction
not to be entitled to indemnification. 

  
 -21- 

 3.8. Contribution in Lieu of Indemnification. If the indemnification provided for in Section 3.7
hereof is unavailable to a party that would have been an indemnified party in respect of any Damages referred to therein, then each party that would have been an indemnifying party thereunder will, in lieu of indemnifying such indemnified party,
contribute to the amount paid or payable by such indemnified party as a result of such Damages in such proportion as is appropriate to reflect the relative fault of the indemnifying party and such indemnified party, respectively, in connection with
the statements or omissions which resulted in such Damages. Relative fault will be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by the indemnifying party or such indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission
provided, that each Holder’s liability with respect to any particular registration will be limited to an amount equal to the net proceeds received by such Holder from the Registrable Securities sold by such Holder in such registration. The
Company and each Holder agree that it would not be just and equitable if contribution pursuant to this Section 3.8 were determined by pro rata allocation or by any other method of allocation that does not take account of the equitable
considerations referred to above in this Section 3.8. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. 
 3.9. Rule 144 Requirements; Form S-3 Registrations. 

(a) From time to time after the earlier to occur of (a) the ninetieth (90th)
day following the date on which there first becomes effective a registration statement filed by the Company under the Securities Act, or (b) the date on which the Company registers a class of securities under Section 12 of the Exchange
Act, the Company will make commercially reasonable efforts in good faith to take all steps necessary to ensure that the Company will be eligible to register securities on Form S-3 (or any comparable or
successor form adopted by the Commission) as soon thereafter as possible, and to make publicly available and available to the Holders, pursuant to Rule 144 of the Commission under the Securities Act, such current public information as is necessary
to enable the Holders of Registrable Securities to make sales of Registrable Securities pursuant to that Rule. The Company will furnish to the Holders, upon request at any time after the undertaking of the Company in the preceding sentence first
becomes effective, a written statement signed by the Company, addressed to each Holder, describing briefly the action the Company has taken or proposes to take to comply with the current public information requirements of Rule 144. Upon receipt of a
certificate certifying (i) that such Holder has held and fully paid for such Registrable Securities for a period of not less than one year (or such lesser period after which the exemption from registration pursuant to which Rule 144 may be
available), and (ii) that such Holder has not been an affiliate (as defined in Rule 144) of the Company during the preceding three months, the Company will, at the request of any Holder of Registrable Securities, remove from the stock
certificates representing such 

  
 -22- 

 
Registrable Securities any restrictive legend (or portion thereof) relating to the registration provisions of the Securities Act. After the Company qualifies for the use of Form S-3, then, subject to the provisions of Sections 3.1(b)(iii) and (iv) of this Agreement, the Holders of the Registrable Securities then outstanding will have the right to require the Company to
effect an unlimited number of registrations on Form S-3 (or any equivalent successor form); provided, that the aggregate offering price to the public for each such registration exceeds $2,000,000. The
Company shall keep such registration statement on Form S-3 effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement
has been completed; provided, however, that in the event that such registration of Registrable Securities is intended to be offered on a continuous or delayed basis, subject to compliance with applicable Commission rules, such one hundred
twenty (120) day period shall be extended for up to 60 days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold. 

(b) Suspension Period. Notwithstanding anything in this Agreement to the contrary, if the Company shall furnish to the Holders a
certificate signed by the President or Chief Executive Officer of the Company stating that the Board of Directors of the Company has made the good faith determination (i) that continued use by the Holders of the registration statement on Form S-3 for purposes of effecting offers or sales of Registrable Securities pursuant thereto would require, under the Securities Act, premature disclosure in the registration statement (or the prospectus relating
thereto) of material, nonpublic information concerning the Company, its business or prospects or any proposed material transaction involving the Company, (ii) that such premature disclosure would be materially adverse to the Company, its
business or prospects or any such proposed material transaction or would make the successful consummation by the Company of any such material transaction significantly less likely and (iii) that it is therefore essential to suspend the use by
the Holders of such registration statement (and the prospectus relating thereto) for purposes of effecting offers or sales of Registrable Securities pursuant thereto, then the right of the Holders to use the registration statement (and the
prospectus relating thereto) for purposes of effecting offers or sales of Registrable Securities pursuant thereto shall be suspended for a period (the “Suspension Period”) of not more than 90 days after delivery by the Company of
the certificate referred to in this paragraph (b). During the Suspension Period, none of the Holders or the Company’s executive officers or directors shall offer or sell any Registrable Securities pursuant to or in reliance upon the
registration statement (or the prospectus relating thereto). The Company agrees not to exercise the rights set forth in this paragraph (b) more than twice in any 12-month period. If, in connection
therewith, the Company considers it appropriate for such registration statement to be amended, the Company shall so amend such registration statement as promptly as practicable and such Holders shall suspend any further sales of their Registrable
Securities until the Company advises them that such registration statement has been amended. The time periods referred to herein during which such registration statement must be kept effective shall be extended for an additional number of days equal
to the number of days during which the right to sell securities was suspended pursuant to this paragraph. 

  
 -23- 

 3.10. Participation in Underwritten Registrations. No person may participate in any underwritten
registration pursuant to this Section 3 unless such person (a) agrees to sell such person’s securities on the basis provided in any underwriting arrangements approved by the persons entitled, under the provisions hereof, to approve
such arrangements, and (b) completes and executes all questionnaires, powers of attorney, custody agreements, indemnities, underwriting agreements and other documents reasonably required by the terms of such underwriting arrangements. Any
Holder to be included in any underwritten registration will be entitled at any time to withdraw such Registrable Securities from such registration prior to its effective date in the event that such Holder disapproves of any of the terms of the
related underwriting agreement. 
 3.11. Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company
shall not, without the prior written consent of the Holders holding at least 60% of the Registrable Securities then outstanding (or deemed outstanding), enter into any agreement with any holder or prospective holder of any securities of the Company
that would allow such holder or prospective holder (a) to include any of such securities in any registration filed under this Section 3, unless under the terms of such agreement, such holder or prospective holder may include such
securities in any such registration only to the extent that the inclusion of such securities will not reduce the amount of the Registrable Securities of the Holders that are included, (b) to demand registration of their securities, (c) any
registration rights unless such holder is bound by obligations similar to the obligations of the Holders set forth in Sections 3.3, 3.5, 3.6, 3.7, 3.8, 3.9, and 3.10, or (d) otherwise conflict with the registration rights granted to the Holders
under this Agreement. 
 4. DEFINITIONS. 

For all purposes of this Agreement the following terms will have the meanings set forth or cross-referenced in this Section 4: 

“Acquisition” shall have the meaning ascribed to such term in the Charter. 

“Affiliate” means any other person directly or indirectly controlling, controlled by, or under direct or indirect common
control with the Company (or other referenced person) and includes (a) any person who is an officer, director, or direct or indirect beneficial holder of at least 5% of the then outstanding capital stock of the Company (or other referenced
person), and any of the Family Members of any such beneficial holder, or (b) any person of which the Company (or other referenced person) and/or its Affiliates (as defined in clause (a) above), directly or indirectly, either beneficially
own(s) at least 5% of the then outstanding equity securities or constitute(s) at least a 5% equity participant. 
 “Affiliate
Stockholder” of any Right Holder shall mean any general or limited partner or retired partner of any such person that is a partnership, any member or retired member of any such person that is a limited liability company, or any person or
entity that, directly or indirectly, through one or more intermediaries, controls, or is controlled by, or is under common control with, such Right Holder, including any affiliated funds. 

  
 -24- 

 “Charter” means the Company’s Eighth Amended and Restated Certificate of
Incorporation, as the same may be amended and/or restated and in effect from time to time. 
 “CHV” means CHV IV, L.P. 

“Code” means the Internal Revenue Code of 1986, as amended. 

“Commission” means the Securities and Exchange Commission. 

“Common Stock” means the Common Stock, $0.01 par value per share, of the Company. 

“Convertible Note Purchase Agreement” shall mean each of the Convertible Subordinated Note Purchase Agreement dated as of
February 18, 2014 by and among the Company and the investors listed on the schedule thereto, and the Convertible Subordinated Note Purchase Agreement dated as of November 21, 2014, as amended, by and among the Company and the investors
listed on the schedule thereto, and “Convertible Note Purchase Agreements” shall mean the foregoing agreements, collectively. 

“Damages” (whether or not such term is capitalized) means all damages, losses, claims, demands, actions, causes of action,
suits, litigations, arbitrations, liabilities, costs and expenses, including investigatory and court costs and the fees and expenses of counsel and experts. 

“Derivative Securities” means (i) all shares of stock and other securities that are convertible into or exchangeable for
shares of capital stock of the Company, including shares of Preferred Stock, and (ii) all options, warrants and other rights to acquire shares of capital stock of the Company or securities convertible into or exchangeable for shares of capital
stock of the Company. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder. 
 “Family Members” means, as applied to any individual, his or her spouse, his or her
and his or her spouse’s lineal ancestors and descendants and their respective spouses, any trust created for the benefit of any such person(s), and each custodian of property of any such person(s), and/or the estate of any such person(s). 

“GAAP” means generally accepted accounting principles that are (i) consistent with the principles promulgated or adopted
by the Financial Accounting Standards Board and its predecessors, (ii) applied on a basis consistent with prior periods, and (iii) such that, insofar as the use of accounting principles is pertinent, a certified public accountant could
deliver an unqualified opinion with respect to financial statements in which such principles have been properly applied. 
 “GE
Ventures” means GE Ventures Limited and/or its Affiliates. 

  
 -25- 

 “Holders” means the holders of Registrable Securities that are parties to this
Agreement, and “Holder” means any one of the Holders. Unless the context otherwise requires, a Holder will be deemed to hold, at any particular time, all shares of Common Stock issued or issuable upon exercise, conversion or
exchange of Derivative Securities held by such Holder at such time. 
 “including” (regardless of whether capitalized)
means including without limitation. 
 “Initial Public Offering” shall mean the closing of the Company’s first
underwritten public offering of Common Stock under the Securities Act. 
 “Intellectual Property” shall mean intellectual
property or proprietary rights of any description including (i) rights in any patent, patent application (including any provisionals, continuations, divisions,
continuations-in-part, extensions, renewals, reissues, revivals and reexaminations, any national phase PCT applications, any PCT international applications, and all
foreign counterparts), copyright, industrial design, URL, domain name, trademark, service mark, logo, trade dress or trade name, (ii) related registrations and applications for registration, (iii) trade secrets, moral rights or publicity
rights, (iv) inventions, discoveries, or improvements, modification, know-how, technique, methodology, writing, work of authorship, design or data, whether or not patented, patentable, copyrightable or
reduced to practice, including any inventions, discoveries, improvements, modification, know-how, technique, methodology, writing, work of authorship, design or data embodied or disclosed in any:
(1) computer source codes (human readable format) and object codes (machine readable format); (2) specifications; (3) manufacturing, assembly, test, installation, service and inspection instructions and procedures; (4) engineering,
programming, service and maintenance notes and logs; (5) technical, operating and service and maintenance manuals and data; (6) hardware reference manuals; and (7) user documentation, help files or training materials, and
(v) good will related to any of the foregoing. 
 “Investor Growth Capital” means Investor Growth Capital Limited,
Investor Group, L.P. and IGC Fund VI, L.P. 
 “Key Officers” shall mean the Chief Executive Officer and each Vice President
(or higher level) who reports directly to the Chief Executive Officer of the Company. 
 “Lien” means any lien, claim,
mortgage, security interest, charge, encumbrance and restriction on transfer of any kind, except, in the case of references to securities, any of the same arising under (i) applicable securities laws solely by reason of the fact that such
securities were issued pursuant to exemptions from registration under such securities laws or (ii) this Agreement or the Other Agreements. 

“New Leaf” means New Leaf Ventures II, L.P. and its Affiliates. 

“Other Agreements” means the Purchase Agreements and the Stockholders’ Agreement. 

  
 -26- 

 “person” (regardless of whether capitalized) means any natural person, entity or
association, including any corporation, partnership, limited liability company, government (or agency or subdivision thereof), trust, joint venture or proprietorship. 

“Pfizer” means Pfizer Inc. and its Affiliates. 

“Polaris” means Polaris Venture Partners V, L.P. and its Affiliates. 

“Preferred Stock” means the Series A-1 Preferred Stock, the Series A-2 Preferred Stock, the Series B Preferred Stock, the Series C Preferred Stock, the Series D Preferred Stock, the Series E Preferred Stock, the Series F Preferred Stock and the Series G Preferred Stock. 

“Proportional Adjustment” means a proportional or other equitable adjustment made upon the occurrence of a stock split,
reverse stock split, stock dividend, stock combination, reclassification or other similar change. 
 “Purchase Agreements”
means the Series A-2 Purchase Agreement, the Series B Purchase Agreement, the Series C Purchase Agreement, the Series D Purchase Agreement, the Series E Purchase Agreement, the Convertible Note Purchase
Agreements, the Series F Purchase Agreement and the Series G Purchase Agreement. 
 “QPIV” means QPIV, LLC and its
Affiliates. 
 “Qualified Public Offering” shall have the meaning ascribed to such term in the Charter. 

“registration” (regardless of whether capitalized) refers to a registration effected by preparing and filing a registration
statement in compliance with the Securities Act and the declaration or ordering by the Commission of effectiveness of such registration statement. 

“Registrable Securities” means, at any particular time, (i) all shares of Common Stock issued, or issuable, in respect
of the Series A-2 Preferred Stock, the Series B Preferred Stock, the Series C Preferred Stock, the Series D Preferred Stock, the Series E Preferred Stock, the Series F Preferred Stock and the Series G
Preferred Stock, (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Stockholder after the date hereof, and
(iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares
referenced in clauses (i) and (ii) above. Securities will cease to be Registrable Securities when they have been sold pursuant to an effective registration statement under the Securities Act, or distributed to the public through a
broker, dealer or market maker pursuant to Rule 144 under the Securities Act, or any other exemption from the registration requirements of the Securities Act under which the transferee receives securities that are not “restricted
securities” within the meaning of that term as defined in Rule 144(a)(3). 

  
 -27- 

 “Required Senior Preferred Holders” shall have the meaning ascribed to such term
in the Charter. 
 “Securities Act” means the Securities Act of 1933, as amended, or any successor federal statute and the
rules and regulations of the Commission thereunder, all as the same are in effect at the relevant time of reference. 
 “Series A-1 Preferred Stock” means the Series A-1 Convertible Preferred Stock, $0.01 par value per share, of the Company, the terms of which are as set forth in the Charter.

 “Series A-2 Preferred Stock” means the Series
A-2 Convertible Preferred Stock, $0.01 par value per share, of the Company, the terms of which are as set forth in the Charter. 

“Series A-2 Substantial Stockholder” means any Series
A-2 Stockholder holding of record not less than 1,200,000 shares of Series A-2 Preferred Stock (such number to be subject to Proportional Adjustment), provided,
that KBL Healthcare, L.P. shall also be deemed to be a Series A-2 Substantial Stockholder for purposes of all sections of this Agreement other than Section 2.8 for such time as such entity holds of record
at least 500,000 shares of Series A-2 Preferred Stock (such number to be subject to Proportional Adjustment). For purposes of this definition: all shares of capital stock held by InterWest Partners VIII, L.P.,
InterWest Investors VIII, L.P. and InterWest Investors Q VIII, L.P., respectively, and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each other such entity, as appropriate; all shares of
capital stock held by Investor Growth Capital Limited and Investor Group, L.P., and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each other such entity, as appropriate; all shares of
capital stock held by ONSET IV, L.P. shall be aggregated with those of its Affiliates and permitted transferees; and all shares of capital stock held by KBL Healthcare, L.P. and KBL Partnership, L.P., and their Affiliates and permitted transferees,
shall be aggregated with those shares of capital stock held by each other such entity, as appropriate. 
 “Series B Preferred
Stock” means the Series B Convertible Preferred Stock, $0.01 par value per share, of the Company, the terms of which are as set forth in the Charter. 

“Series B Substantial Stockholder” means any Series B Stockholder holding of record not less than 850,000 shares of Series B
Preferred Stock (such number to be subject to Proportional Adjustment). For purposes of this definition: all shares of capital stock held by InterWest Partners VIII, L.P., InterWest Investors VIII, L.P. and InterWest Investors Q VIII, L.P.,
respectively, and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each other such entity, as appropriate; all shares of capital stock held by Investor Growth Capital Limited and Investor
Group, L.P., and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each other such entity, as appropriate; all shares of capital stock held by ONSET IV, L.P. shall be aggregated with those of
its Affiliates and permitted transferees; and all shares of capital stock held by KBL Healthcare, L.P. and KBL Partnership, L.P., and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each
other such entity, as appropriate; 

  
 -28- 

 
and all shares of capital stock held by Three Arch Partners IV, L.P., Three Arch Associates IV, L.P., Three Arch Capital, L.P. and TAC Associates, L.P., respectively, and their Affiliates and
permitted transferees, shall be aggregated with those shares of capital stock held by each other such entity, as appropriate. 

“Series C Preferred Stock” means the Series C Convertible Preferred Stock, $0.01 par value per share, of the Company, the
terms of which are as set forth in the Charter. 
 “Series C Substantial Stockholder” means any Series C Stockholder
holding of record not less than 1,047,904 shares of Series C Preferred Stock (such number to be subject to Proportional Adjustment). For purposes of this definition: all shares of capital stock held by InterWest Partners VIII, L.P., InterWest
Investors VIII, L.P. and InterWest Investors Q VIII, L.P., respectively, and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each other such entity, as appropriate; all shares of capital
stock held by Investor Growth Capital Limited and Investor Group, L.P., and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each other such entity, as appropriate; all shares of capital
stock held by ONSET IV, L.P. shall be aggregated with those of its Affiliates and permitted transferees; and all shares of capital stock held by KBL Healthcare, L.P. and KBL Partnership, L.P., and their Affiliates and permitted transferees, shall be
aggregated with those shares of capital stock held by each other such entity, as appropriate; all shares of capital stock held by Three Arch Partners IV, L.P., Three Arch Associates IV, L.P., Three Arch Capital, L.P. and TAC Associates, L.P.,
respectively, and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each other such entity, as appropriate; and all shares of capital stock held by QPIV, LLC shall be aggregated with those of
its Affiliates and permitted transferees. 
 “Series D Preferred Stock” means the Series D Convertible Preferred Stock,
$0.01 par value per share, of the Company, the terms of which are as set forth in the Charter. 
 “Series D Substantial
Stockholder” means any Series D Stockholder holding of record not less than 2,459,016 shares of Series D Preferred Stock (such number to be subject to Proportional Adjustment). For purposes of this definition: all shares of capital stock
held by InterWest Partners VIII, L.P., InterWest Investors VIII, L.P. and InterWest Investors Q VIII, L.P., respectively, and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each other such
entity, as appropriate; all shares of capital stock held by Investor Growth Capital Limited and Investor Group, L.P., and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each other such
entity, as appropriate; all shares of capital stock held by ONSET IV, L.P. shall be aggregated with those of its Affiliates and permitted transferees; and all shares of capital stock held by KBL Healthcare Ventures, L.P. and its Affiliates and
permitted transferees, shall be aggregated with those shares of capital stock held by each other such entity, as appropriate; all shares of capital stock held by Three Arch Partners IV, L.P., Three Arch Associates IV, L.P., Three Arch Capital, L.P.
and TAC Associates, L.P., respectively, and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each other 

  
 -29- 

 
such entity, as appropriate; all shares of capital stock held by QPIV, LLC shall be aggregated with those of its Affiliates and permitted transferees; and all shares of capital stock held by New
Leaf Ventures II, L.P. shall be aggregated with those of its Affiliates and permitted transferees. 
 “Series E Preferred
Stock” means the Series E Convertible Preferred Stock, $0.01 par value per share, of the Company, the terms of which are as set forth in the Charter. 

“Series E Substantial Stockholder” means any Series E Stockholder holding of record not less than 2,000,000 shares of Series
E Preferred Stock (such number to be subject to Proportional Adjustment). For purposes of this definition: all shares of capital stock held by Polaris Venture Partners V, L.P., Polaris Venture Partners Entrepreneurs’ Fund V, L.P., Polaris
Venture Partners Special Founders’ Fund V, L.P. and Polaris Venture Partners Founders’ Fund V, L.P., respectively, and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each other
such entity, as appropriate; all shares of capital stock held by InterWest Partners VIII, L.P., InterWest Investors VIII, L.P. and InterWest Investors Q VIII, L.P., respectively, and their Affiliates and permitted transferees, shall be aggregated
with those shares of capital stock held by each other such entity, as appropriate; all shares of capital stock held by Investor Growth Capital Limited and Investor Group, L.P., and their Affiliates and permitted transferees, shall be aggregated with
those shares of capital stock held by each other such entity, as appropriate; all shares of capital stock held by ONSET IV, L.P. shall be aggregated with those of its Affiliates and permitted transferees; all shares of capital stock held by Three
Arch Partners IV, L.P., Three Arch Associates IV, L.P., Three Arch Capital, L.P. and TAC Associates, L.P., respectively, and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each other such
entity, as appropriate; all shares of capital stock held by QPIV, LLC shall be aggregated with those of its Affiliates and permitted transferees; all shares of capital stock held by New Leaf Ventures II, L.P. shall be aggregated with those of its
Affiliates and permitted transferees; and all shares of capital stock held by Pfizer Inc. shall be aggregated with those of its Affiliates and permitted transferees. 

“Series F Preferred Stock” means the Series F Convertible Preferred Stock, $0.01 par value per share, of the Company, the
terms of which are set forth in the Charter. 
 “Series F Substantial Stockholder” means any Series F Stockholder holding
of record not less than 10,000,000 shares of Series F Preferred Stock (such number to be subject to Proportional Adjustment). For purposes of this definition: all shares of capital stock held by Polaris Venture Partners V, L.P., Polaris Venture P
Entrepreneurs’ Fund V, L.P., Polaris Venture Partners Special Founders’ Fund V, L.P. and Polaris Venture Partners Founders’ Fund V, L.P., respectively, and their Affiliates and permitted transferees, shall be aggregated with those
shares of capital stock held by each other such entity, as appropriate; all shares of capital stock held by InterWest Partners VIII, L.P., InterWest Investors VIII, L.P. and InterWest Investors Q VIII, L.P., respectively, and their Affiliates and
permitted transferees, shall be aggregated with those shares of capital stock held by each other such entity, as appropriate; all shares of capital stock held by Investor Growth Capital Limited, Investor Group, L.P. and IGC Fund VI, L.P.,
respectively, and their Affiliates and permitted transferees, shall be aggregated with those shares 

  
 -30- 

 
of capital stock held by each other such entity, as appropriate; all shares of capital stock held by ONSET IV, L.P. shall be aggregated with those of its Affiliates and permitted transferees; all
shares of capital stock held by Three Arch Partners IV, L.P., Three Arch Associates IV, L.P., Three Arch Capital, L.P. and TAC Associates, L.P., respectively, and their Affiliates and permitted transferees, shall be aggregated with those shares of
capital stock held by each other such entity, as appropriate; all shares of capital stock held by QPIV, LLC shall be aggregated with those of its Affiliates and permitted transferees; all shares of capital stock held by New Leaf Ventures II, L.P.
shall be aggregated with those of its Affiliates and permitted transferees; all shares of capital stock held by Pfizer Inc. shall be aggregated with those of its Affiliates and permitted transferees; and all shares of capital stock held by GE
Ventures Limited shall be aggregated with those of its Affiliates and permitted transferees. 
 “Series G Preferred Stock”
means the Series G Convertible Preferred Stock, $0.01 par value per share, of the Company, the terms of which are set forth in the Charter. 

“Series G Substantial Stockholder” means any Series G Stockholder holding of record not less than 2,029,164 shares of Series
G Preferred Stock (such number to be subject to Proportional Adjustment). For purposes of this definition: all shares of capital stock held by Polaris Venture Partners V, L.P., Polaris Venture P Entrepreneurs’ Fund V, L.P., Polaris Venture
Partners Special Founders’ Fund V, L.P. and Polaris Venture Partners Founders’ Fund V, L.P., respectively, and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each other such
entity, as appropriate; all shares of capital stock held by InterWest Partners VIII, L.P., InterWest Investors VIII, L.P. and InterWest Investors Q VIII, L.P., respectively, and their Affiliates and permitted transferees, shall be aggregated with
those shares of capital stock held by each other such entity, as appropriate; all shares of capital stock held by IGC Fund VI, L.P. and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each
other such entity, as appropriate; all shares of capital stock held by ONSET IV, L.P. shall be aggregated with those of its Affiliates and permitted transferees; all shares of capital stock held by Three Arch Partners IV, L.P., Three Arch Associates
IV, L.P., Three Arch Capital, L.P. and TAC Associates, L.P., respectively, and their Affiliates and permitted transferees, shall be aggregated with those shares of capital stock held by each other such entity, as appropriate; all shares of capital
stock held by QPIV, LLC shall be aggregated with those of its Affiliates and permitted transferees; all shares of capital stock held by New Leaf Ventures II, L.P. shall be aggregated with those of its Affiliates and permitted transferees; all shares
of capital stock held by Pfizer Inc. shall be aggregated with those of its Affiliates and permitted transferees; all shares of capital stock held by GE Ventures Limited shall be aggregated with those of its Affiliates and permitted transferees; and
all shares of capital stock held by CHV shall be aggregated with those of its Affiliates and permitted transferees. 

“Stockholders’ Agreement” means the Sixth Amended and Restated Stockholders’ Agreement, dated as of the date
hereof, among the Company and certain of its stockholders, as amended from time to time. 

  
 -31- 

 “Subsidiary(ies)” means, with respect to any person, any corporation a majority
(by number of votes) of the outstanding shares of any class or classes of which are at the relevant time of reference owned directly or indirectly by such person or by a Subsidiary of such person, if the holders of the shares of such class or
classes (a) are ordinarily, in the absence of contingencies, entitled to vote for the election of a majority of the directors (or persons performing similar functions) of the issuer thereof, even though the right so to vote has been suspended
by the happening of such a contingency, or (b) are at the time entitled, as such holders, to vote for the election of a majority of the directors (or persons performing similar functions) of the issuer thereof, whether or not the right so to
vote exists by reason of the happening of a contingency. 
 “Substantial Stockholder” means any Series A-2 Substantial Stockholder, any Series B Substantial Stockholder, any Series C Substantial Stockholder, any Series D Substantial Stockholder, any Series E Substantial Stockholder, any Series F Substantial
Stockholder and any Series G Substantial Stockholder. 
 “Super Board Approval” shall have the meaning ascribed to such
term in the Charter. 
 “Three Arch Partners” means Three Arch Partners IV, L.P., Three Arch Associates IV, L.P., Three
Arch Capital, L.P., TAC Associates, L.P. and their Affiliates. 
 “Underwriters’ Maximum Number” means, with respect
to an underwritten registration, that number of securities to which such registration should be limited, in the reasonable opinion of the managing underwriters of such registration, in the light of marketing factors. 

5. MISCELLANEOUS PROVISIONS. 
 5.1. Amendments,
Consents, Waivers, Etc. 
 (a) This Agreement or any provision hereof may be amended or terminated by the agreement of the Company
and Stockholders holding at least 60% of the outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), and, except as otherwise provided by this Agreement,
the observance of any provision of this Agreement that is for the benefit of any party other than the Company may be waived (either generally or in a particular instance, and either retroactively or prospectively), and any consent, approval or other
action to be given or taken by the Stockholders pursuant to this Agreement may be given or taken by the written consent of Stockholders holding at least 60% of the outstanding Registrable Securities held by all Stockholders (assuming the conversion
of all outstanding Preferred Stock into shares of Common Stock). Notwithstanding any provision contained herein to the contrary, (i) no such amendment, termination or waiver shall adversely affect any Stockholder, Series A-2 Stockholder, Series B Stockholder, Series C Stockholder, Series D Stockholder, Series E Stockholder, Series F Stockholder or Series G Stockholder in a manner different from or disproportionate to any adverse
effect such amendment, termination or waiver would have on any other Stockholder, Series A-2 Stockholder, Series B Stockholder, Series C Stockholder, 

  
 -32- 

 
Series D Stockholder, Series E Stockholder, Series F Stockholder or Series G Stockholder, respectively, without such party’s consent, (ii) any person may in writing waive, as to and for
itself, the benefits of any provision of this Agreement without the consent of any other party, (iii) the right of any Stockholder to appoint an Observer pursuant to Section 2.8 may not be amended, modified or waived without the consent of
that Stockholder, (iv) the definition of “Series F Substantial Stockholder” cannot be amended, modified or waived without the consent of GE Ventures and (v) the definition of “Series G Substantial Stockholder” cannot be
amended, modified or waived without the consent of CHV. 
 (b) No course of dealing between the Company and any of the Stockholders
will operate as a waiver of any of the Company’s or any Stockholder’s rights under this Agreement. No waiver of any breach or default hereunder will be valid unless in a writing signed by the waiving party. No failure or other delay by any
person in exercising any right, power or privilege hereunder will be or operate as a waiver thereof, nor will any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or
privilege. 
 (c) The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto
that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Section 5.1 shall be binding on all parties hereto, regardless of whether any such party has
consented thereto. 
 (d) Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the
Company’s Series G Preferred Stock after the date hereof pursuant to the Series G Purchase Agreement or the exercise of any Derivative Security, any purchaser of such shares of Series G Preferred Stock shall become a party to this Agreement by
executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed a “Series G Stockholder” and a “Stockholder” for all purposes hereunder. No action or consent by the Stockholders
shall be required to add such Additional Stockholder to the Schedule of Series G Stockholders hereto or for such joinder to this Agreement by such Additional Stockholder, so long as such Additional Stockholder has agreed in writing to be
bound by all of the obligations as a “Series G Stockholder” and “Stockholder” hereunder. 
 5.2. Notices. All notices,
requests, payments, instructions or other documents to be given hereunder will be in writing or by written telecommunication, and will be deemed to have been duly given if (a) delivered personally (effective upon delivery), (b) mailed by
certified mail, return receipt requested, postage prepaid (effective five business days after dispatch), (c) sent by a reputable, established courier service that provides evidence of delivery and guarantees next business day delivery (effective the
next business day), or (d) sent by telecopier or email followed within 24 hours by confirmation by one of the foregoing methods (effective upon receipt of the telecopy or email in complete, readable form), addressed to (i) the Company at
3222 Phoenixville Pike, Malvern, PA 19355, Attention: Chief Executive Officer, Facsimile (610) 482-9986 and (ii) the Stockholders at the addresses listed on the Schedules to this Agreement (or to such
other address as the recipient party may have furnished to the Company for the purposes of this Section 5.2). 

  
 -33- 

 5.3. Counterparts. This Agreement may be executed by the parties in separate counterparts, each of
which when so executed and delivered will be an original, but all of which together will constitute one and the same agreement. In pleading or proving this Agreement, it will not be necessary to produce or account for more than one such counterpart.
Each party hereto will receive by delivery, facsimile transmission or electronic mail a duplicate original of this Agreement executed by each party, and each party agrees that the delivery of this Agreement by facsimile transmission or by electronic
mail in “portable document format” will be deemed to be an original of this Agreement so transmitted. 
 5.4. Captions. The captions
of sections or subsections of this Agreement are for reference only and will not affect the interpretation or construction of this Agreement. 
 5.5.
Binding Effect and Benefits. This Agreement will bind and inure to the benefit of the parties hereto and their respective successors and permitted transferees and assigns, provided such transferees and assigns agree in writing to
be bound by the terms and conditions of this Agreement. The provisions of this Agreement that are for the Stockholders’ benefit will inure to the benefit of all permitted transferees of Series A-2
Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock, and the applicable provisions of this Agreement that bind the
Stockholders will bind all transferees of Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series
G Preferred Stock. Such transferees and assigns to whom rights are transferred or assigned pursuant to this Section 5.5 will be thereafter deemed to be Stockholders for the purpose of the execution of such transferred rights and may not again
transfer such rights to any other person or entity, other than in accordance with this terms and conditions of this Agreement and the Other Agreements. 

Nothing in this Agreement is intended to or will confer any rights or remedies on any person other than the parties hereto, permitted
transferees of Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock, and
their respective successors and permitted transferees. Neither this Agreement nor any of the rights or duties of the Company set forth herein shall be assigned by the Company, in whole or in part, without having first received the written consent of
Stockholders holding at least 60% of the outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock). 

5.6. Assignment of Rights. The rights of the Stockholders under this Agreement may be assigned, in whole or in part, to (i) any Affiliate
Stockholder or (ii) an assignee or transferee who, after such assignment or transfer, holds at least five percent (5%) of the outstanding shares of capital stock of the Company on a fully-diluted basis (subject to Proportional Adjustment), it
being acknowledged and agreed that any such assignment, including an assignment contemplated 

  
 -34- 

 
by the preceding clauses (i) or (ii) shall be subject to and conditioned upon any such assignee’s delivery to the Company and the other Stockholders of an agreement in writing to be
bound by the terms and conditions of this Agreement that were applicable to the assignor of such assignee. 
 5.7. Construction. The language
used in this Agreement is the language chosen by the parties to express their mutual intent, and no rule of strict construction will be applied against any party. 

5.8. Further Assurances. From time to time on and after the date hereof, the Company will promptly execute and deliver all such further
instruments and assurances, and will promptly take all such further actions, as the Stockholders or any of them may reasonably request in order more effectively to effect or confirm the transactions contemplated by this Agreement and/or any of the
Other Agreements and to carry out the purposes hereof and thereof. 
 5.9. Severability. No invalidity or unenforceability of any section of
this Agreement or any portion thereof will affect the validity or enforceability of any other section or the remainder of such section. 
 5.10.
Equitable Relief. Each of the parties acknowledges that any breach by such party of his, her or its obligations under this Agreement would cause substantial and irreparable damage to one or more of the other parties and that money damages
would be an inadequate remedy therefor. Accordingly, each party agrees that the other parties or any of them will be entitled to an injunction, specific performance, and/or other equitable relief to prevent the breach of such obligations. 

5.11. Entire Agreement. This Agreement, together with the exhibits and schedules hereto and the Other Agreements, contains the entire
understanding and agreement among the parties, or between or among any of them, and supersedes any prior or contemporaneous understandings or agreements between or among any of them, with respect to the subject matter hereof. 

5.12. Publicity. The purchasers of Series G Preferred Stock or any of them will have the right to publicize their investment in the Company as
contemplated hereby by means of a “tombstone” advertisement or other customary advertisement in newspapers and other media. No party to this Agreement shall issue any press release or other public document or make any public statement
relating to CHV’s purchase and ownership of shares of Preferred Stock, this Agreement, the Stockholders Agreement, the Series G Purchase Agreement, or the matters contained herein or therein, in each case, which mentions CHV or any Affiliate
thereof (including without limitation amounts invested by, rights granted to and other terms applicable to any of the foregoing entities) without the prior written consent of CHV; provided, that the foregoing shall not apply to any
announcement by any party required pursuant to applicable law or regulations so long as CHV is provided with a reasonable time to review and provide comments on any such announcement prior to its publication (and the party proposing to make such
announcement shall reasonably and in good faith consider such revisions as are requested by CHV). 

  
 -35- 

 5.13. Confidentiality. Each Stockholder agrees that such Stockholder will keep confidential and
will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention
to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 5.13 by such Stockholder), (b) is or has been
independently developed or conceived by the Stockholder without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Stockholder by a third party without a breach of any obligation of
confidentiality such third party may have to the Company; provided, however, that a Stockholder may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary
to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Stockholder, if such prospective purchaser agrees to be bound by the provisions of
this Subsection 5.13; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Stockholder in the ordinary course of business, provided that such Investor informs such
Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Stockholder promptly notifies the Company of such
disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 
 5.14. Governing Law. This Agreement will be
governed by and interpreted and construed in accordance with the internal laws of the State of Delaware, as applied to agreements under seal made, and entirely to be performed, within Delaware. 

5.15. Jurisdiction. The parties hereto agree that any suit, action or proceeding instituted against one or more of them with respect to this
Agreement (including any exhibits hereto) shall be brought in federal court in the Southern District of New York. The parties hereto, by the execution and delivery of this Agreement, irrevocably waive any obligation or any right of immunity on the
ground of venue, the convenience of the forum or the jurisdiction of such court, or from the execution of judgments resulting therefrom, and the parties hereto irrevocably accept and submit to the jurisdiction of the aforesaid court in any suit,
action or proceeding and consent to the service of process by certified mail at the address specified in Section 5.2 hereof. 
 [The
remainder of this page is intentionally left blank.] 

  
 -36- 

 [Signature Page to Sixth Amended and Restated Investors’ Rights Agreement] 

The undersigned, consisting of the Company, the purchasers of Series G Preferred Stock and those Stockholders who hold at least 60% of the
outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), hereby execute and deliver this Agreement as of the date first set forth above. 

 

					
	COMPANY:	  	 NEURONETICS, INC.

			
		  	By:	  	 /s/ Christopher Thatcher

		  	Name:	  	Christopher Thatcher
		  	Title:	  	President and Chief Executive Officer

 [Signature Page to Sixth Amended and Restated Investors’ Rights Agreement] 

The undersigned, consisting of the Company, the purchasers of Series G Preferred Stock and those Stockholders who hold at least 60% of the
outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), hereby execute and deliver this Agreement as of the date first set forth above. 

 

							
	STOCKHOLDERS:	 		  	CHV IV, L.P.
				
		 		  	By	  	 Ascension Health Ventures IV, LLC,
 Its
General Partner

				
		 		  	By:	  	 /s/ Matthew I. Hermann

		 		  		  	Name: Matthew I. Hermann
		 		  		  	Title: Senior Managing Director

 [Signature Page to Sixth Amended and Restated Investors’ Rights Agreement] 

The undersigned, consisting of the Company, the purchasers of Series G Preferred Stock and those Stockholders who hold at least 60% of the
outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), hereby execute and deliver this Agreement as of the date first set forth above. 

 

							
	STOCKHOLDERS:	  		  	GE VENTURES LIMITED
				
		  		  	By:	  	 /s/ David Mayhew

		  		  	Name:	  	David Mayhew
		  		  	Title:	  	Authorized Signatory

 [Signature Page to Sixth Amended and Restated Investors’ Rights Agreement] 

The undersigned, consisting of the Company, the purchasers of Series G Preferred Stock and those Stockholders who hold at least 60% of the
outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), hereby execute and deliver this Agreement as of the date first set forth above. 

 

							
	STOCKHOLDERS:	  	POLARIS VENTURE PARTNERS V, L.P.	  	
				
		  	By:	  	 Polaris Venture Management Co. V, L.L.C.,

Its General Partner
	  	
				
		  	By:	  	 /s/ Max Eisenberg
	  	
		  		  	Max Eisenberg, Attorney-in-Fact	  	
			
		  	POLARIS VENTURE PARTNERS ENTREPRENEURS’ FUND V, L.P.	  	
				
		  	By:	  	 Polaris Venture Management Co. V, L.L.C.,

Its General Partner
	  	
				
		  	By:	  	 /s/ Max Eisenberg
	  	
		  		  	Max Eisenberg, Attorney-in-Fact	  	
			
		  	POLARIS VENTURE PARTNERS FOUNDERS’ FUND V, L.P.	  	
				
		  	By:	  	 Polaris Venture Management Co. V, L.L.C.,

Its General Partner
	  	
				
		  	By:	  	 /s/ Max Eisenberg
	  	
		  		  	Max Eisenberg, Attorney-in-Fact	  	
			
		  	POLARIS VENTURE PARTNERS SPECIAL FOUNDERS’ FUND V, L.P.	  	
				
		  	By:	  	 Polaris Venture Management Co. V, L.L.C.,

Its General Partner
	  	
				
		  	By:	  	 /s/ Max Eisenberg
	  	
		  		  	Max Eisenberg, Attorney-in-Fact	  	

 [Signature Page to Sixth Amended and Restated Investors’ Rights Agreement] 

The undersigned, consisting of the Company, the purchasers of Series G Preferred Stock and those Stockholders who hold at least 60% of the
outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), hereby execute and deliver this Agreement as of the date first set forth above. 

 

							
	STOCKHOLDERS:	 		 	PFIZER INC.
				
		 		 	 By:
	 	 /s/ Barbara Dalton

Name: Barbara Dalton
 Title:   Vice
President

 [Signature Page to Sixth Amended and Restated Investors’ Rights Agreement] 

The undersigned, consisting of the Company, the purchasers of Series G Preferred Stock and those Stockholders who hold at least 60% of the
outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), hereby execute and deliver this Agreement as of the date first set forth above. 

 

							
	STOCKHOLDERS:	 		 	 NEW LEAF VENTURES II, L.P.

				
		 		 	By:    	 	New Leaf Venture Associates II, L.P.
		 		 	Its:    	 	General Partner
				
		 		 	By:    	 	New Leaf Venture Management II, L.L.C.
		 		 	Its:    	 	General Partner
				
		 		 	By:    	 	 /s/ Ronald M.
Hunt                    

		 		 		 	 Name:  Ronald M. Hunt

		 		 		 	 Title:    Managing Director

 [Signature Page to Sixth Amended and Restated Investors’ Rights Agreement] 

The undersigned, consisting of the Company, the purchasers of Series G Preferred Stock and those Stockholders who hold at least 60% of the
outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), hereby execute and deliver this Agreement as of the date first set forth above. 

 

							
	STOCKHOLDERS:	 		 	 QPIV, LLC

				
		 		 	 By:
	 	 /s/ P. Sherill Neff

		 		 		 	 Name:  P. Sherrill Neff

		 		 		 	 Title:    Authorized Member on behalf of Quaker

             Partners

 [Signature Page to Sixth Amended and Restated Investors’ Rights Agreement] 

The undersigned, consisting of the Company, the purchasers of Series G Preferred Stock and those Stockholders who hold at least 60% of the
outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), hereby execute and deliver this Agreement as of the date first set forth above. 

 

							
	STOCKHOLDERS:	 		 	Industry Ventures Healthcare, L.L.C.
			
		 		 	By: Industry Ventures Management VII, L.L.C.,

		 		 	its General Partner
				
		 		 	By:	 	     /s/ Justin Burden

    Name:  Justin Burden

    Title:    Member

 [Signature Page to Sixth Amended and Restated Investors’ Rights Agreement] 

The undersigned, consisting of the Company, the purchasers of Series G Preferred Stock and those Stockholders who hold at least 60% of the
outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), hereby execute and deliver this Agreement as of the date first set forth above. 

 

									
	STOCKHOLDERS:	 	                            	 	 THREE ARCH PARTNERS IV, L.P.

				
		 		 	By:	 	 Three Arch Management IV, L.L.C.,

its General Partner

					
		 		 		 	By:	 	 /s/
Wilfred Jaeger                    

		 		 		 	Name:	 	Wilfred Jaeger
		 		 		 	Title:  	 	Managing Member
			
		 		 	THREE ARCH ASSOCIATES IV, L.P.
				
		 		 	By:	 	 Three Arch Management IV, L.L.C., its

General Partner

					
		 		 		 	By:	 	 /s/
Wilfred Jaeger                    

		 		 		 	Name:	 	Wilfred Jaeger
		 		 		 	Title:	 	Managing Member
			
		 		 	 THREE ARCH CAPITAL, L.P.

				
		 		 	By:	 	TAC Management, L.L.C., its General Partner
					
		 		 		 	By:	 	 /s/
Wilfred Jaeger                    

		 		 		 	Name:	 	Wilfred Jaeger
		 		 		 	Title:	 	Managing Member
			
		 		 	 TAC ASSOCIATES, L.P.

				
		 		 	By:	 	TAC Management, L.L.C., its General Partner
					
		 		 		 	By:	 	 /s/
Wilfred Jaeger                    

		 		 		 	Name:	 	Wilfred Jaeger
		 		 		 	Title:	 	Managing Member

 [Signature Page to Sixth Amended and Restated Investors’ Rights Agreement] 

The undersigned, consisting of the Company, the purchasers of Series G Preferred Stock and those Stockholders who hold at least 60% of the
outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), hereby execute and deliver this Agreement as of the date first set forth above. 

 

							
	STOCKHOLDERS:	  		  	INVESTOR GROWTH CAPITAL LIMITED
				
		  		  	By:	  	 /s/ Michael V. Oporto

		  		  	Name:	  	Michael V. Oporto
		  		  	Title:	  	Director
			
		  		  	INVESTOR GROUP, L.P.
				
		  		  	By:	  	Investor Growth Capital, LLC, its General Partner
				
		  		  	By:	  	 /s/ Michael V. Oporto

		  		  		  	Name:Michael V. Oporto
		  		  		  	Title:Secretary
			
		  		  	IGC FUND VI, L.P.
				
	 	  	 	  	By:	  	Investor Growth Capital, LLC, its General Partner
				
	 	  	 	  	By:	  	 /s/ Michael V. Oporto

	 	  	 	  	 	  	Name:Michael V. Oporto
	 	  	 	  	 	  	Title:Secretary

 [Signature Page to Sixth Amended and Restated Investors’ Rights Agreement] 

The undersigned, consisting of the Company, the purchasers of Series G Preferred Stock and those Stockholders who hold at least 60% of the
outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), hereby execute and deliver this Agreement as of the date first set forth above. 

 

							
	STOCKHOLDERS:	 	ONSET IV, L.P.
			
		 	By:	 	    ONSET IV Management, LLC,
    its General Partner
				
		 		 	    By:	 	/s/ Rob Kuhling
		 		 	    Name:	 	Rob Kuhling
		 		 	    Title:	 	

 [Signature Page to Sixth Amended and Restated Investors’ Rights Agreement] 

The undersigned, consisting of the Company, the purchasers of Series G Preferred Stock and those Stockholders who hold at least 60% of the
outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), hereby execute and deliver this Agreement as of the date first set forth above. 

 

							
	STOCKHOLDERS:	 	INTERWEST PARTNERS VIII, L.P.
		 	By:	 	InterWest Management Partners VIII, LLC,
its General Partner
				
		 		 	By:	 	 /s/ Gilbert H. Kliman

		 		 	Name:	 	Gilbert H. Kliman
		 		 	Title:	 	Managing Director
		
		 	INTERWEST INVESTORS VIII, L.P.
		 	By:	 	InterWest Management Partners VIII, LLC,
its General Partner
				
		 		 	By:	 	 /s/ Gilbert H. Kliman

		 		 	Name:	 	Gilbert H. Kliman
		 		 	Title:	 	Managing Director
		
		 	INTERWEST INVESTORS Q VIII, L.P.
		 		 	By:	 	InterWest Management Partners VIII, LLC,
its General Partner
				
		 		 	By:	 	 /s/ Gilbert H. Kliman

		 		 	Name:	 	Gilbert H. Kliman
		 		 	Title:	 	Managing Director

 [Signature Page to Sixth Amended and Restated Investors’ Rights Agreement] 

The undersigned, consisting of the Company, the purchasers of Series G Preferred Stock and those Stockholders who hold at least 60% of the
outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), hereby execute and deliver this Agreement as of the date first set forth above. 

 

							
	STOCKHOLDERS:	 		 	KBL HEALTHCARE VENTURES, L.P.
		 		 	By: KBL Healthcare, LLC its General Partner
				
		 		 	By:	 	 /s/ Marlene Krauss

		 		 	Name:	 	Marlene Krauss
		 		 	Title:	 	
			
		 		 	KBL HEALTHCARE, L.P.
		 		 	By:	 	KBL SBIC, Inc., its General Partner
				
		 		 	By:	 	 /s/ Marlene Krauss

		 		 	Name:	 	
		 		 	Title:	 	
			
		 		 	KBL PARTNERSHIP, L.P.
		 		 	By:	 	KBL Healthcare, LLC, its General Partner
				
		 		 	By:	 	 /s/ Marlene Krauss

		 		 	Name:	 	
		 		 	Title:	 	

 [Signature Page to Sixth Amended and Restated Investors’ Rights Agreement] 

The undersigned, consisting of the Company, the purchasers of Series G Preferred Stock and those Stockholders who hold at least 60% of the
outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), hereby execute and deliver this Agreement as of the date first set forth above. 

 

					
	STOCKHOLDERS:	 	AMV PARTNERS I, L.P.
			
		 	By:	 	 Accuitive Medical Ventures, LLC, its General

Partner

			
		 	By:	 	/s/ Thomas Weldon                                 
                       
		 	Name: Thomas Weldon
		 	Title:

 [Signature Page to Sixth Amended and Restated Investors’ Rights Agreement] 

The undersigned, consisting of the Company, the purchasers of Series G Preferred Stock and those Stockholders who hold at least 60% of the
outstanding Registrable Securities held by all Stockholders (assuming the conversion of all outstanding Preferred Stock into shares of Common Stock), hereby execute and deliver this Agreement as of the date first set forth above. 

 

			
	 STOCKHOLDERS:
	  	 /s/ Brian Farley

Brian Farley

 Schedule of Series G Stockholders 

CHV IV, L.P. 
 GE Ventures Limited 

Polaris Venture Partners V, L.P. 
 Polaris Venture
Partners Entrepreneurs’ Fund V, L.P. 
 Polaris Venture Partners Special Founders’ Fund V, L.P. 

Polaris Venture Partners Founders’ Fund V, L.P. 

Pfizer Inc. 
 New Leaf Ventures II, L.P. 

Industry Ventures Healthcare, L.L.C. 
 Three Arch
Partners IV, L.P. 
 Three Arch Associates IV, L.P. 

Three Arch Capital, L.P. 
 TAC Associates L.P. 

 IGC Fund VI, L.P. 

ONSET IV, L.P. 
 InterWest Partners VIII, L.P.

 InterWest Investors VIII, L.P. 
 InterWest
Investors Q VIII, L.P. 
 KBL Partnership, L.P. 

KBL Healthcare Ventures, L.P. 
 AMV Partners I, L.P.

 Brian Farley 

 Schedule of Series F Stockholders 

GE Ventures Limited 
 Polaris Venture Partners V, L.P.

 Polaris Venture Partners Entrepreneurs’ Fund V, L.P. 

Polaris Venture Partners Special Founders’ Fund V, L.P. 

Polaris Venture Partners Founders’ Fund V, L.P. 

Pfizer Inc. 
 New Leaf Ventures II, L.P. 

QPIV, LLC 
 Three Arch Partners IV, L.P. 

Three Arch Associates IV, L.P. 
 Three Arch Capital,
L.P. 
 TAC Associates L.P. 

 IGC Fund VI, L.P. 

ONSET IV, L.P. 
 InterWest Partners VIII, L.P.

 InterWest Investors VIII, L.P. 
 InterWest
Investors Q VIII, L.P. 
 KBL Healthcare, L.P. 

KBL Partnership, L.P. 
 KBL Healthcare Ventures, L.P.

 Weldon Foundation 
 AMV Partners I, L.P.

 Michael Dale 

 Brian Farley 

Bruce Shook 
 Charles E. Larsen 

 Schedule of Series E Stockholders 

Polaris Venture Partners V, L.P. 
 Polaris Venture
Partners Entrepreneurs’ Fund V, L.P. 
 Polaris Venture Partners Special Founders’ Fund V, L.P. 

Polaris Venture Partners Founders’ Fund V, L.P. 

Pfizer Inc. 
 New Leaf Ventures II, L.P. 

QPIV, LLC 
 Three Arch Partners IV, L.P. 

Three Arch Associates IV, L.P. 
 Three Arch Capital,
L.P. 
 TAC Associates L.P. 

 Investor Growth Capital Limited 

Investor Group, L.P. 
 ONSET IV, L.P. 

InterWest Partners VIII, L.P. 
 InterWest Investors
VIII, L.P. 
 InterWest Investors Q VIII, L.P. 

Weldon Foundation 
 Michael Dale 

Brian Farley 

 Schedule of Series D Stockholders 

New Leaf Ventures II, L.P. 
 QPIV, LLC 

Three Arch Partners IV, L.P. 
 Three Arch Associates
IV, L.P. 
 Three Arch Capital, L.P. 
 TAC
Associates L.P. 
 Investor Growth Capital Limited 

Investor Group, L.P. 
 ONSET IV, L.P. 

 InterWest Partners VIII, L.P. 

InterWest Investors VIII, L.P. 
 InterWest Investors Q
VIII, L.P. 
 KBL HEALTHCARE VENTURES, L.P. 

Weldon Foundation 
 Michael Dale 

Brian E. Farley 

 Schedule of Series C Stockholders 

QPIV, LLC 
 Three Arch Partners IV, L.P. 

Three Arch Associates IV, L.P. 
 Three Arch Capital,
L.P. 
 TAC Associates L.P. 
 AMV Partners I,
L.P. 
 Investor Growth Capital Limited 

Investor Group, L.P. 
 ONSET IV, L.P. 

 InterWest Partners VIII, L.P. 

InterWest Investors VIII, L.P. 
 InterWest Investors Q
VIII, L.P. 
 KBL HEALTHCARE, L.P. 
 KBL
Partnership, L.P. 

 Schedule of Series B Stockholders 

Three Arch Partners IV, L.P. 
 Three Arch Associates
IV, L.P. 
 Three Arch Capital, L.P. 
 TAC
Associates L.P. 
 AMV Partners I, L.P. 

Investor Growth Capital Limited 
 Investor Group, L.P.

 ONSET IV, L.P. 
 InterWest Partners VIII,
L.P. 
 InterWest Investors VIII, L.P. 
 InterWest
Investors Q VIII, L.P. 
 KBL HEALTHCARE, L.P. 

KBL Partnership, L.P. 

 Schedule of Series A-2 Stockholders 

Investor Growth Capital Limited 
 Investor Group, L.P.

 ONSET IV, L.P. 
 InterWest Partners VIII,
L.P. 
 InterWest Investors VIII, L.P. 
 InterWest
Investors Q VIII, L.P. 
 KBL HEALTHCARE, L.P. 

KBL Partnership, L.P. 

 Schedule of Series A-1 Stockholders 

Thomas D. Weldon Revocable Trust 
 Charles E. Larsen

 Norman R. Weldon 

 EXHIBIT A 

RESTRICTIVE COVENANT AND INVENTION ASSIGNMENT AGREEMENT 

FOR EMPLOYEES AND CONSULTANTS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]